Recombinant canine herpesviruses

FIELD OF THE INVENTION
The present invention relates to canine herpesvirus (CHV), and particularly to novel recombinant CHV and recombinant CHV genomes, including those that contain heterologous nucleic acid molecules. The present invention also relates to the use of such genomes and viruses in a variety of applications, including as therapeutic compositions to protect animals from disease. The present invention also relates to novel isolated CHV nucleic acid molecules, to proteins encoded by such nucleic acid molecules, and to use of such CHV nucleic acid molecules to insert heterologous nucleic acid molecules into CHV genomes.
BACKGROUND OF THE INVENTION
Dogs and other canids are affected by a number of diseases against which it would be desirable to develop protective vaccines. Live vaccines, and particularly live viral vector vaccines, are attractive vaccine vector candidates as they appear to be associated with longer-lasting immunity than inactivated virus vaccines or subunit vaccines. One disadvantage of live vaccines, however, has been that attenuated virus strains often revert to virulence. Another disadvantage has been the host range of a number of viral vaccines. In an attempt to deliver genes to an animal, several viral and bacterial systems, such as poxviruses, adenoviruses, Salmonella, and BCG (Bacillus Calmette-Guerin), have been genetically manipulated to generate vectors containing heterologous antigen genes in order to immunize a host with a vaccine in which the antigens are presented in a "live" configuration. See, for example, the following two review articles: Esposito et al., pp. 195-247, 1989, Advances in Veterinary Science and Comparative Medicine, Vol. 33; Dougan et al., pp. 271-300, 1989, Advances in Veterinary Science and Comparative Medicine, Vol. 33.
Several herpes virus vaccines, such as those based on bovine herpes virus (BHV), cytomegalovirus (CMV), Epstein Barr virus (EBV), equine herpes virus (EHV), feline herpes virus (FHV), herpes simplex virus (HSV), Marek's disease virus (MDV), pseudorabies virus (PRV), turkey herpes virus (HVT), and varicella zoster virus (VZV) have been developed and several have shown at least some efficacy as vaccines against the virus per se or as vectors carrying other genes in certain indications. The listed herpes viruses, however, also have the drawback that even if attenuated, they are subject to reversion.
Canine herpes virus (CHV) infection is a relatively benign infection except in newborn puppies. A few vaccines to protect against CHV infection have been reported including a small-plaque variant CHV vaccine disclosed in U.S. Pat. No. 4,213,965, by Carmichael, issued Jul. 22, 1980. The nucleotide sequences of CHV genes encoding gB, gC, gD and UL45 homologs have been reported by Limbach et al., 1994, J. Gen. Virol. 75, 2029-2039, but these proteins, while proposed as vaccine candidates against CHV, were not tested as such by Limbach et al., ibid.
The inventors are not aware of any reports which describe the use of CHV as a vaccine vector, either with respect to inactivating genes in the CHV genome using recombinant DNA techniques, and/or to delivering protective compounds to a canid, in spite of the need to develop safe and efficacious delivery systems to protect canids, and especially dogs, from disease. Two U.S. patents (i.e., U.S. Pat. No. 5,266,489, by Rey-Senelonge et al., issued Nov. 30, 1993; and U.S. Pat. No. 5,223,424, by Cochran et al., issued Jun. 29, 1993) at best speculate on the insertion of genes into certain CHV loci, but neither claims CHV vectors or vaccines, nor provides data supporting such speculations. U.S. Pat. No. 5,266,489, ibid., claimed HVT having a foreign gene inserted into the ribonucleotide reductase (RR) small subunit gene of the HVT genome, but also disclosed without support the insertion of foreign genes into the RR small subunit genes of BHV, CHV, CMV, duck herpes virus, EBV, EHV, FHV, HSV, PRV and VZV. The inventors, however, have demonstrated the inaccuracy of this disclosure in that the inventors have found, and disclosed in the present application, that the CHV genome lacks the RR small subunit gene. That is, the CHV RR small subunit gene does not exist to provide a target for the insertion of foreign genes.
U.S. Pat. No. 5,223,424, ibid., claimed specific hybrid PRV constructs having deletions in the TK, repeat, or and/or gX regions and heterologous sequences inserted into the repeat and/or gX regions, but also proposed without data the ability to insert foreign genes into the repeat region of the CHV genome, even though that genome had not yet been mapped. Also disclosed were certain BHV and HVT constructs and proposals, without data, to delete and insert genes in other herpesviruses, such as EHV and FHV, HSV and MDV. It is also of note that a patent application (now U.S. Pat. No. 5,273,876, by Hock et al, issued Dec. 28, 1993) that was filed significantly later than U.S. Pat. No. 5,223,424, ibid., and shares two co-inventors with U.S. Pat. No. 5,223,424, ibid., states in column 2, lines 57-61, "Among the herpesviruses, only four herpesviruses (herpes simplex of humans, herpes saimiri of monkeys, pseudorabies virus and varicella-zoster virus) have been engineered to contain foreign DNA sequences previous to this disclosure," thereby indicating the lack of CHV, or a number of other, herpes virus vectors.
Thus, there remains a need for new and improved methods to vaccinate canids to protect them from diseases, such as those caused by genetic or metabolic disorders as well as those caused by infectious agents such as protozoan parasites, helminth parasites, ectoparasites, fungi, bacteria, and viruses.
SUMMARY OF THE INVENTION
The present invention relates to a new method to protect animals from disease using a recombinant virus or virus genome. When a recombinant CHV of the present invention is administered to an animal, the virus is able to infect cells within the animal. Infected cells are able to express nucleic acid sequences present on the recombinant CHV genome to produce protective compounds, such as proteins and RNAs, capable of protecting the animal from a variety of diseases. Using methods taught in the present invention, vaccines can be generated that are capable of protecting an animal from any disease for which a protective compound can be produced. As such, the present invention is of extremely broad scope and includes a wide variety of vaccines that have a variety of applications.
The present invention includes a recombinant CHV that comprises a recombinant CHV genome. The invention also includes recombinant CHV genomes. In one embodiment, a recombinant CHV has an inactive gene within its genome, with a preferred recombinant CHV in this embodiment being a CdUTPase negative CHV, a CgC negative CHV, a CgE negative CHV, a CgG negative CHV, a CgI negative CHV, a CPK negative CHV, a CTK negative CHV, a CIR6 negative CHV, a CUS2 negative CHV, a CUS9 negative CHV, a CUL49 negative CHV, a CUL51 negative CHV, a CUL45 negative CHV, a CgD negative CHV, a CgB negative CHV, a CUL48 negative CV, a CUL52 is negative CHV, a CgL negative CHV, a CUL49.5 negative CHV, a CICP0 negative CHV, a CICP4 negative CHV, and/or a CUS8.5 negative CHV. In the case of the CUS8.5 negative CHV, a CUS8.5 negative CHV refers to a CHV in which the CUS8.5 open reading frame is disrupted.
The present invention also includes a recombinant CHV genome that comprises a heterologous nucleic acid molecule, which preferably encodes a protective compound that protects a canid from disease. Such a heterologous nucleic acid molecule can be located in an essential gene, a nonessential gene, and/or in an intergenic region. Insertion of a heterologous nucleic acid into a CHV genome can, but need not, inactivate a gene within that genome. Also included in the present invention are methods to produce a recombinant CHV and a recombinant CHV genome, as well as a canine cell line that complements a defect in a gene essential to CHV reproduction in vitro.
One embodiment of the present invention is a method to increase recombinant CHV plaque forming efficiency. Such a method can include the steps of introducing a recombinant CHV genome into a canine cell expressing CHV alpha transinducing factor and culturing the cell to produce recombinant CHV. In another embodiment, the method includes the steps of co-introducing a recombinant CHV genome and a CHV alpha transinducing factor gene into a canine cell and culturing the cell to produce recombinant CHV. The present invention also includes a canine cell line comprising a CHV alpha transinducing factor gene.
One embodiment of the present invention is a therapeutic composition that includes a recombinant CHV, a recombinant CHV genome, or a mixture thereof. The present invention also includes a method to protect an animal from disease by administering such a therapeutic composition to the animal.
The present invention also includes an isolated CHV nucleic acid molecule that hybridizes under stringent hybridization conditions with at least one of the following nucleic acid regions: a CdUTPase gene, a CgE gene, a CgG gene, a CgI gene, a CPK gene, a CTK gene, a CIR6 gene, a CUS2 gene, a CUS9 gene, a CUL49 gene, a CUL51 gene, a CUL48 gene, a CUL52 gene, a CgL gene, a CUL49.5 gene, a CICP4 gene, a CUS8.5 open reading frame, and/or a region of the CHV genome spanning from about the 3' end of the coding region of the CUL41 gene through about the 3' end of the coding region of the CUL38 gene. Also included are recombinant molecules, recombinant viruses, recombinant vectors, and recombinant cells that include such CHV nucleic acid molecules. The present invention also includes CHV proteins encoded by such CHV nucleic acid molecules and antibodies that selectively bind to such CHV proteins, as well as methods to produce such CHV nucleic acid molecules, recombinant molecules, recombinant viruses, recombinant vectors, recombinant cells, CHV proteins and antibodies. Also included in the present invention are therapeutic compositions including such CHV nucleic acid molecules, CHV proteins and antibodies, as well as methods to use such compositions to protect an animal from disease.

BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 depicts a schematic map of two contiguous HindIII fragments that include at least portions of CHV UL48 UL49, dUTPase, UL51 and UL52 genes.
FIG. 2 depicts a schematic map of the AscI fragment that includes the unique short region of CHV.
FIG. 3 depicts a schematic map of the AscI/blunt fragment that includes the terminal inverted repeat region of CHV.
FIG. 4 depicts a schematic map of a region of the CHV genome spanning at least from the CUS9 gene through the CIR6 gene.
FIG. 5 depicts a schematic map of a region of the CHV genome spanning at least from a portion of the CUL52 gene through at least a portion of the CUL48 gene.

DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to canine herpesviruses (CHV), and particularly to recombinant CHV and recombinant CHV genomes as well as to methods to produce and use such viruses and genomes. The present invention also includes identification of regions of the CHV genome that are preferred targets for deletion and/or for insertion of heterologous nucleic acid molecules. As used herein, the term "canine" refers to "of the family Canidae" and, as such, includes reference to dogs (including wild and domesticated dogs), foxes, wolves, jackals, coyotes, and other members of the family Canidae. Similarly, a "canid" is any member of the family Canidae. As used herein, the term CHV refers to any herpesvirus endogenous to the family Canidae. A particularly preferred CHV of the present invention is a recombinant CHV that infects dogs.
One embodiment of the present invention is the use of a recombinant CHV, and particularly of a CHV having a recombinant CHV genome that includes a (i.e., one or more than one) heterologous nucleic acid molecule, as a live CHV-based therapeutic composition, or vaccine, to protect an animal from a disease against which the heterologous nucleic acid molecule is targeted. Live vaccines are advantageous because they are believed to confer more vigorous and longer-lasting immunity than subunit or killed vaccines. While not being bound by theory, it is believed that such advantages are due to the ability of the genetic information carried by the virus to enter cells of the treated animal, replicate itself, and direct the expression of a protective compound, such as a protective protein or a protective RNA, for extended periods of time. Thus, the therapeutic composition need not be administered frequently and, at least in some embodiments, the virus vaccine can function as a self-booster.
CHV is particularly useful as a delivery vehicle for a heterologous nucleic acid molecule to protect canids from a disease for a variety of reasons, including, but not limited to, CHV's limited host range and pathogenicity. CHV, to the inventors' knowledge, has the most limited host range of any herpesvirus, including FHV, in that CHV's host range appears to be substantially limited to canine cells. As far as the inventors are aware, the only report of CHV infection of a cell type other than canine cells is limited infection of mink lung cells; see, for example, Peterson et al, 1988, Comp. Immunol. Microbiol. Infect. Diseases 11, 93-98. This limited host range illustrates the safety of CHV in that the virus apparently cannot be transmitted to a variety of species unrelated to canids.
Furthermore, CHV exhibits only limited pathogenicity. Although the virus has been shown to cause a fatal hemorrhagic disease in hypothermic neonatal pups (i.e., essentially all pups experimentally infected with CHV and maintained at room temperature (i.e., from about 25.degree. C. to 27.degree. C. ) within a week of birth die from the infection), CHV causes insignificant respiratory infection in adult dogs; see, for example, Carmichael, 1970, J. Am. Vet. Med. Assn. 156, 1714-1721. Moreover, prolonged survival or recovery of experimentally infected neonatal pups maintained at 38.4.degree. C. to 39.5.degree. C. was observed. Adult dogs exposed to CHV do, however, become infected since virus shedding has been shown to occur for at least two weeks post-inoculation; and latency is postulated to occur, since CHV has been isolated from primary cultured cells of normal healthy dogs; see, for example, Carmichael, ibid. Furthermore, maternal antibody, or passive transfer of antibody from seropositive dogs has been shown to protect puppies from an otherwise fatal CHV challenge; see, for example, Carmichael, ibid. Due to its limited pathogenicity, CHV apparently need not be attenuated to the extent required for other viruses used as live vaccine vectors. In addition, vaccination of a dam with CHV can lead to passive protection in her pups.
Another advantage of CHV is its limited temperature range. CHV grows well at temperatures ranging from about 34.degree. C. to about 36.degree. C., with optimal growth occurring at about 35.degree. C. CHV, however, does not grow well at temperatures less than or equal to about 33.degree. C. or at temperatures greater than or equal to about 37.degree. C. As such CHV is significantly more temperature sensitive than any other known wild type herpesvirus, including FHV.
Yet another advantage of CHV is its potential for use as a single, multivalent therapeutic composition against a variety of canine pathogens. That is, the CHV genome can be manipulated to incorporate multiple heterologous nucleic acid molecules without disrupting the ability of the genome to be packaged (i.e., assembled) into a live virus. Examples of multivalent therapeutic compositions are described below.
As far as the inventors are aware, this application is the first report of the genetic engineering of a CHV genome, particularly for the development of efficacious canid vaccines, in spite of a long felt need for efficacious vaccines against canine pathogens. The inventors have developed methods to identify CHV genes and intergenic regions, particularly those having utility as targets for the insertion of heterologous nucleic acid molecules, despite the difficulty of using known herpesvirus sequences to identify such regions due to the AT-rich nature of the CHV genome. The CHV genome contains about 70% adenosine and thymidine residues, compared to other known herpesvirus genomes which, on the average, contain from about 30% to about 58% adenosine and thymidine residues (e.g., HSV, BHV, and PRV contain about 30%, EHV about 54%, and FHV about 58%, adenosine and thymidine residues). As such, it is very difficult to design primers or probes using known herpesvirus sequences to identify CHV analogs.
One embodiment of the present invention is a recombinant CHV. As used herein, a recombinant CHV is a CHV that comprises (i.e., has or includes) a genome that has been genetically engineered (i.e., subjected to recombinant nucleic acid (i.e., DNA or RNA) techniques, such as those disclosed in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press; Sambrook et al., ibid., is incorporated by reference herein in its entirety) to differ from the genome of a natural CHV isolate (i.e., a herpesvirus endogenous to the family Canidae). Such a genetically engineered genome is referred to herein as a recombinant CHV genome and is described in more detail below.
A recombinant CHV of the present invention includes not only a recombinant CHV genome but also an envelope and capsid in which the genome is packaged. The viral envelope and capsid are preferably a CHV envelope and a CHV capsid, encoded at least in part by CHV genes, thereby imparting to the recombinant CHV the host range of a natural CHV isolate. It is to be noted, however, that the present invention also includes recombinant CHV having envelopes and/or capsids that have been modified to, for example, alter (e.g., broaden, narrow, or completely change) the host range of the recombinant CHV genome. Such modifications can be accomplished by one skilled in the art by, for example, modifying CHV envelope and/or capsid genes and/or replacing such genes with those of another virus. Altered genes can be located on the CHV genome itself and/or in the genome of the cell in which the recombinant virus is produced.
A recombinant CHV genome of the present invention is a CHV genome in which nucleotides have been deleted, inserted, substituted or inverted using recombinant techniques known to those skilled in the art such that the recombinant CHV genome is no longer the same as a natural CHV genome. A recombinant CHV genome of the present invention is capable of effecting expression (e.g., transcription, translation) of coding regions that are operatively linked to regulatory sequences within the genome. As used herein, a coding region is a stretch of nucleotides that encodes an RNA molecule and/or a protein. Coding regions can be endogenous to CHV or can be heterologous nucleic acid molecules of the present invention, which are described in more detail below. The phrase operatively linked refers to the positioning of a coding region in the CHV genome such that the coding region is able to be expressed when the genome is inside a cell. Regulatory sequences include transcription control sequences, translation control sequences, and other regulatory sequences that control the expression of coding regions. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences. Suitable regulatory sequences include any regulatory sequence that can function in the present invention. Preferred regulatory sequences are disclosed herein.
A recombinant CHV genome of the present invention can include a gene that has been inactivated. As used herein, a gene includes a coding region as well as the regulatory sequences involved in expression of that coding region. An inactive gene refers to a gene that no longer exhibits the function of its natural counterpart. Methods to inactivate a gene include, but are not limited to, deletion of one or more nucleotides within the gene, insertion of one or more nucleotides into the gene, replacement of one or more nucleotides within the gene by other nucleotides (i.e., nucleotide substitution), and/or inversion of nucleotides within the gene such that the resulting gene no longer has the function of the corresponding natural gene. Such alterations can be effected anywhere within the gene, such as within the coding region, within the regulatory sequences and/or in regions surrounding the coding region or regulatory sequences such that the alteration(s) cause gene inactivation. In one embodiment, an entire gene or the coding region and/or regulatory sequences thereof can be deleted or replaced.
One embodiment of the present invention is an attenuated recombinant CHV. As used herein, an attenuated CHV is a CHV that does not cause 100% mortality if used to infect canid neonates less than 1 week old that are maintained in room temperature. A preferred attenuated CHV of the present invention causes less than about 90% and preferably less than about 70% mortality when used to infect canid neonates less than 1 week of age maintained at room temperature.
An attenuated recombinant CHV can be produced by inactivating a CHV gene that, due to that gene's inactivation, results in an attenuated virus. Methods to inactivate a gene are disclosed above. An attenuated CHV can be identified by exposing pups less than 1 week old to the recombinant virus to be tested and determining the percentage of exposed pups that die; such an exposure method is disclosed, for example, in Carmichael, ibid. If less than 100% percent of the pups die, the virus being tested is attenuated in accordance with the present invention. Suitable CHV genes to inactivate in order to produce an attenuated CHV include any gene that when inactivated leads to an attenuated virus, as determined using an assay as disclosed above. A preferred attenuated recombinant CHV of the present invention is a CHV having a recombinant genome in which a heterologous nucleic acid molecule is inserted into a gene, the insertion resulting in an attenuated virus.
An attenuated recombinant CHV has utility, for example, as a therapeutic composition to protect an animal from CHV infection and/or as a live CHV-based vaccine carrying a heterologous nucleic acid molecule. It is to be noted, however, that, as disclosed above, it is believed that CHV need not be attenuated for use as a live vaccine vector due to the low pathogenicity of natural CHV, particularly as compared to that of other herpesviruses.
One embodiment of the present invention is a recombinant CHV that can reproduce (i.e., grow) in tissue culture; that is, the virus is a reproduction competent CHV. A reproduction competent CHV is a CHV that upon in vitro infection of an appropriate host cell is able to use host cell machinery, as well as its own regulatory control regions and/or encoded enzymes, to effect self-reproduction, i.e., to form infectious virus.
Reproduction competent recombinant CHV genomes can have gene alterations in one or more genes non-essential for growth in vitro. Suitable gene targets (i.e., genes to alter) include any non-essential CHV gene. A non-essential CHV gene can be identified by altering a CHV gene within a CHV genome (e.g., by genetic engineering or classical mutagenesis) and demonstrating that the altered genome is capable of effecting self-reproduction in tissue culture. Preferred non-essential CHV genes to target include, but are not limited to, a CHV deoxyuridine triphosphate pyrophosphatase (CdUTPase) gene, a CHV glycoprotein C (CgC) gene, a CHV glycoprotein E (CgE) gene, a CHV glycoprotein G (CgG) gene, a CHV glycoprotein I (CgI) gene, a CHV serine-threonine protein kinase US3 (CPK) gene, a CHV thymidine kinase (CTK) gene, a CHV IR6 (CIR6) gene, a CHV US2 (CUS2) gene, a CHV tegument phosphoprotein US9 (CUS9) gene, a CHV membrane protein UL49 (CUL49) gene, a CHV membrane protein CHV UL49.5 (CUL49.5) gene, a CHV regulatory protein ICP0 (cICP0) gene, a CHV membrane protein UL51 (CUL51) gene, and a CHV membrane protein UL45 (CUL45) gene. Particularly preferred non-essential genes to target include a CdUTPase gene, a CgC gene, a CgE gene, a CgG gene, a CgI gene, a CUS2 gene and a CUS9 gene. It is to be noted that CHV regions and genes disclosed herein are named in accordance with herpesvirus nomenclature in that the names include "C" for canine and the rest of the name indicating the corresponding herpes simplex virus (HSV) homolog (e.g., "dUTPase"). For example, the CHV unique short region (CUS) is the shorter region of the CHV genome that has unique sequences, analogous to the US region of HSV; the CHV unique long region (CUL) is the longer region of CHV that has unique sequences, analogous to the UL region of HSV; and the CHV inverted repeat regions (CIRs) are analogous to the HSV IR regions. CUS genes are CHV genes that are homologs of (i.e., genes that share some degree of similarity with) HSV genes located in the US region of the HSV genome. CUL genes are CHV genes that are homologs of HSV genes located in the UL region of the HSV genome. CIR genes are CHV genes that are homologs of HSV genes located in the IR regions of the HSV or EHV genome. It is also to be noted that although the UL, US, and IR designations refer to the respective genes' locations in the HSV genome, they do not necessarily refer to the respective genes' locations in the CHV genome. For example, while CUS2 is partially in the IR region of CHV, HSV US2 is entirely in the US region of HSV.
Another embodiment of the present invention is a recombinant CHV that is defective for reproduction in tissue culture. A reproduction defective CHV is a CHV that when inserted into an appropriate host cell is unable to form infectious virus. Such a defective CHV has at least one inactive gene that encodes a protein essential for reproduction, including, but not limited to proteins essential for viral entry, immediate early or early gene expression, DNA replication, capsid assembly, and viral egress. Suitable gene targets include any essential CHV gene, with preferred targets being genes encoding proteins involved in viral entry and/or egress. CHV defective in viral entry and/or egress are easy to complement and are advantageous over most other reproduction defective mutants in that such virus are able to undergo one round of viral replication. An essential CHV gene can be identified by altering a CHV gene within a CHV genome and demonstrating (a) that the altered genome is not capable of effecting self-reproduction in tissue culture under wild type conditions or, if a temperature sensitive mutant, at a non-permissive temperature; and (b) that the altered genome can reproduce in a complementing cell line that expresses an active protein corresponding to the essential gene defect on the CHV genome (assuming the defect can be complemented in trans), or at a permissive temperature. Preferred essential CHV genes to target include, but are not limited to, a CHV glycoprotein D (CgD) gene, a CHV glycoprotein B (CgB) gene, a CHV alpha trans-inducing factor UL48 (CUL48) gene, a CHV helicase/primase UL52 (CUL52) gene, a CHV glycoprotein L (CgL) gene and a CHV ICP4 (cICP4) gene. Particularly preferred essential genes to target include a CgD gene and a CgB gene.
The present invention also includes cell lines that complement replication defective CHVs and use of such cell lines to produce replication defective viruses. As such, the present invention includes canine cell lines that complement, or supplement, a CHV defect in a gene encoding CgD, CgB, CUL48, or CUL52, and/or CgL. Such cell lines can be produced by a variety of means known to those skilled in the art. For example, a cell capable of complementing a CgD negative, or CgD-, CHV (i.e., a virus with a CHV genome having an inactive CgD gene), can be produced by stable integration of an active CgD gene into the cellular genome or by co-transfection of the CgD- CHV with a nucleic acid molecule capable of complementing the defective CgD gene. Such a nucleic acid molecule can be a nucleic acid containing an active CgD gene operatively linked to regulatory sequences to enable expression of the CgD gene in the transfected cell. In another embodiment, such a nucleic acid molecule can be incorporated into a virus that is co-infected with the CgD- CHV. Such methods can also be used to produce cell lines complementing other replication defective CHVs of the present invention. Any canine cell line that CHV can infect and that expresses the complementary active protein can be used in the production of reproduction-defective CHV. Examples include, but are not limited to, the following cell lines available from American Type Culture Collection (ATCC), Rockville, Md.: ATCC 2; CRL-1542 A-72 (Tumor, canine), ATCC CRL-1430 Cf2Th (Thymus, canine, Canis familiaris), ATCC CRL-10389 DH82 (Monocyte-macrophage, canine), ATCC CRL-8468 D17 (Osteogenic sarcoma, canine), ATCC CCL-183 D-17 (Primary osteogenic sarcoma, canine, Canis familiaris), ATCC CCL-34.1 DoC11 (S+L-) (Kidney, canine, Canis familiaris), ATCC CCL-34 MDCK (NBL-2) (Kidney, canine, Canis familiaris), and ATCC CCL-34.2 MDCK/SF (Kidney, canine, Canis familiaris), such cell lines expressing, preferably in a stable manner, the desired essential gene(s) for complementation. Particularly preferred complementing cell lines include MDCK cells that stably express CgD, CgB, CUL48, CUL52 and/or CgL.
An additional preferred CHV open reading frame to inactivate, or disrupt, includes a CUS8.5 open reading frame.
While not being bound by theory, it is believed that a reproduction defective virus-based vaccine may be safer than a reproduction competent virus-based vaccine. On the other hand, a reproduction competent virus-based vaccine may be more efficacious than a reproduction defective virus-based vaccine. Since CHV, as disclosed above, exhibits low pathogenicity, a reproduction competent recombinant CHV is a preferred embodiment of the present invention.
As heretofore disclosed, one embodiment of the present invention is a recombinant CHV having one or more inactive genes. Preferred recombinant CHV of the present invention include genomes in which one or more of the following CHV genes have been inactivated, preferably using recombinant techniques: a CdUTPase gene, a CgC gene, a CgE gene, a CgG gene, a CgI gene, a CPK gene, a CTK gene, a CIR6 gene, a CUS2 gene, a CUS9 gene, a CUL49 gene, a CUL51 gene, a CUL45 gene, a CgD gene, a CgB gene, a CUL48 gene, and a CUL52 gene, a CgL gene, a CUL49.5 gene, a CICP0 gene, a CICP4 gene, and a CUS8.5 open reading frame. Other than the genes encoding CgD, CgB, CUL48, CUL52, CgL and CICP4, the preferred genes to inactivate are nonessential genes. Each of the preferred genes to inactivate is a preferred target for the insertion of heterologous nucleic acid molecules; such insertion is a preferred method to inactivate these genes. More preferred recombinant CHV include genomes in which one or more of the following CHV genes have been inactivated, preferably using recombinant techniques: a CdUTPase gene, a CgC gene, a CgE gene, a CgG gene, a CgI gene, a CUS2 gene, a CUS9 gene, a CgD gene, and/or a CgB gene being more preferred. Also preferred are the corresponding recombinant CHV genomes.
Particularly preferred recombinant CHV of this embodiment include a CdUTPase negative CHV, a CgC negative CHV, a CgE negative CHV, a CgG negative CV, a CgI negative CHV, a CPK negative CHV, a CTK negative CHV, a CIR6 negative CHV, a CUS2 negative CHV, a CTK negative CHV, a CUL49 negative CHV, a CUL51 negative CHV, a CUL45 negative CHV, a CgD negative CHV, a CgB negative CHV, a CUL48 negative CHV, a CUL52 negative CHV, a CgL negative CHV, a CUL49.5 negative CHV, a CICP0 negative CHV, a CICP4 negative CHV, and a CUS8.5 negative CHV. Particularly preferred recombinant CHV include a CdUTPase negative CHV, a CgC negative CHV, a CgE negative CHV, a CgG negative CHV, a CgI negative CHV, a CUS2 negative CHV, a CUS9 negative CHV, a CgD negative CHV, and a CgB negative CHV. Also preferred are the corresponding recombinant CHV genomes, as well as recombinant CHV and CHV genomes having more than one of these preferred genes inactivated. Examples of such CHV include, but are not limited to: a CUS2 negative, CdUTPase negative CHV; a CUS2 negative, CdUTPase negative, CgG negative CHV; and a CUS2 negative, CdUTPase negative, CgG negative, CgC negative CHV, a CUL49.5, CdUTPase negative CHV.
One embodiment of the present invention includes a recombinant CHV comprising a recombinant CHV genome comprising a heterologous nucleic acid molecule; i.e., the recombinant CHV genome includes one or more heterologous nucleic acid molecule(s) located, or positioned, in the CHV genome. The present invention also includes a recombinant CHV genome having a heterologous nucleic acid molecule in the genome. Also included is the use of such a CHV and/or CHV genome as a therapeutic composition as well as in the production of a compound encoded by the heterologous nucleic acid molecule(s).
As used herein, a heterologous nucleic acid molecule is a nucleic acid molecule that is not derived from CHV; that is, a heterologous nucleic acid molecule is isolated from a source other than CHV. An isolated nucleic acid molecule of the present invention can be obtained from its natural source, can be produced using recombinant DNA technology (e.g., by amplification, such as by polymerase chain reaction (PCR) amplification and/or cloning) or can be produced by chemical synthesis.
In accordance with the present invention, a heterologous nucleic acid molecule can be inserted into a CHV genome simply to inactivate a CHV gene. A heterologous nucleic acid molecule can also be inserted into a CHV genome to serve as a target for the insertion of a second heterologous nucleic acid molecule, such as to introduce a restriction enzyme site or a recombination site otherwise not present in the CHV genome. For example, CHV strain D 004 (available from ATCC), which does not contain a Sse83871, I-Sce-I, or NotI restriction enzyme site, can be genetically engineered to include one or more sites by inserting into the genome a heterologous nucleic acid molecule containing a Sse83871, I-Sce-I, and/or NotI site(s). Such a heterologous nucleic acid molecule is a good target for the insertion of another heterologous nucleic acid molecule. Other restriction enzyme sites lacking in CHV can be identified using techniques known to those skilled in the art. Without being bound by theory, it is believed that CHV is more likely to lack GC-rich restriction enzyme sites than AT-rich sites, since the CHV genome is AT-rich, as disclosed above.
Another example of a heterologous nucleic acid molecule to insert into a CHV genome is a gene encoding a selectable marker, such as, but not limited to, an E. coli lacZ gene, a green fluorescent protein gene, a chloramphenicol transacetylase gene, a xanthine-guanine phosphoribosyl transferase gene, a .beta.-glucuronidase gene, a neomycin resistance gene, an E. coli hygromycin resistance gene, and a heterologous thymidine kinase gene (e.g., HSV, FHV; assuming the CHV genome is a CTK negative genome). The presence of such a gene in a CHV genome allows for the selection of recombinant CHV having such a marker gene, and includes the ability to distinguish recombinant CHV from natural CHV isolates. In addition, a second heterologous nucleic acid molecule can be inserted into such a selectable marker gene, thereby inactivating the protein encoded by the marker gene, allowing for yet another method to select for CHV having a desirable heterologous nucleic acid molecule. Methods to select CHV having selectable marker genes, as well as for the inactivation of such markers, is known to those skilled in the art.
A preferred embodiment of the present invention is a recombinant CHV genome, and corresponding virus, in which the genome contains a heterologous nucleic acid molecule operatively linked to a transcription control sequence. As such, the heterologous nucleic acid molecule can be transcribed when transfected into a cell. A heterologous nucleic acid molecule can be joined to CHV transcription control sequences, can be joined to its own or other homologous transcription control sequences, and/or can be joined to transcription control sequences heterologous to both the heterologous nucleic acid molecule and CHV. The heterologous nucleic acid molecule can also be operatively linked to other regulatory sequences. Suitable regulatory sequences include any regulatory sequence that can function in the present invention. Preferred transcription control sequences include those sequences that can function in canine cells, including, but not limited to: mammalian, preferably canine; viral; or natural (i.e., endogenous to the heterologous nucleic acid molecule) transcription control sequences. Examples of transcription control sequences include antibiotic resistance gene, baculovirus, Heliothis zea insect virus, vaccinia virus, herpesvirus, poxvirus, adenovirus, simian virus 40, retrovirus, actin, Rous sarcoma virus, heat shock, and mammalian hormone transcription control sequences. Additional suitable transcription control sequences include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins). In one embodiment, expression of a heterologous nucleic acid molecule inserted into a CHV genome is mediated, at least in part, by a human cytomegalovirus (CMV) immediate early promoter and a bovine growth hormone polyadenylation site.
A heterologous nucleic acid molecule of the present invention can be located in any region of the CHV genome (i.e., in the UL, US, and/or IR regions), including, but not limited to, in an essential gene, in a non-essential gene, or in an intergenic region. As such, a heterologous nucleic acid molecule can be located in a coding region, a regulatory region, an intron, an untranslated region, or a non-transcribed region of a gene. A heterologous nucleic acid molecule can also be located in a direct or inverted repeat, including direct and/or inverted repeats within the IR, US or UL regions of CHV. For example, a heterologous nucleic acid molecule can be located in one or more CHV origins of replication (Cori), such as in CoriS.
In one embodiment, a heterologous nucleic acid molecule is located in a CHV genome such that a gene is inactivated. Suitable and preferred gene targets are as disclosed above, with non-essential gene targets being preferred.
In another embodiment, a heterologous nucleic acid molecule is located in a region of the CHV genome spanning from about the 3' end of the coding region of the CUL41 gene through about the 3' end of the coding region of the CUL38 gene. CUL41 gene refers to the CHV homolog of the HSV virion host shutoff protein UL41 gene. CUL38 gene refers to the CHV homolog of the HSV capsid protein VP19C UL38 gene. In most herpesviruses analyzed by cloning and sequencing techniques to date, the region between UL41 and UL38 contains genes encoding the large and small subunits of ribonucleotide reductase. The inventors have found, however, that the ribonucleotide reductase genes appear to be at least partially deleted in CHV in such a manner that there is an intergenic target in that region for heterologous nucleic acid molecule insertion.
A preferred recombinant CHV genome of the present invention comprises a heterologous nucleic acid molecule located in a region of the genome such that the heterologous nucleic acid molecule-containing CHV genome can be easily distinguished from a CHV genome not containing the heterologous nucleic acid molecule; that is, the heterologous nucleic acid molecule is inserted into a selectable region of the genome. Suitable selectable regions include any region of the CHV genome that, upon introduction of a heterologous nucleic acid molecule, leads to a detectable (e.g., growth-related, biochemical, or molecular) change in the CHV genome or CHV containing the genome. Examples of such selectable regions include, but are not limited to, a CTK gene and a CdUTPase gene. CHV genomes in which a heterologous nucleic acid molecule is inserted into a CTK gene or a CdUTPase gene can be selected using methods known to those skilled in the art; see for example, Kit et al, 1983, Virology 130, 381-389; and Holliday et al, 1991, Antiviral Research 16, 197-203.
Additional examples of selectable regions include restriction endonuclease sites, such as the HindIII site or XbaI site in the CdUTPase gene and the AscI site in the CUS2 gene. The AscI site is particularly preferred as there are no other AscI sites in the CHV genome. As such, a particularly preferred CHV of the present invention is a recombinant CHV having a CHV genome including a heterologous nucleic acid molecule in an AscI site in the CHV genome. Even more preferred is recombinant CHV strain D 004 having a heterologous nucleic acid molecule in an AscI site in the CHV genome. Also preferred are the corresponding genomes. Examples of methods to insert a heterologous nucleic acid molecule into a genome, including into restriction endonuclease site(s) in the genome, are disclosed herein. Such methods are known to those skilled in the art.
One embodiment of the present invention is a recombinant CHV genome having a heterologous nucleic acid molecule in one of the following regions of the CHV genome: a region spanning the 9,300 nucleotide AscI restriction endonuclease fragment, denoted herein as nCAsc.sub.9300, that apparently includes the entire US region; a region spanning the 10,000 nucleotide fragment from AscI to the end of the genome, denoted herein as nCAsc.sub.10000, that apparently essentially comprises an IR region, including the CIR6 gene; a region spanning the 3,000 nucleotide HindIII fragment, denoted herein as nCHin.sub.3000, that spans from a portion of CUL48 through a portion of the CdUTPase gene; a region spanning the 1,900 nucleotide HindIII fragment, denoted herein as nCHin.sub.1900, that includes the remainder of the CdUTPase gene through a portion of CUL52; a region spanning the 5,500 nucleotide HindIII fragment, denoted herein as nCHin.sub.5500, that includes at least a portion of CgL, CICP0, and CICP4; and/or a region spanning the 8,500 nucleotide HindIII fragment, denoted herein as nCHin.sub.8500, that includes a portion of CUL48, CUL45 and CgC. Details regarding the production of these and certain other nucleic acid molecules of the present invention are provided in the Examples section.
Also included in the present invention is a recombinant CHV genome having a heterologous nucleic acid molecule in a region of the genome spanning at least one of the following: a CHV US region comprising nCUS.sub.5495, a CHV UL region comprising nCgC/CUL45.sub.2100, a CgE gene comprising nCgE.sub.750, a CgI gene comprising nCgI.sub.161, a CUS9 gene comprising nCUS9.sub.579, a CHV UL region comprising nCdUTP/CUL51.sub.743, a CTK gene comprising nCTK.sub.280, a CUL48 gene comprising nCUL48.sub.294, a CUL49 gene included in nCHin.sub.3000, a CUL52 gene comprising nCUL52.sub.146, a CHV UL region comprising nCUL.sub.1823, a CHV UL region comprising nCUL49/CUL48.sub.2044, a CHV IR region comprising nCICP4.sub.626, a CHV UL region comprising nCgL.sub.655, a CHV UL region comprising nCUL52.sub.749, a CHV UL region comprising nCdUTP.sub.3200, as well as allelic variants of such (i.e., said, any of these) regions. As such, the present invention also includes a recombinant CHV genome having a heterologous nucleic acid molecule in a region of the genome spanning at least one of the following: a CIR6 gene including nCIR6.sub.552, a CUS2 gene including nCUS2.sub.1176, a CPK gene including nCPK.sub.1203, a CgG gene including nCgG.sub.1248, a CgD gene including nCgD.sub.357, a CdUTPase gene including nCdUTP.sub.459, a CUL51 gene including nCUL51.sub.261, a CgD gene including nCgD.sub.1038, a CgI gene including nCgI.sub.1095, a CgE gene including nCgE.sub.1569, a CUS8.5 open reading frame including nCUS8.5.sub.237, a CUS9 gene including nCUS9.sub.360, a CUL49 gene including nCUL49.sub.420, a CUL48 gene including nCUL48.sub.1269, a CICP4 gene including nCICP4.sub.626, a CgL gene including nCgL.sub.655, a CdUTPase gene including nCdUTP.sub.918, a CUL49 gene including nCUL49.sub.255, a CUL49.5 gene including nCUL49.5.sub.261, and a CUL52 gene including nCUL52.sub.749, as well as allelic variants of such regions.
As used herein, an allelic variant of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a nucleic acid molecule, or region, that occurs at essentially the same locus in another CHV genome as the nucleic acid molecule in CHV strain D 004, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic variant can also comprise an alteration in the 5' or 3' untranslated regions of the gene, such as in regulatory control regions. Allelic variants are well known to those skilled in the art and would be expected to be found among the family of canine herpesviruses.
The present invention also includes a recombinant CHV genome having a heterologous nucleic acid molecule in a region of the genome spanning at least one of the following nucleic acid molecules: nCUS.sub.5495 (and, as such, nCIR6.sub.552, nCUS2.sub.1176, nCPK.sub.1203, nCgG.sub.1248, and/or nCgD.sub.357), nCgC/CUL45.sub.2100, nCgE.sub.750, nCgI.sub.161, nCUS9.sub.579, nCdUTP/CUL51.sub.743 (and, as such, nCdUTP.sub.459 and nCUL51.sub.261), nCTK.sub.2801 nCUL48.sub.294, nCUL52.sub.146, nCUS.sub.10592, nCgD.sub.1038, nCgI.sub.1095, nCgE.sub.1569, nCUS8.5.sub.237, nCUS9.sub.360, nCUL49/CUL48.sub.2044, nCUL49.sub.420, nCUL48.sub.1269, nCICP4.sub.626, nCgL.sub.655, nCUL.sub.1823, nCdUTP.sub.918, nCUL49.5.sub.261, nCUL49.sub.255, nCUL52.sub.749, and/or nCdUTP.sub.3200, as well as allelic variants of such regions.
A particularly preferred CHV genome of the present invention includes a heterologous nucleic acid molecule located in a region of the CHV genome comprising (e.g., including, represented by, or identified by) at least one of the following nucleic acid sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:86, and/or SEQ ID NO:87, as well as complements of such regions and allelic variants of such regions. The relationships between certain nucleic acid molecules and nucleic acid sequences of the present invention are detailed below. It should be noted that since nucleic acid sequencing technology is not entirely error-free, the sequences represented by the SEQ ID NOs in the present invention at best represent apparent nucleic acid or amino acid sequences of CHV nucleic acid molecules or proteins of the present invention. It is also to be noted that a double-stranded nucleic acid molecule of the present invention for which a nucleic acid sequence has been determined for one strand that is represented by a SEQ ID NO also comprises a complementary strand having a sequence that is a complement of that SEQ ID NO. As such, nucleic acid molecules of the present invention, which can be either double-stranded or single-stranded, include those nucleic acid molecules that form stable hybrids under stringent hybridization conditions with either a given SEQ ID NO denoted herein and/or with the complement of that SEQ ID NO, which may or may not be denoted herein. Methods to deduce a complementary sequence are known to those skilled in the art.
The present invention includes a recombinant CHV genome that includes a heterologous nucleic acid molecule that encodes a protective compound; the present invention also includes a recombinant CHV containing such a genome. As used herein, a protective compound is a compound that when administered to an animal protects that animal from a disease corresponding to that compound. For example, a compound derived from Dirofilaria immitis protects an animal from heartworm and other related infections, whereas a compound derived from a virus protects an animal from disease caused by that and related viruses. As used herein, the ability of a compound to protect an animal from a disease refers to the ability of that protective compound to treat, ameliorate and/or prevent the disease.
A protective compound of the present invention includes, but is not limited to, a protective protein and a protective RNA species. Essentially any heterologous nucleic acid molecule that encodes a protective protein or RNA can be used in the present invention. A protective protein of the present invention can be, for example, an immunogen that elicits an immune response which will protect an animal from the corresponding disease or some other compound (e.g., an immunomodulator, a toxin, an enzyme, an antibody, or other binding protein) that neutralizes and/or reduces the disease. A protective RNA of the present invention can be, for example, an RNA-based drug, a ribozyme, a molecule capable of triple helix formation, or an antisense RNA that effectively prevents the expression of a detrimental protein, thereby protecting an animal from disease.
It is within the scope of the present invention to produce therapeutic compositions against a variety of diseases, including infectious diseases, genetic diseases, and other metabolic diseases, including diseases that lead to abnormal cell growth, degenerative processes, and/or immunological defects. Therapeutic compositions of the present invention can protect animals from a variety of diseases including, but not limited to, allergies, autoimmune diseases, cancers, cardiovascular diseases, graft rejection, hematopoietic disorders, immunodeficiency diseases, immunoproliferative diseases, immunosuppressive disorders, infectious diseases, inflammatory diseases, jaundice, septic shock, other immunological defects, as well as other genetic or metabolic defects.
One preferred embodiment of the present invention is a recombinant CHV having a heterologous nucleic acid molecule within its genome that encodes a compound that protects a canid, or other animal susceptible to CHV infection, from infectious disease. Such disease can be caused by a variety of infectious agents, including, but not limited to, helminth parasites, protozoan parasites, ectoparasites, fungi (including yeast), bacteria and/or viruses. It should also be noted that although some infectious agents have not been definitively classified into one of these groups, such infectious agents are also included in the present invention. A preferred protective compound is derived from (e.g., obtained from natural source or produced using recombinant or synthetic chemistry techniques) an infectious agent.
Preferred helminth infectious agents to target include nematodes, cestodes and trematodes, with filariid, ascarid, capillarid, strongylid, strongyloides, trichostrongyle, and trichurid, parasitic helminths being more preferred, and filariid nematodes being even more preferred. More preferred parasitic helminths to target include the following: Aelurostrongylus, Ancylostoma, Angiostrongylus, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Crenosoma, Dictyocaulus, Dioctophyme, Dipetalonema, Diphyllobothrium, Diplydium, Dirofilaria (e.g., D. immitis), Dracunculus, Echinococcus, Enterobius, Filaroides, Haemonchus, Loa, Mansonella, Muellerius, Nanophyetus, Necator, Nematodirus, Oesophagostomum, Onchocerca, Opisthorchis, Ostertagia, Parafilaria, Paragonimus, Parascaris, Physaloptera, Protostrongylus, Setaria, Spirometra, Spirocera, Stephanofilaria, Strongyloides, Strongylus, Taenia, Thelazia, Toxascaris, Toxocara, Trichinella, Trichostrongylus, Trichuris. Uncinaria, and Wuchereria . More preferred helminths to target, particularly with respect to being canine pathogens include Ancylostoma, Angiostrongylus, Brugia, Capillaria, Crenosoma, Dioctophyme, Dipetalonema, Diphyllobothrium, Diplydium, Dirofilaria, Echinococcus, Filaroides, Nanophyetus, Opisthorchis, Paragonimus, Physaloptera, Spirometra, Spirocera, Strongyloides, Taenia, Toxascaris, Toxocara, Trichinella, Trichuris, and Uncinaria.
Preferred protozoal infectious agents to target include Acetospora, Apicoplexa, Ciliophora, Labyrinthomorphorpha, Microspora, Myxozoa and Sarcomastigophora, with Babesia, Balantidium, Besnoitia, Cryptosporidium, Eimeria, Encephalitozoon, Entamoeba, Giardia, Hammondia, Hepatozoon, Isospora, Leishmania, Microsporidia, Neospora, Nosema, Pentatrichomonas, Plasmodium, Pneumocystis, Sarcocystis, Schistosoma, Theileria, Toxoplasma, and Trypanosoma, being more preferred. More preferred protozoans to target, particularly with respect to being canine pathogens, include Babesia, Balantidium, Besnoitia, Cryptosporidium, Encephalitozoon, Entamoeba, Giardia, Hammondia, Hepatozoon, Isospora, Leishmania, Microsporidia, Neospora, Pentatrichomonas, Pneumocystis, Sarcocystis, Schistosoma, Toxoplasma, and Trypanosoma.
Preferred ectoparasite infectious agents to target include fleas, flies, mosquitoes, ticks, mites, lice, spiders, ants and true bugs, with fleas being more preferred. More preferred are fleas of the genera Ctenocephalides, Ctopsyllus, Diamanus, Echidnophaga Nosopsyllus, Pulex, Tunga, and Xenopsylla, with Ctenocephalides canis and Ctenocephalides felis fleas being particularly preferred.
Preferred fungal agents include Absidia, Acremonium, Alternaria, Aspergillus, Basidiobolus, Bipolaris, Blastomyces, Candida, Chlamydia, Coccidioides, Conidiobolus, Cryptococcus, Curvalaria, Epidermophyton, Exophiala, Geotrichum, Histoplasma, Madurella, Malassezia, Microsporum, Moniliella, Mortierella, Mucor, Paecilomyces, Penicillium, Phialemonium, Phialophora, Prototheca, Pseudallescheria, Pseudomicrodochium, Pythium, Rhinosporidium, Rhizopus, Scolecobasidium, Sporothrix, Stemphylium, Trichophyton, Trichosporon, and Xylohypha.
Preferred bacterial infectious agents to target include Actinomyces, Bacillus, Bacteroides, Bordetella, Bartonella (e.g., B. henselae), Borrelia (e.g., B. burgdorferi), Brucella, Campylobacter, Capnocytophaga, Clostridium, Corynebacterium, Coxiella, Dermatophilus, Enterococcus, Ehrlichia (e.g., E. canis), Escherichia, Francisella, Fusobacterium, Haemobartonella, Helicobacter, Klebsiella, L-form bacteria, Leptospira, Listeria, Mycobacteria, Mycoplasma, Neorickettsia, Nocardia, Pasteurella, Peptococcus, Peptostreptococcus, Proteus, Pseudomonas, Rickettsia, Rochalimaea, Salmonella, Shigella, Staphylococcus, Streptococcus, and Yersinia (e.g., Y. pestis).
Preferred virus infectious agents to target include adenoviruses, caliciviruses, coronaviruses, distemper viruses, hepatitis viruses, herpesviruses, immunodeficiency viruses, infectious peritonitis viruses, leukemia viruses, oncogenic viruses, panleukopenia viruses, papilloma viruses, parainfluenza viruses, parvoviruses, rabies viruses, and reoviruses, as well as other cancer-causing or cancer-related viruses.
A preferred recombinant CHV of the present invention includes a recombinant CHV genome having a heterologous nucleic acid molecule encoding a protective compound that elicits an immune response. As used herein, a protective compound that elicits an immune response refers to a compound that when administered to an animal in an appropriate manner, known to those skilled in the art, leads to the production of an immune response in that animal against the protective compound. The immune response, which can include humoral and/or cell-mediated components, preferably protects the immunized animal against the disease(s) targeted by the protective compound. As such, preferred protective compounds include, but are not limited to, antigens associated with diseases, as disclosed herein. Particularly preferred protective compounds of the present invention include Dirofilaria immitis antigens, Toxoplasma gondii antigens, Sarcocystis antigens, Bartonella henselae antigens, Yersinia pestis antigens, flea antigens, flea allergens, viral antigens, and cancer antigens. Even more preferred protective compounds are those disclosed in the following patent applications and patent publications, which are incorporated by reference herein in their entireties: U.S. Pat. No. 5,356,622, issued Oct. 18, 1994; U.S. Pat. No. 5,399,485, issued Mar. 21, 1995; U.S. Pat. No. 5,418,137, issued May 23, 1995; PCT Publication No. WO 92/13560, published Aug. 20, 1992; PCT Publication No. WO 93/10225, published May 27, 1993; PCT Publication No. WO 93/23077, published Nov. 25, 1993; PCT Publication No. WO 94/15593, published Jul. 21, 1994; PCT Publication No. WO 94/17813, published Aug. 18, 1994; PCT Publication No. WO 94/17824, published Aug. 18, 1994; PCT Publication No. WO 95/24198, published Sep. 14, 1995; PCT Publication No. WO 95/32988, published Dec. 7, 1995; U.S. Ser. No. 08/401,509, filed Mar. 9, 1995; U.S. Ser. No. 08/415,365, filed Mar. 30, 1995; U.S. Ser. No. 08/450,944, filed May 23, 1995; U.S. Ser. No. 08/473,034, filed Jun. 6, 1995; U.S. Ser. No. 08/482,304, filed Jun 7, 1995; U.S. Ser. No. 08/485,434, filed Jun. 7, 1995; U.S. Ser. No. 08/486,036, filed Jun. 7, 1995; U.S. Ser. No. 08/558,735 filed Nov. 16, 1995; PCT Ser. No. PCT/US95/13200, filed Oct. 6, 1995; PCT Ser. No. PCT/US95/14442, filed Oct. 18, 1995; U.S. Ser. No. 08/630,822, filed Apr. 10, 1996; U.S. Ser. No. 08/602,262, filed Feb. 15, 1996; PCT Ser. No.: PCT/US96/03133, filed Mar. 8, 1996; U.S. Ser. No. 08/639,075, filed Apr. 24, 1996; PCT Ser. No. PCT/US96/07709, filed May 23, 1996; and PCT Ser. No. PCT/US96/09848, filed Jun. 7, 1996, and related filings.
Another preferred protective compound of the present invention is an immunomodulator. Suitable immunomodulators include compounds that enhance the immune response as well as compounds that suppress the immune response. Compounds that enhance the immune response include compounds that preferentially enhance humoral immunity as well as compounds that preferentially enhance cell-mediated immunity. Suitable compounds can be selected depending on the disease being targeted. Suitable immunomodulators include, but are not limited to, cytokines, chemokines, superantigens, and other immunomodulators as well as compounds that induce the production of cytokines, chemokines and other immunomodulators. Examples of such protective compounds include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interferon gamma, interferon gamma inducing factor I (IGIF), transforming growth factor beta (TGF-.beta.), RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), and Leishmania elongation initiating factor (LEIF).
One preferred embodiment of the present invention is a recombinant CHV having more than one heterologous nucleic acid molecule included in the CHV genome. Such a CHV can include two or more heterologous nucleic acid molecules encoding two or more protective compounds to protect an animal from a given disease (e.g., two or more heartworm antigens), or can include two or more heterologous nucleic acid molecules encoding protective compounds each targeted against a different disease (e.g., a compound to protect an animal against heartworm and a compound to protect an animals against a viral infection). A preferred multivalent CHV can also include an heterologous nucleic acid molecule encoding a protective compound that elicits an immune response as well as an heterologous nucleic acid molecule encoding an immunomodulator to enhance the desired immune response. Also included in the present invention are protective compounds that are fusion, or multivalent, proteins comprising more than one functional domain.
The present invention also includes recombinant CHV genomes. As such, the invention includes any CHV genome disclosed herein, including those included in recombinant CHV of the present invention. Also included in the present invention are cells comprising recombinant CHV genomes of the present invention. As used herein, a cell comprising a recombinant CHV genome is a cell into which a recombinant CHV genome has been introduced. Such introduction can be accomplished by any method by which a nucleic acid molecule can be inserted into a cell. Such methods, known to those skilled in the art, include, but are not limited to, infection (i.e., with a virus comprising the genome), transfection, transformation, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. A preferred cell comprises a recombinant CHV having a heterologous nucleic acid molecule, which preferably is operatively linked to a transcription control sequence. Cells containing CHV genomes are useful in the production of recombinant CHV. Methods to produce recombinant CHV are disclosed herein.
The present invention also includes isolated CHV nucleic acid molecules. As used herein, a CHV nucleic acid molecule is a nucleic acid molecule that is derived from CHV. As such, the nucleic acid molecule can be produced, for example, by recovery of such a nucleic acid molecule directly from a CHV genome, by recombinant DNA techniques, or by chemical synthesis. That the CHV nucleic acid molecule is isolated indicates that the molecule is removed from its natural milieu. An isolated CHV nucleic acid molecule can include DNA, RNA, or derivatives of either DNA or RNA.
A preferred CHV nucleic acid molecule of the present invention is a CHV nucleic acid molecule that hybridizes under stringent hybridization conditions with at least one of the following: with a CdUTPase gene, a CgC gene, a CgE gene, a CgG gene, a CgI gene, a CPK gene, a CTK gene, a CIR6 gene, a CUS2 gene, a CUS9 gene, a CUL49 gene, a CUL51 gene, a CUL45 gene, a CgD gene, a CUL48 gene, a CgL gene, a CUL49.5 gene, a CICP4 gene, a CUS8.5 open reading frame, and/or a CUL52 gene; with other regions of a CUS; and/or with a region of the CHV genome spanning from about the 3' end of the coding region of the CUL41 gene through about the 3' end of the coding region of the CUL38 gene. The identifying characteristics of such regions, including the CHV genes listed, are heretofore described.
As used herein, stringent hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules, including oligonucleotides, are used to identify molecules having similar nucleic acid sequences. Stringent hybridization conditions typically permit isolation of nucleic acid molecules having at least about 70% nucleic acid sequence identity with the nucleic acid molecule being used as a probe in the hybridization reaction. Formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting 30% or less mis-match between two nucleic acid molecules are disclosed, for example, in Meinkoth et al, 1984, Anal. Biochem 138, 267-284; Meinkoth et al, ibid, is incorporated by reference herein in its entirety. An example of such conditions includes, but is not limited to, the following: Oligonucleotide probes of about 18-25 nucleotides in length with T.sub.m 's ranging from about 50.degree. C. to about 65.degree. C., for example, can be hybridized to nucleic acid molecules typically immobilized on a filter (e.g., nitrocellulose filter) in a solution containing 2.times. SSPE, 1% Sarkosyl, 5.times. Denhardts and 0.1 mg/ml denatured salmon sperm DNA at a temperature as calculated using the formulae of Meinkoth et al., ibid. for about 2 to about 12 hours. The filters are then washed 3 times in a wash solution containing 2.times. SSPE, 1% Sarkosyl at about 55.degree. C. for about 15 minutes each. The filters can be further washed in a wash solution containing 2.times. SSPE, 1% Sarkosyl at about 55.degree. C. for about 15 minutes per wash.
A CHV nucleic acid molecule of the present invention can include an isolated natural CHV gene or a homolog thereof, the latter of which is described in more detail below. A CHV nucleic acid molecule of the present invention can include one or more regulatory regions, full-length or partial coding regions, or combinations thereof. The minimal size of a CHV nucleic acid molecule of the present invention is the minimal size that can form a stable hybrid with one of the aforementioned CHV genes and other regions under stringent hybridization conditions.
Isolated CHV nucleic acid molecules include natural nucleic acid molecules and homologs thereof, including, but not limited to, natural allelic variants and modified nucleic acid molecules in which nucleotides have been inserted, deleted, substituted, and/or inverted in such a manner that such modifications do not substantially interfere with the nucleic acid molecule's ability to encode a CHV protein of the present invention or to form stable hybrids under stringent conditions with natural gene isolates.
A CHV nucleic acid molecule homolog can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al., ibid.). CHV nucleic acid molecule homologs can be selected from a mixture of modified nucleic acids by screening for the function of the protein encoded by the nucleic acid molecule and/or by hybridization with a CHV region as defined above.
An isolated CHV nucleic acid molecule of the present invention can include a nucleic acid sequence that encodes at least one CHV protein of the present invention; such proteins are discussed in further detail below. Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a CHV protein.
One embodiment of the present invention is a CHV nucleic acid molecule that, when administered to an animal, is capable of protecting that animal from CHV infection. Such a CHV nucleic acid molecule can be, or encode, an antisense RNA, a molecule capable of triple helix formation, a ribozyme, or other nucleic acid-based drug compound. In an additional embodiment, a CHV nucleic acid molecule of the present invention can encode a protective protein, the nucleic acid molecule being delivered to the animal by direct injection (i.e, as a naked nucleic acid) or in a vehicle such as a recombinant virus vaccine or a recombinant cell vaccine.
One embodiment of the present invention is a CHV nucleic acid molecule that hybridizes under stringent hybridization conditions with nCUS.sub.5495, nCgC/CUL45.sub.2100, nCgE.sub.750, nCgI.sub.161, nCUS9.sub.579, nCdUTP/CUL51.sub.743, nCTK.sub.280, nCUL48.sub.294, a nCUL49 included in nCHin.sub.3000, nCUL521.sub.46, nCgI.sub.1095, nCgE.sub.1569, nCUS8.5.sub.237, nCUS9.sub.360, nCUL49/CUL48.sub.2044, nCUL49.sub.420, nCUL48.sub.1269, nCICP4.sub.626, nCgL.sub.655, nCUL.sub.1823, nCdUTP.sub.918, nCUL49.5.sub.261, nCUL49.sub.255, and/or nCUL52.sub.749. Such a CHV nucleic acid molecule can also hybridize under stringent hybridization conditions with nCAsc.sub.9300, nCAsc.sub.10000, nCHin.sub.3000, nCHin.sub.1900, nCHin.sub.5500, nCHin.sub.8500, nCIR6.sub.552, nCUS2.sub.1176, nCPK.sub.1203, nCgG.sub.1248, nCgD.sub.357, nCdUTP.sub.459, nCTK.sub.279, nCUS9.sub.450, nCUL48.sub.291, nCUL51.sub.261, nCUL52.sub.144, nCgI.sub.159, nCUS.sub.10592, nCICP4.sub.624, nCgL.sub.516, nCUL52.sub.747, nCdUTP.sub.858, and/or nCdUTP.sub.3200. At least some of such CHV nucleic acid molecules can hybridize under stringent hybridization conditions with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:85, SEQ ID NO:86, and/or SEQ ID NO:87, as well as complements of such sequences.
SEQ ID NO:1 and SEQ ID NO:2 represent the deduced nucleic acid sequences of the two complementary strands of nCUS.sub.5495. Translation of SEQ ID NO:1 and SEQ ID NO:2 indicates that nucleic acid molecule nCUS.sub.5495 encodes CIR6, CUS2, CPK and CgG proteins as well as a portion of a CgD protein. Specifically, SEQ ID NO:2 includes: a coding region for a CIR6 protein of about 183 amino acids, denoted herein as nCIR6.sub.552 and represented by SEQ ID NO:3, assuming a start codon spanning about nucleotides 4566-4568 and a stop codon spanning about nucleotides 5115-5117 of SEQ ID NO:2; and a coding region for a CUS2 protein of about 391 amino acids, denoted herein as nCUS2.sub.1176 and represented by SEQ ID NO:5, assuming a start codon spanning about nucleotides 3232-3234 and a stop codon spanning about nucleotides 4405-4407 of SEQ ID NO:2. The amino acid sequences of the respective encoded proteins PCIR6.sub.183 and PCUS2.sub.391 are represented by SEQ ID NO:4 and SEQ ID NO:6. SEQ ID NO:1 includes: a coding region for a CPK protein of about 400 amino acids, denoted herein as nCPK.sub.1203 and represented by SEQ ID NO:7, assuming a start codon spanning about nucleotides 2384-2386 and a stop codon spanning about nucleotides 3584-3586 of SEQ ID NO:1; a coding region for a CgG protein of about 415 amino acids, denoted herein as nCgG.sub.1248 and represented by SEQ ID NO:9, assuming a start codon spanning about nucleotides 3698-3700 and a stop codon spanning about nucleotides 4943-4945 of SEQ ID NO:1; and a partial coding region for a CgD protein of about 119 amino acids, denoted herein as nCgD.sub.357 and represented by SEQ ID NO:11, assuming a start codon spanning about nucleotides 5137-5139. The amino acid sequences of the respective encoded proteins PCPK.sub.400, PCgG.sub.415, and PCgD.sub.119 are represented by SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12.
SEQ ID NO:13 and SEQ ID NO:14 represent the deduced nucleic acid sequences of the two complementary strands of nCdUTP/CUL51.sub.743. SEQ ID NO:13 includes a partial coding region for a CdUTPase protein of about 152 amino acids, denoted herein as nCdUTP.sub.459 and represented by SEQ ID NO:15, assuming a first in-frame codon spanning about nucleotides 3-5, and a stop codon spanning about nucleotides 459-461 of SEQ ID NO:13. The amino acid sequence of the encoded protein PCdUTP.sub.152 is represented by SEQ ID NO:16. SEQ ID NO:14 includes a partial coding region for a CUL51 protein of about 86 amino acids, denoted herein as nCUL51.sub.261 and represented by SEQ ID NO:33, assuming a first in-frame codon spanning about nucleotides 1-3, and a stop codon spanning about nucleotides 259-261 of SEQ ID NO:14. The amino acid sequence of the encoded protein PCUL51.sub.86 is represented by SEQ ID NO:34.
SEQ ID NO:17 and SEQ ID NO:19 represent the deduced nucleic acid sequences of the two complementary strands of nCUS9.sub.579. SEQ ID NO:17 includes a coding region for a CUS9 protein of about 149 amino acids, denoted herein as nCUS9.sub.450 and represented by SEQ ID NO:20, assuming a start codon spanning about nucleotides 54-56 and a stop codon spanning about nucleotides 501-503 of SEQ ID NO:17. The amino acid sequence of the encoded protein PCUS9.sub.149 is represented by SEQ ID NO:18.
SEQ ID NO:21 and SEQ ID NO:23 represent the deduced nucleic acid sequences of the two complementary strands of nCUL48.sub.294. SEQ ID NO:21 includes a partial coding region for a CUL48 protein of about 97 amino acids, denoted herein as nCUL48.sub.291 and represented by SEQ ID NO:24, assuming a first in-frame codon spanning about nucleotides 3-5 of SEQ ID NO:21. The amino acid sequence of the encoded protein PCUL48.sub.97 is represented by SEQ ID NO: 22.
SEQ ID NO:25 and SEQ ID NO:27 represent the deduced nucleic acid sequences of the two complementary strands of nCUL52.sub.146. SEQ ID NO:25 includes a partial coding region for a CUL52 protein of about 48 amino acids, denoted herein as nCUL52.sub.144 and represented by SEQ ID NO:28, assuming a first in-frame codon spanning about nucleotides 1-3 of SEQ ID NO:25. The amino acid sequence of the encoded protein PCUL52.sub.48 is represented by SEQ ID NO:26.
SEQ ID NO:29 and SEQ ID NO:31 represent the deduced nucleic acid sequences of the two complementary strands of nCgI.sub.161. SEQ ID NO:29 includes a partial coding region for a CgI protein of about 53 amino acids, denoted herein as nCgI.sub.159 and represented by SEQ ID NO:32, assuming a first in-frame codon spanning about nucleotides 3-5 of SEQ ID NO:29. The amino acid sequence of the encoded protein PCgI.sub.53 is represented by SEQ ID NO:30.
SEQ ID NO:35 and SEQ ID NO:37 represent the deduced nucleic acid sequences of the two complementary strands of nCTK.sub.280. SEQ ID NO:35 includes a partial coding region for a CTK protein of about 93 amino acids, denoted herein as nCTK.sub.279 and represented by SEQ ID NO:38, assuming a first in-frame codon spanning about nucleotides 2-4 of SEQ ID NO:35. The amino acid sequence of the encoded protein PCTK.sub.93 is represented by SEQ ID NO:36.
The identities of additional nucleic acid molecules, nucleic acid sequences, proteins, and amino acid sequences are presented in the Examples.
Comparison of the CHV nucleic acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:87 with known sequences indicates that none of these CHV nucleic acid sequences share more than about 70% identity (many, if not all, sharing significantly less identity) with a known nucleic acid sequence. As such, a preferred CHV nucleic acid molecule has a nucleic acid sequence that is at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95%, and even more preferably at least about 99% identical to nucleic acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:86, and/or SEQ ID NO:87, as well as complements of such sequences.
A more preferred CHV nucleic acid molecule of the present invention includes at least a portion of CHV nucleic acid molecule nCAsc.sub.9300, nCAsc.sub.10000, nCHin.sub.3000, nCHin.sub.1900, nCHin.sub.5500, nCHin.sub.8500, nCUS.sub.5495, nCIR6.sub.552, nCUS2.sub.1176, nCPK.sub.1203, nCgG.sub.1248, nCdUTP/CUL51.sub.743, nCdUTP.sub.459, nCUS9.sub.579, nCUS9.sub.450, nCUL48.sub.294, nCUL48.sub.291, nCUL52.sub.146, nCUL52.sub.144, nCgI.sub.161, nCgI.sub.159, nCgE.sub.750, nCTK.sub.280, nCTK.sub.279, nCUL51.sub.261, nCUS.sub.10592, nCgI.sub.1095, nCgE.sub.1569, nCUS8.5.sub.237, nCUS9.sub.360, nCUL49/CUL48.sub.2044, nCUL49.sub.420, nCUL48.sub.1269, nCICP4.sub.626, nCICP4.sub.624, nCgL.sub.655, nCgL.sub.516, nCUL.sub.1823. nCdUTP.sub.918, nCUL49.5.sub.261, nCUL49.sub.255, nCUL52.sub.749, nCUL52.sub.747, nCdUTP.sub.858, and/or nCdUTP.sub.3200, as well as allelic variants of those CHV nucleic acid molecules. Such CHV nucleic acid molecules can include nucleotides in addition to those included in the defined fragments; examples of such CHV nucleic acid molecules include full-length genes, full-length coding regions, or nucleic acid molecules encoding multivalent proteins. Particularly preferred CHV nucleic acid molecules are nCAsc.sub.9300, nCAsc.sub.10000, nCHin.sub.3000, nCHin.sub.1900, nCHin.sub.5500, nCHin.sub.8500, nCUS.sub.5495, nCIR6.sub.552, nCUS2.sub.1176, nCPK.sub.1203, nCgG.sub.1248, nCdUTP/CUL51.sub.743, nCdUTP.sub.459, nCUS9.sub.579, nCUS9.sub.450, nCUL48.sub.294, nCUL48.sub.291, nCUL52.sub.146, nCUL52.sub.144, nCgI.sub.161, nCgI.sub.159, nCgE.sub.750, nCTK.sub.280, nCTK.sub.279, nCUL51.sub.261, nCUS.sub.10592, nCgI.sub.1095, nCgE.sub.1569, nCUS8.5.sub.237, nCUS9.sub.360, nCUL49/CUL48.sub.2044, nCUL49.sub.420, nCUL48.sub.1269, nCICP4.sub.626, nCICP4.sub.624, nCgL.sub.655, nCgL.sub.516, nCUL.sub.1823, nCdUTP.sub.918, nCUL49.5.sub.261, nCUL49.sub.255, nCUL52.sub.749, nCUL52.sub.747, nCdUTP.sub.858, and/or nCdUTP.sub.3200.
Similarly, a preferred CHV nucleic acid molecule of the present invention includes at least a portion of nucleic acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:86, and/or SEQ ID NO:87; or a complement of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:38, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, and/or SEQ ID NO:87; as well as allelic variants of such nucleic acid molecules. More preferred is a nucleic acid molecule that includes at least one of the following nucleic acid sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28f SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:86, and/or SEQ ID NO:87; or a complement of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:38, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, and/or SEQ ID NO:87; also included are nucleic acid molecules that are allelic variants of nucleic acid molecules having those nucleic acid sequences. Such nucleic acid molecules can include nucleotides in addition to those included in the SEQ ID NOs.
The present invention also includes CHV nucleic acid molecules encoding a protein, including nucleic acid molecules that have been modified to accommodate codon usage properties of the cells in which such nucleic acid molecules are to be expressed. CHV proteins of the present invention are described in more detail below. Particularly preferred nucleic acid molecules are those that encode a protein having at least one of the following amino acid sequences: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, and/or SEQ ID NO:88.
The present invention also includes CHV nucleic acid molecules that are oligonucleotides capable of hybridizing, under stringent hybridization conditions, with complementary regions of other, preferably longer, CHV nucleic acid molecules of the present invention. Oligonucleotides of the present invention can be RNA, DNA, or derivatives of either. The minimal size of such oligonucleotides is the size required to form a stable hybrid between a given oligonucleotide and the complementary sequence on another nucleic acid molecule of the present invention. Minimal size characteristics are disclosed herein. The size of the oligonucleotide must also be sufficient for the use of the oligonucleotide in accordance with the present invention. Oligonucleotides of the present invention can be used in a variety of applications including, but not limited to, as probes to identify additional nucleic acid molecules, as primers to amplify or extend nucleic acid molecules or in therapeutic applications to inhibit CHV infection as disclosed herein.
The present invention also includes an isolated CHV protein encoded by a CHV nucleic acid molecule of the present invention. As such, the present invention includes a CHV protein encoded by a CHV nucleic acid molecule that hybridizes under stringent hybridization conditions with at least one of the following: a CdUTPase gene, a CgC gene, a CgE gene, a CgG gene, a CgI gene, a CPK gene, a CTK gene, a CIR6 gene, a CUS2 gene, a CUS9 gene, a CUL49 gene, a CUL51 gene, a CUL45 gene, a CgD gene, a CUL48 gene, and/or a CUL52 gene; and/or with other portions of a CUS region; and/or with a CgL gene, a CUL49.5 gene, a CICP4 gene, and/or a CUS8.5 open reading frame.
According to the present invention, an isolated, or biologically pure, protein, is a protein that has been removed from its natural milieu. As such, "isolated" and "biologically pure" do not necessarily reflect the extent to which the protein has been purified. An isolated protein of the present invention can be obtained from its natural source, can be produced using recombinant DNA technology or can be produced by chemical synthesis. As used herein, a CHV protein can be a full-length protein or any homolog of such a protein. Examples of CHV homologs include CHV proteins in which amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and/or addition of glycerophosphatidyl inositol) such that the homolog retains a desired activity of the natural protein, such as, but not limited to, enzymatic activity, activity important for viral growth, and/or ability to elicit an immune response. These activities can be measured using techniques known to those skilled in the art.
CHV protein homologs can be the result of natural allelic variation or natural mutation. CHV protein homologs of the present invention can also be produced using techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the gene encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis.
The minimal size of a CHV protein homolog of the present invention is a size sufficient to be encoded by a nucleic acid molecule capable of forming a stable hybrid (i.e., hybridize under stringent hybridization conditions) with the complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. As such, the size of the nucleic acid molecule encoding such a protein homolog is dependent on nucleic acid composition and percent homology between the nucleic acid molecule and complementary sequence. It should also be noted that the extent of homology required to form a stable hybrid can vary depending on whether the homologous sequences are interspersed throughout the nucleic acid molecules or are clustered (i.e., localized) in distinct regions on the nucleic acid molecules. The minimal size of such nucleic acid molecules is typically at least about 12 to about 15 nucleotides in length if the nucleic acid molecules are GC-rich and at least about 15 to about 17 bases in length if they are AT-rich. As such, the minimal size of a nucleic acid molecule used to encode a CHV protein homolog of the present invention is from about 12 to about 18 nucleotides in length. There is no limit, other than a practical limit, on the maximal size of such a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, or multiple genes, or portions thereof. Similarly, the minimal size of a CHV protein homolog of the present invention is from about 4 to about 6 amino acids in length, with preferred sizes depending on whether full-length, fusion, or other functional portions of such proteins are desired.
One embodiment of the present invention is a CHV protein that can protect an animal from disease, preferably by eliciting an immune response against CHV, and/or can detect CHV infection in an animal. The minimum size of such a protein is a minimum size sufficient to form an epitope, a size that typically is at least from about 5 to about 9 amino acids. As is appreciated by those skilled in the art, an epitope can include amino acids that naturally are contiguous to each other as well as amino acids that, due to the tertiary structure of the natural protein, are in sufficiently close proximity to form an epitope.
The present invention also includes mimetopes of CHV proteins that can be used in accordance with methods as disclosed for CHV proteins of the present invention. As used herein, a mimetope of a CHV protein of the present invention refers to any compound that is able to mimic the activity of such a CHV protein, often because the mimetope has a structure that mimics the CHV protein. Mimetopes can be, but are not limited to: peptides that have been modified to decrease their susceptibility to degradation; anti-idiotypic and/or catalytic antibodies, or fragments thereof; non-proteinaceous immunogenic portions of an isolated protein (e.g., carbohydrate structures); and synthetic or natural organic molecules, including nucleic acids. Such mimetopes can be designed using computer-generated structures of proteins of the present invention. Mimetopes can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides or other organic molecules, and screening such samples by affinity chromatography techniques using the corresponding binding partner.
One embodiment of the present invention is a fusion, or multivalent, protein that includes a CHV protein-containing domain attached to another functional domain. Such a domain can be an entire protein, or function portion thereof. Examples of such domains include not only protective compounds as disclosed above, but also domains that enhance a protein's stability (e.g., during production, storage and/or use) or that aid in protein purification.
A preferred isolated protein of the present invention is a protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nCIR6.sub.552, nCUS2.sub.1176, nCPK.sub.1203, nCgG.sub.1248, nCgD.sub.357, nCgC/CUL45.sub.2100, nCdUTP.sub.459, nCUS9.sub.450, nCUL48.sub.291, nCUL52.sub.144, nCgI.sub.159, nCgE.sub.750, nCTK.sub.279, nCUL51.sub.261, nCgI.sub.1095, nCgE.sub.1569, nCUS8.5.sub.237, nCUS9.sub.360, nCUL49/CUL48.sub.2044, nCUL49.sub.420, nCUL48.sub.1269, nCICP4626, nCgL.sub.655, nCUL.sub.1823, nCdUTP.sub.918, nCUL49.5.sub.261, nCUL49.sub.255, and/or nCUL52.sub.749. Also included is a protein that hybridizes under stringent hybridization conditions with nCAsc.sub.9300, nCAsc.sub.10000, nCHin.sub.3000, nCHin.sub.1900, nCHin.sub.5500, and/or nCHin.sub.8500. A further preferred isolated protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having the complement of nucleic acid sequence SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:38, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, and/or SEQ ID NO:87, or by an allelic variant of any of such nucleic acid molecules. Proteins encoded by nucleic acid sequences SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:38, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, and SEQ ID NO:87 have amino acid sequences SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, and SEQ ID NO:88, respectively.
Comparison of the CHV amino acid sequences SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, and SEQ ID NO:88 with known sequences indicates that none of these CHV amino acid sequences share more than about 75% identity (many, if not all, sharing significantly less identity) with a known amino acid sequence.
A preferred CHV protein has an amino acid sequence that is at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95%, and even more preferably at least about 99% identical to amino acid sequence SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, and/or SEQ ID NO:88.
A more preferred CHV protein includes at least a portion of PCIR6.sub.183, PCUS2.sub.391, PCPK.sub.4001 PCgG.sub.415, PCdUTP.sub.152, PCUS9.sub.149, PCUL48.sub.97, PCUL52.sub.48, PCUL51.sub.86, PCgI.sub.53, PCTK.sub.93, PCgI.sub.364, PCgE.sub.522, PCUS8.5.sub.78, PCUS9.sub.119, PCUL49.sub.139, PCUL48.sub.422, PCICP4.sub.208, PCgL.sub.171, PCdUTP.sub.305, PCUL49.5.sub.86, PCUL49.sub.85, and/or PCUL52.sub.249, as well as proteins encoded by allelic variants of the nucleic acid molecules encoding such proteins. Also preferred are proteins including at least a portion of CgE and/or CUL49 proteins. A particularly preferred CHV protein includes PCIR6.sub.183, PCUS2.sub.391, PCPK.sub.400, PCgG.sub.415, PCdUTP.sub.152, PCUS9.sub.149, PCUL48.sub.97, PCUL52.sub.48, PCUL51.sub.86, PCgI.sub.53, PCTK.sub.93, PCgI.sub.364, PCgE.sub.522, PCUS8.5.sub.78, PCUS9.sub.119, PCUL49.sub.139, PCUL48.sub.422, PCICP4.sub.208, PCgL.sub.171, PCdUTP.sub.305, PCUL49.5.sub.86, PCUL49.sub.85, and/or PCUL52.sub.249 (including, but not limited to the encoded proteins, full-length proteins, processed proteins, multivalent proteins). Similarly, a preferred CHV protein of the present invention includes at least a portion of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, and/or SEQ ID NO:88. A particularly preferred CHV protein includes SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, and/or SEQ ID NO:88. Also included are proteins encoded by allelic variants of the nucleic acid molecules encoding such proteins.
The present invention also includes a recombinant vector, which includes at least one isolated CHV nucleic acid molecule inserted into any vector capable of delivering the CHV nucleic acid molecule into a host cell. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a virus or a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulating of CHV nucleic acid molecules of the present invention. Suitable and preferred CHV nucleic acid molecules to include in a recombinant vector are disclosed herein.
One embodiment of the present invention is a recombinant vector comprising an inactive CHV gene. Such a recombinant vector, also referred to as a transfer vector, can be used to produce a CHV comprising a CHV genome having an inactive gene by, for example, co-transfecting such a transfer vector with a CHV genome into a host cell and selecting for a CHV comprising a recombinant CHV genome having an inactive gene. Such a recombinant CHV genome is produced in the host cell by homologous recombination between the inactive gene on the transfer vector and the corresponding active gene on the transfected CHV genome. Transfection, culturing and purification methods to obtain recombinant CHV and CHV genomes are known to the art; see, for example, Graham et al., 1973, Virology 52:456-467; Graham et al, ibid. is incorporated by reference herein in its entirety.
Another embodiment of the present invention is a recombinant vector comprising a CHV nucleic acid molecule that includes a heterologous nucleic acid molecule (i.e., a heterologous nucleic acid molecule is located within a CHV nucleic acid molecule). Suitable and preferred heterologous nucleic acid molecules are disclosed herein. Such a heterologous nucleic acid molecule can be operatively linked to a transcription control sequence, as disclosed above. A recombinant vector comprising a CHV nucleic acid molecule into which a heterologous nucleic acid molecule is inserted is also a transfer vector. Such a transfer vector can be co-transfected with a CHV genome into a host cell to produce a recombinant CHV having a CHV genome including a heterologous nucleic acid molecule, using methods as described above. Recombinant CHV can be selected by identifying those CHV that have the heterologous nucleic acid molecule. If the recombinant vector comprises a selectable marker into which the heterologous nucleic acid molecule is inserted, selection methods as disclosed herein can also be used to identify recombinant CHV. A preferred embodiment is a recombinant vector comprising a CHV nucleic acid molecule having a heterologous nucleic acid molecule in which a majority of the CHV nucleic acid molecule is deleted; a sufficient size of the CHV nucleic acid molecule is retained to allow homologous recombination to occur with the corresponding target gene on the CHV genome. Examples of insertion of a heterologous nucleic acid molecule into a CHV genomic restriction site and into a CHV gene, as well as use of a selectable marker are provided in the Examples section.
Transfer vectors of the present invention are preferably able to replicate in bacterial, and particularly E. coli, hosts, thereby enabling easy manipulation of the CHV nucleic acid molecules, and, if included, heterologous nucleic acid molecules, prior to insertion of such CHV nucleic acid molecules into a CHV genome. Such manipulations, including culturing of E. coli comprising such vectors, is described, for example, in Sambrook et al, ibid.
In one embodiment, recombinant CHV are produced by co-transfection of a set of overlapping cosmid clones comprising the entire viral CHV genome, at least one of the cosmid clones having been genetically engineered to, for example, contain an inactive CHV gene and/or a heterologous nucleic acid molecule. Details of such a method are presented in the Examples.
Any canid host cell is suitable for recombinant CHV production. Examples of suitable and preferred host cells are provided herein. After transfection, transfected cells are cultured in an effective medium, using techniques such as those described in Graham et al, ibid. As used herein, an effective medium refers to any medium in which the transfected cells can produce recombinant CHV. An effective medium is typically an aqueous medium comprising assimilable carbohydrate, nitrogen and phosphate sources, as well as appropriate salts, minerals, metals and other nutrients, such as vitamins, growth factors and hormones. Culturing is carried out at a temperature, pH and oxygen content appropriate for the transfected cell. Such culturing conditions are well within the expertise of one of ordinary skill in the art.
Recombinant CHV can be recovered from the cultured transfected cells using a combination of standard techniques such as, but not limited to, freeze/thaw cycles, sonication, sucrose gradient centrifugation, and/or high speed centrifugation. Recombinant CHV genomes can be recovered from the cultured transfected cells using a combination of standard techniques such as, but not limited to, those described by Walboomers et al, 1976, Virology 74, 256-258.
Preferably, a recombinant CHV or recombinant CHV genome of the present invention is recovered in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the recombinant CHV or CHV genome as a vaccine without substantial negative side effects.
The present invention also includes a method to increase recombinant CHV plaque forming efficiency, thereby facilitating the production of recombinant CHV and CHV genomes. The phrase to increase recombinant CHV plaque forming efficiency refers to the ability to increase, or enhance, the production of CHV above the frequency of plaque forming units produced when a CHV genome is transfected into a cell in the absence of additional factors. The method includes the step of expressing the CHV alpha transinducing factor gene (i.e., CUL48 gene, also called the CHV alpha-tif gene) when a CHV genome is introduced into a canine cell.
Herpesviruses studied to date carry into infected cells a transcriptional activator called alpha transinducing factor (also called VP16 or Vmw65); see, for example, Batterson et al., 1983, J. Virol., 46:371-377. This transactivator protein interacts, along with cellular proteins, with a cis-acting sequence element present in the upstream regulatory regions of herpesvirus immediate early genes. Since purified herpesvirus DNA is infectious in the absence of alpha-tif, it is not absolutely required for expression of immediate early genes, but its presence in stably transfected cell lines has been shown to enhance infectivity of herpes simplex virus type-1 viral DNA; see, for example, Werstuck et al., 1990, J. Virol., 64:984-991.
Expression of the CHV alpha-tif gene can be accomplished in a variety of ways, including, but not limited to, the following. In one embodiment, a recombinant CHV genome is introduced into a canine cell expressing CHV alpha transinducing factor and the cells are cultured to produce recombinant CHV. A canine cell expressing CHV alpha-tif is a canine cell that has been genetically engineered to produce CHV alpha-tif in either a stable or transient manner. Such a canine cell can be produced by introducing a CUL48 nucleic acid molecule of the present invention into a canine cell line in such a manner that the CUL48 nucleic acid molecule can direct the expression of active alpha-tif. An example of a useful CUL48 nucleic acid molecule is such nCUL48.sub.1269. Details regarding the production of an alpha-tif-expressing canine cell and the use such a cell in the production of recombinant CHV and CHV genomes is present in the Examples.
In another embodiment, recombinant CHV plaque forming efficiency is increased by co-introducing a recombinant CHV genome and a CHV alpha transinducing factor gene into a canine cell and culturing the cell to produce recombinant CHV. The CHV alpha transinducing factor gene can be introduced as part of a recombinant molecule of the present invention. Details regarding this method are also presented in the Examples.
The present invention also includes canine cell lines that include a CHV alpha-tif gene; such cell lines are able to express alpha-tif, thereby facilitating CHV production. One example of such a cell line is a canine cell line transfected with CHV nucleic acid molecule nCUL48.sub.1269.
One embodiment of the present invention is a recombinant molecule that includes a CHV nucleic acid molecule operatively linked to a transcription control sequence. Such a recombinant molecule, when introduced into a host cell, can direct the expression of the CHV nucleic acid molecule(s), thereby leading to the production of one or more CHV protein of the present invention. Such a recombinant molecule preferably is replication competent. Suitable and preferred CHV nucleic acid molecules to include in such a recombinant molecule are as disclosed herein for suitable and preferred CHV nucleic acid molecules per se.
Isolated CHV proteins of the present invention can be produced in a variety of ways, including production and recovery of natural proteins, production and recovery of recombinant proteins, and chemical synthesis of the proteins. In one embodiment, an isolated protein of the present invention is produced by culturing a cell capable of expressing the protein under conditions effective to produce the protein, and recovering the protein. A preferred cell to culture is a recombinant cell that is capable of expressing one or more CHV proteins, the recombinant cell being produced by transforming a host cell with one or more nucleic acid molecules of the present invention. Transformation of a nucleic acid molecule into a cell can be accomplished by any method by which a nucleic acid molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. A recombinant cell may remain unicellular or may grow into a tissue, organ or a multicellular organism. Transformed nucleic acid molecules of the present invention can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained. Suitable and preferred CHV nucleic acid molecules with which to transform a cell are as disclosed herein for suitable and preferred CHV nucleic acid molecules per se.
Suitable host cells to transform include any cell that can be transformed with a CHV nucleic acid molecule of the present invention. Host cells can be either untransformed cells or cells that are already transformed with at least one nucleic acid molecule. Host cells of the present invention either can be endogenously (i.e., naturally) capable of producing CHV proteins of the present invention or can be capable of producing such proteins after being transformed with at least one CHV nucleic acid molecule of the present invention. Host cells of the present invention can be any cell capable of producing at least one protein of the present invention, and include bacterial, fungal (including yeast), parasite (including helminth, protozoa and ectoparasite), insect, other animal and plant cells. Preferred host cells include bacterial, yeast, insect and mammalian cells. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those which function in bacterial, yeast, insect and mammalian cells, such as, but not limited to, tac, lac, trp, trc, oxy-pro, omp/lpp, rrnB, bacteriophage lambda (such as lambda p.sub.L and lambda p.sub.R and fusions that include such promoters), bacteriophage T7, T7lac, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alpha-mating factor, Pichia alcohol oxidase, alphavirus, phosphate-regulated and nitrate-regulated transcription control sequences as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells, including those disclosed herein for expression of heterologous nucleic acid molecules, including endogenous CHV transcription control regions.
Recombinant cells of the present invention can be used to produce one or more proteins by culturing such cells under conditions effective to produce such a protein, and recovering the protein. Effective conditions to produce a protein include, but are not limited to, appropriate media, bioreactor, temperature, pH and oxygen conditions that permit protein production. Such culturing conditions are well within the expertise of one of ordinary skill in the art.
Depending on the vector and host system used for production, resultant CHV proteins may either remain within the recombinant cell; be secreted into the fermentation medium; be secreted into a space between two cellular membranes, such as the periplasmic space in E. coli; or be retained on the outer surface of a cell or viral membrane.
The phrase "recovering the protein" refers simply to collecting the whole fermentation medium containing the protein and need not imply additional steps of separation or purification. Proteins of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization. Proteins of the present invention are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the protein as a therapeutic composition or diagnostic. A therapeutic composition for animals, for example, should exhibit no substantial toxicity and should be capable of stimulating the production of antibodies in a treated animal.
The present invention also includes isolated antibodies capable of selectively binding to a CHV protein of the present invention or to a mimetope thereof. Such antibodies are also referred to herein as anti-CHV antibodies. Isolated antibodies are antibodies that have been removed from their natural milieu. The term "isolated" does not refer to the state of purity of such antibodies. As such, isolated antibodies can include anti-sera containing such antibodies, or antibodies that have been purified to varying degrees.
As used herein, the term "selectively binds to" refers to the ability of antibodies of the present invention to preferentially bind to specified proteins and mimetopes thereof of the present invention. Binding can be measured using a variety of methods known to those skilled in the art.
Antibodies of the present invention can be either polyclonal or monoclonal antibodies. Antibodies of the present invention include functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies, that are capable of selectively binding to at least one of the epitopes of the protein or mimetope used to obtain the antibodies. Antibodies of the present invention also include chimeric antibodies that can bind to more than one epitope. Preferred antibodies are raised in response to proteins, or mimetopes thereof, that are encoded, at least in part, by a nucleic acid molecule of the present invention.
A preferred method to produce antibodies of the present invention includes (a) administering to an animal an effective amount of a protein or mimetope thereof of the present invention to produce the antibodies and (b) recovering the antibodies. In another method, antibodies of the present invention are produced recombinantly using techniques as heretofore disclosed to produce CHV proteins of the present invention. Antibodies raised against defined proteins or mimetopes can be advantageous because such antibodies are not substantially contaminated with antibodies against other substances that might otherwise cause interference in a diagnostic assay or an assay to monitor recombinant CHV administration, or side effects if used in a therapeutic composition.
Antibodies of the present invention have a variety of potential uses that are within the scope of the present invention. For example, such antibodies can be used (a) as compounds to monitor recombinant CHV or recombinant CHV genome administration, (b) as therapeutic compounds to passively immunize an animal in order to protect the animal from CHV infection, and/or (c) as reagents in assays to detect CHV infection.
One embodiment of the present invention is a therapeutic composition that includes a recombinant CHV, a recombinant CHV genome, or a mixture (i.e., combination) of one or more recombinant CHVs and/or recombinant CHV genomes. As used herein, a therapeutic composition, or vaccine, is a formulation that, when administered to an animal in an effective manner, is capable of protecting that animal from a disease against which the therapeutic composition is targeted. Some therapeutic compositions of the present invention can modulate (i.e., either elicit or suppress) an immune response to protect an animal from disease, whereas other therapeutic compositions can protect an animal in other ways, as disclosed herein. A therapeutic composition of the present invention can be used to prevent and/or treat a disease depending on whether the composition is administered as a prophylactic or after the animal has the disease.
A therapeutic composition of the present invention, when administered to an animal in an effective manner, can infect the cells of the animal (in a manner essentially harmless to the animal) and direct the production of a protective compound able to protect the animal from a disease targeted by the therapeutic composition. If a recombinant CHV includes a protective compound in its envelope and/or capsid, the CHV can function as an immunogen per se.
As disclosed herein, therapeutic compositions can be designed to target a variety of diseases, depending on the nature of the heterologous nucleic acid molecule(s) included in such recombinant CHV and recombinant CHV genomes. Examples of such diseases, and the nature of the corresponding heterologous nucleic acid molecules, are disclosed herein. Furthermore, therapeutic compositions of the present invention can comprise multivalent vaccines. For example, a CHV genome can encode a variety of protective compounds, and/or more than one recombinant CHV genome and/or recombinant CHV can be administered. The present invention also includes the use of a recombinant CHV or recombinant CHV genome to protect an animal against CHV infection. Such a therapeutic composition can, but need not, include a heterologous nucleic acid molecule.
A therapeutic composition of the present invention is preferably administered to a canid, due to the host range specificity of CHV. Suitable canids include dogs (including domesticated and wild dogs), foxes, wolves, jackals, coyotes, and other members of the family Canidae. Particularly preferred canids to treat include domesticated dogs.
It is, however, also within the scope of the present invention to administer therapeutic compositions to other animals. Recombinant CHV can be administered to any animal susceptible to such therapy. Without being bound by theory, it is believed that sufficiently high doses of a recombinant CHV composition of the present invention may be infectious in other animals, particularly other mammals. Mink and other mink-like mammals (e.g., those of the family Mustelidae, such as ermines, ferrets, fishers, martens, otters, and weasels), in particular, may be susceptible to CHV infection, as suggested by the ability of CHV to infect mink lung cells. The host range of recombinant CHV of the present invention can also be altered, as disclosed herein, to infect other animal cells. It is also to be noted that CHV genomes of the present invention can be administered as naked DNA vaccines or in association with other carriers (e.g., liposomes). In accordance with these embodiments, any animal, including, but not limited to, mammals, birds, amphibians, and arthropods (including arachnids and insects) can be administered a therapeutic composition of the present invention. Preferred animals to treat include dogs, cats, humans, ferrets, prairie dogs, other rodents, horses, cattle, sheep, pigs, and poultry, as well as other pets, work animals, economic food animals and zoo animals.
Therapeutic compositions of the present invention can be formulated in an excipient that the animal to be treated can tolerate. Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the excipient can comprise dextrose, human serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration.
In one embodiment of the present invention, the vaccine can also include an adjuvant and/or a carrier. One advantage of live virus-based vaccines, such as the recombinant CHVs of the present invention, is that adjuvants and carriers are not required to produce an efficacious vaccine, and in some cases, the advantages of recombinant CHV vaccines of the present invention would be precluded by the use of some adjuvants. However, it should be noted that use of adjuvants or carriers is not precluded by the present invention. Adjuvants are typically substances that generally enhance the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; other viral coat proteins; other bacterial-derived preparations; block copolymer adjuvants, such as Hunter's Titermax.TM. adjuvant (Vaxce.TM., Inc. Norcross, Ga.); Ribi adjuvants (available from Ribi Immunochem Research, Inc., Hamilton, Mont.); and saponins and their derivatives, such as Quil A (available from Superfos Biosector A/S, Denmark). Carriers are typically compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release formulations, biodegradable implants, liposomes, bacteria, viruses, oils, esters, and glycols.
In one embodiment, a therapeutic composition of the present invention is administered to an animal in an effective manner to enable the animal to produce sufficient protective compound(s) and/or to directly mount a sufficient immune response to protect the animal from disease. Acceptable protocols to administer therapeutic compositions in an effective manner include enumeration of individual dose size, number of doses, frequency of dose administration, and mode of administration. Determination of such protocols can be accomplished by those skilled in the art. A suitable single dose is a dose that is capable of protecting an animal from disease when administered one or more times over a suitable time period.
A preferred single dose of a recombinant CHV of the present invention is from about 1.times.10.sup.4 to about 1.times.10.sup.7 virus plaque forming units (pfu) per kilogram body weight of the animal. Booster vaccinations can be administered from about 2 weeks to several years after the original vaccination. Booster vaccinations preferably are administered when the immune response of the animal becomes insufficient to protect the animal from disease. A preferred administration schedule is one in which from about 1.times.10.sup.4 to about 1.times.10.sup.7 virus plaque forming units per kilogram (kg) body weight of the animal are administered from about 1 to about 2 times over a time period of from about 12 to about 18 months. Modes of administration can include, but are not limited to, subcutaneous, intradermal, intravenous, intranasal, oral, transdermal and intramuscular routes.
A recombinant CHV genome can be administered in a variety of ways, with intramuscular, subcutaneous, intradermal, transdermal, intranasal and oral routes of administration being preferred. A preferred single dose of a recombinant CHV genome ranges from about 1 nanogram (ng) to about 100 micrograms (.mu.g), depending on the route of administration and/or method of delivery, as can be determined by those skilled in the art; see, for example, Wolff et al., 1990, Science 247, 1465-1468. Suitable delivery methods include, for example, injection, as drops, aerosolized and/or topical administration. Suitable excipients include, for example, physiologically acceptable aqueous solutions (e.g., phosphate buffered saline as well as others disclosed above), liposomes (including neutral or cationic liposomes), and other lipid membrane-based vehicles (e.g., micelles or cellular membranes).
In one embodiment, a therapeutic composition of the present invention is administered to a dam to protect her offspring from disease. In this method, the dam is administered the therapeutic composition at such a time as to be able to develop an immune response such that she can passively transfer antibodies produced against a protective compound of the present invention to her offspring. Such a method can also be used to protect offspring from CHV infection and is particularly useful since neonates are most affected by CHV infection.
The efficacy of a therapeutic composition of the present invention to protect an animal from disease can be tested in a variety of ways including, but not limited to, detection of protective protein or RNA within the treated animal, detection of protective antibodies within the treated animal, detection of cellular immunity within the treated animal, or challenge of the treated animal with an appropriate infectious agent, or other disease component, to determine whether the animal is now protected from the disease caused by such an agent or other component. Such techniques are known to those skilled in the art. In one embodiment, anti-CHV antibodies of the present invention are used to monitor recombinant CHV infection and can be used to distinguish wild type infections from infections using recombinant CHV of the present invention (i.e., by using antibodies that specifically recognize either recombinant CHV of the present invention or wild type virus).
In one embodiment, the efficacy of a therapeutic composition of the present invention may be improved by co-administering (a) a recombinant CHV or recombinant CHV genome and (b) a protective compound (e.g., subunit vaccine) encoded by a CHV nucleic acid molecule or heterologous nucleic acid molecule present in the CHV genome. While not being bound by theory, it is believed that administration of a protective compound in conjunction with the recombinant CHV or CHV genome can boost the immune response, particularly the antibody titer. The protective compound can be administered prior to, concomitant with, and/or following administration of the recombinant CHV or CHV genome. The protective compound can be either produced naturally, recombinantly, or synthetically. The protective compound should be sufficiently pure to allow for effective use of the compound as a vaccine; i.e., it should not cause substantial side effects. The protective compound can be joined (i.e., conjugated) to a carrier or other material that enhances the immunogenicity of the compound.
The present invention also includes the use of CHV nucleic acid molecules, CHV proteins, and anti-CHV antibodies as therapeutic compositions to protect animals from CHV infection. Methods to administer such compositions to canids are known to those skilled in the art. For example, a preferred single dose of a protein, mimetope or antibody therapeutic composition is from about 1 microgram (.mu.g) to about 10 milligrams (mg) of the therapeutic composition per kilogram body weight of the animal. Booster vaccinations can be administered from about 2 weeks to several years after the original administration. Booster vaccinations preferably are administered when the immune response of the animal becomes insufficient to protect the animal from disease. A preferred administration schedule is one in which from about 10 .mu.g to about 1 mg of the therapeutic composition per kg body weight of the animal is administered from about one to about two times over a time period of from about 2 weeks to about 12 months. Modes of administration can include, but are not limited to, subcutaneous, intradermal, intravenous, intranasal, oral, transdermal and intramuscular routes. A CHV nucleic acid molecule, including recombinant molecules, can be administered as described herein for administration of CHV genomes or CHV of the present invention. Recombinant molecules including heterologous nucleic acid molecules can also be used as therapeutic compositions to protect an animal from disease, using methods as disclosed herein.
It is also within the scope of the present invention to use isolated CHV proteins, mimetopes, CHV nucleic acid molecules and anti-CHV antibodies of the present invention as diagnostic reagents to detect CHV infection. Methods to use such diagnostic reagents to diagnose infection are well known to those skilled in the art.
The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention.
EXAMPLES
It is to be noted that the Examples include a number of molecular biology, virology, microbiology, immunology and biochemistry techniques considered to be known to those skilled in the art. Disclosure of such techniques can be found, for example, in Sambrook et al., ibid.; Ausubel et al, 1993, Current Protocols in Molecular Biology, Greene/Wiley Interscience, New York, N.Y.; Graham et al, ibid.; and related references. Ausubel et al, ibid. is incorporated by reference herein in its entirety. Nucleic acid and amino acid sequences of the present invention were compared to known sequences using BLAST (NCBI) and DNAsis (Hitachi Software, San Bruno, Calif.).
Example 1
This Example demonstrates the isolation of certain CHV nucleic acid molecules of the present invention.
The disclosed CHV nucleic acid molecules were amplified from a CHV genome by PCR amplification using a variety of primers designed in view of published herpesvirus sequences. The following PCR conditions were used: 0.2 millimolar (mM) dNTPs, 1 .mu.M of each primer, 1.times. PCR buffer (available from Perkin Elmer Cetus, Emeryville, Calif.), 50 ng of CHV DNA (isolated from CHV strain D 004 as described in Example 2) and 0.5 .mu.l of a thermostable DNA polymerase, all in an about 100 .mu.l total volume. The PCR reactions included an initial denaturation for 3 minutes at 95.degree. C., five cycles of 1 minute each at 95.degree. C., 35.degree. C. for 1 minute, 72.degree. C. for 1 minute, 35 cycles of 1 minute each at 95.degree. C., 37.degree. C. for 1 minute, 72.degree. C. for 1 minute, and finally 10 minutes at 72.degree. C. The resultant PCR products were directly cloned into the pCRII TA cloning vector (available from Invitrogen Corp., San Diego, Calif.) according to the manufacturer's specifications. Primers which were successful in amplifying fragments from a CHV genome, which was determined to be very AT-rich compared to other herpesvirus genomes, are described below.
A. Isolation of a nucleic acid molecule including a partial CHV dUTPase gene and a partial CHV UL51 gene
The following primers were designed using dUTPase protein sequence derived from HSV-1 (McGeoch et al, 1988, J. Gen. Virol. 69, 1531-1574), EHV-4 (Riggio et al, 1993, Arch. Virol. 133, 171-178), BHV-1 (Liang et al, 1993, Virology 195, 42-50), and EBV (Lees et al, 1993, Virology 195, 578-586: Primer 212S (dUTPase forward) having nucleic acid sequence 5' GG CGA ATT CCI AAR MGI GAI GAR GAY G 3', denoted herein as SEQ ID NO:39; and Primer 365A (dUTPase reverse) having nucleic acid sequence 5' C GCG GAT CCI GTI SWI CCY AAI CC 3', denoted herein as SEQ ID NO:40. These primers led to the amplification of an about 743 nucleotide fragment, which was significantly larger than expected. Nucleic acid sequence analysis, described in Example 3, indicated that the 743 nucleotide fragment contained part of the CUL51 gene as well as part of the CdUTPase gene; as such, the fragment was denoted nCdUTP/CUL51.sub.743. Nucleic acid sequence analysis also indicated that the dUTPase reverse primer actually hybridized to a region of the CHV DNA genome within the CUL51 gene rather than within the CdUTPase gene. It is believed that the mispriming was due to nucleotide position 19 of SEQ ID NO:40 being a Y instead of an R; the latter sequence would have matched more closely to the targeted priming region, about 290 nucleotides upstream from the 3' end of nucleic acid molecule nCdUTP/CUL51.sub.743. This result demonstrates the sensitivity of PCR amplification to primer design.
B. Isolation of a CHV gE nucleic acid molecule
The following primers were designed using gE protein sequence derived from FHV-1 (Spatz et al, 1994, J Gen. Virol. 75, 1235-1244 ), EHV-1 (Elton et al, 1991, Gene 101, 203-208), and BHV-1 (Leung-Tack et al, 1994, Virology 199, 409-421): Primer 197S (gE forward) having nucleic acid sequence 5' GGC GAA TTC TAY CAY WSI CAY GTI TA 3', denoted herein as SEQ ID NO:41; and Primer 441A (gE reverse) having nucleic acid sequence 5' CGC GGA TCC RTC RTT ISW IGG DAI ISW IGT 3', denoted herein as SEQ ID NO:42. These primers led to the amplification of an about 750 nucleotide fragment, referred to herein as nCgE.sub.750.
C. Isolation of a CHV TK nucleic acid molecule
The following primers were designed using TK protein sequence derived from HSV-1 (McGeoch et al., 1988, ibid.), HSV-2 (Kit et al, 1987, Antimicrob. Agents Chemother. 31, 1483-1490, BHV-1 (Kit et al, U.S. Pat. No. 4,703,011, issued Oct. 27, 1987), FHV-1 (Nunberg et al, 1989, J. Virol. 63, 3240-3249), EHV-1 (Robertson et al, 1988, Nuc. Acids Res. 16, 11303-11317), and PRV (Prieto et al, 1991, J. Gen. Virol. 72, 1435-1439): Primer EJH 002 (TK forward) having nucleic acid sequence 5' GGC GAA TTC GGI AAR WSI ACI RC 3', denoted herein as SEQ ID NO:43; and Primer EJH004 (TK reverse) having nucleic acid sequence 5' GGC GGA TCC GGT TGI CKR TC 3', denoted herein as SEQ ID NO:44. These primers led to the amplification of an about 280 nucleotide fragment, referred to herein as nCTK.sub.280.
D. Isolation of a nucleic acid molecule including CHV gC and CHV UL45 genes
The following primers were designed using gC and UL45 sequences derived from Limbach et al., ibid.: Primer gC sense, having nucleic acid sequence 5' CGCGGATCCAAGGTAATAAGTCAAAATGAG 3', denoted herein as SEQ ID NO:45; and Primer gC ant, having nucleic acid sequence 5' CGCGGATCCGACAAAAACAAAAAGTAATG 3', denoted herein as SEQ ID NO:46. These primers led to the amplification of an about 2100 nucleotide fragment, referred to herein as nCgC/CUL45.sub.2100.
E. Attempt to isolate a CHV ribonucleotide reductase gene
The following primers were designed using ribonucleotide subunit small subunit protein sequence derived from HSV-1 (McGeoch et al, 1988, ibid.), PRV (Dewind et al, 1993, J. Gen. Virol. 74, 351-359), EHV-1 (Telford et al, 1992, Virology 189, 04-316) and BHV-1 (Simard et al, 1992, Virology 190, 689-701): Primer EJH 021 (RR forward) having nucleic acid sequence 5.degree. CCG AAT TCY TIA TGA THY TIA THG ARG G 3', denoted herein as SEQ ID NO:47; and Primer EJH022 (RR reverse) having nucleic acid sequence 51 CCG GAT CCY TCR AAR AAR TTI GTR TGY TT 3', denoted herein as SEQ ID NO:48. These primers did not lead to the amplification of a fragment under a variety of magnesium and amplification conditions, suggesting the lack of a coding region for a ribonucleotide reductase small subunit in CHV. As a control, these primers were shown to be able to easily amplify a ribonucleotide reductase small subunit fragment from an FHV genome.
Example 2
This Example describes the production of CHV genomic libraries.
Canine herpesvirus strain D 004 (Binn, et al., 1967, Proc. Soc. Exp. Biol. Med. 126, 140) was obtained from ATCC. Virus were propagated on Madin-Darby Canine Kidney (MDCK) cells according to standard virological procedures. Viral DNA was prepare from CHV-infected MDCK cells by previously described methods; see, for example, Walboomers et al, ibid. The viral DNA was digested with restriction endonucleases HindIII, PstI, EcoRI or XbaI, and the resultant digests were cloned into either vector pSP72 (available from Promega Corp., Madison, Wis.), or pLitmus 28 or 38 (available from New England Biolabs, Beverly, Mass.). DNA was prepared from the resultant recombinant plasmids and the inserts were sorted according to size.
Example 3
This Example describes the isolation of genomic HindIII restriction fragment nucleic acid molecules containing CdUTPase nucleic acid sequences and the nucleic acid sequencing of at least regions of these nucleic acid molecules.
Nucleic acid molecule nCdUTP/CUL51.sub.743, produced as described in Example 1, was labelled with either .sup.32 P or digoxigenin (available from Boehringer Mannheim Biochemicals (BMB), Indianapolis, Ind.) and used to screen the CHV HindIII fragment-containing library, either by colony hybridization or Southern blotting. Two clones hybridized with nCdUTP/CUL51.sub.743, one containing a HindIII fragment of about 3000 nucleotides, referred to herein as nCHin.sub.3000, and another containing a HindIII fragment of about 1,900 nucleotides, referred to herein as nCHin.sub.1900. The HindIII fragments were further characterized by restriction mapping, as shown in FIG. 1. Also shown is the relative location of nCdUTP/CUL51.sub.743 (referred to therein as nCdUTP.sub.743) with respect to the HindIII fragments.
Nucleic acid molecules nCdUTP/CUL51.sub.743, nCHin.sub.3000, and nCHin.sub.1900 were submitted to DNA sequence analysis, using a sequencing strategy as depicted in FIG. 1. Among sequences obtained were SEQ ID NO:13 and SEQ ID NO:14, which include SEQ ID NO:15 and SEQ ID NO:33, as well as SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27. The relative locations of genes included in these sequences (i.e., the CUL52, CUL51, CdUTPase and CUL48 genes) are shown in FIG. 1. Also shown is the apparent location of the CUL49 gene.
SEQ ID NO:13 and SEQ ID NO:14 represent the deduced nucleic acid sequences of the two complementary strands of nCdUTP/CUL51.sub.743. SEQ ID NO:13 includes a partial coding region for a CdUTPase protein of about 152 amino acids, denoted herein as nCdUTP.sub.459 and represented by SEQ ID NO:15, assuming a first in-frame codon spanning about nucleotides 3-5, and a stop codon spanning about nucleotides 459-461 of SEQ ID NO:13. The amino acid sequence of the encoded protein PCdUTP.sub.152 is represented by SEQ ID NO:16. SEQ ID NO:14 includes a partial coding region for a CUL51 protein of about 86 amino acids, denoted herein as nCUL51.sub.261 and represented by SEQ ID NO:33, assuming a first in-frame codon spanning about nucleotides 1-3, and a stop codon spanning about nucleotides 259-261 of SEQ ID NO:14. The amino acid sequence of the encoded protein PCUL51.sub.86 is represented by SEQ ID NO:34.
SEQ ID NO:21 and SEQ ID NO:23 represent the deduced nucleic acid sequences of the two complementary strands of nCUL48.sub.294. SEQ ID NO:21 includes a partial coding region for a CUL48 protein of about 97 amino acids, denoted herein as nCUL48.sub.291 and represented by SEQ ID NO:24, assuming a first in-frame codon spanning about nucleotides 3-5 of SEQ ID NO:21. The amino acid sequence of the encoded protein PCUL48.sub.97 is represented by SEQ ID NO:22.
SEQ ID NO:25 and SEQ ID NO:27 represent the deduced nucleic acid sequences of the two complementary strands of nCUL52.sub.146. SEQ ID NO:25 includes a partial coding region for a CUL52 protein of about 48 amino acids, denoted herein as nCUL52.sub.144 and represented by SEQ ID NO:28, assuming a first in-frame codon spanning about nucleotides 1-3 of SEQ ID NO:25. The amino acid sequence of the encoded protein PCUL52.sub.48 is represented by SEQ ID NO:26.
Example 4
This Example describes a method to identify restriction enzymes that effect limited cleavage of the CHV genome. Also described is the isolation and sequencing of an AscI fragment containing the entire US region of CHV.
CHV DNA was evaluated for recognition sites for several restriction enzymes with 8-base, or larger, recognition sites. No sites were found for enzymes Sse8387I, I-Sce-I, or NotI. Two AscI sites were found, which were mapped to sites within the inverted repeats surrounding the US region, specifically within CHV gene US2 (see FIG. 2). The AscI fragments, of 9.3, 10.0 and approximately 100-120 kilobases (kb), were cloned into pLitmus 38 and submitted to restriction enzyme mapping analysis. The restriction map of the 9.3-kb AscI fragment, denoted herein as mCAsc.sub.9300 is shown in FIG. 2; this fragment apparently contains the entire CUS region, as well as small portions of the internal and terminal IR regions. The 10.0-kb AscI-blunt fragment, denoted herein as mCAsc.sub.10000, contains most of the terminal IR region and is shown in FIG. 3. The about 100-120-kb AscI-blunt fragment contains the remainder of the CHV genome. Both AscI sites are located just 5' of the diploid copies of the CHV homolog of the EHV-1 IR6 gene (Breeden et al, 1992, Virology 191, 649-660), and the orf1 of BHV-1 (Leung-Tack et al, ibid.). The AscI sites appear to be located within an open reading frame that is the homolog of the EHV US1 gene (Breeden et al ibid.) and the HSV-1 US2 gene (McGeoch et al, 1985, J. Mol. Biol 181, 1-13), although the size is somewhat different from these other genes. No function has been ascribed to the HSV-1 US2 gene product, but it has been shown to be dispensable for growth in tissue culture and to attenuate the virus (Meignier et al, 1988, Virology 162, 251-254).
Nucleic acid molecules nCAsc.sub.9300 and nCAsc.sub.10000 were submitted to DNA sequence analysis using a strategy as depicted in FIG. 2 and FIG. 3. Among sequences obtained were SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:29, and SEQ ID NO:31 The relative locations of genes included in these sequences (i.e., the CUS9, CgI, CgD, CgG, CPK, CUS2, and CIR6 genes) are shown in FIG. 2 and FIG. 3. Also shown is the putative location of the CgE gene.
SEQ ID NO:1 and SEQ ID NO:2 represent the deduced nucleic acid sequences of the two complementary strands of nCUS.sub.5495. Translation of SEQ ID NO:1 and SEQ ID NO:2 indicates that nucleic acid molecule nCUS.sub.5495 encodes CIR6, CUS2, CPK and CgG proteins as well as a portion of a CgD protein. Specifically, SEQ ID NO:2 includes: a coding region for a CIR6 protein of about 183 amino acids, denoted herein as nCIR6.sub.552 and represented by SEQ ID NO:3, assuming a start codon spanning about nucleotides 4566-4568 and a stop codon spanning about nucleotides 5115-5117 of SEQ ID NO:2; and a coding region for a CUS2 protein of about 391 amino acids, denoted herein as nCUS2.sub.1176 and represented by SEQ ID NO:5, assuming a start codon spanning about nucleotides 3232-3234 and a stop codon spanning about nucleotides 4405-4407 of SEQ ID NO:2. The amino acid sequences of the respective encoded proteins PCIR6.sub.183 and PCUS2.sub.391 are represented by SEQ ID NO:4 and SEQ ID NO:6. SEQ ID NO:1 includes: a coding region for a CPK protein of about 400 amino acids, denoted herein as nCPK.sub.1203 and represented by SEQ ID NO:7, assuming a start codon spanning about nucleotides 2384-2386 and a stop codon spanning about nucleotides 3584-3586 of SEQ ID NO:1; a coding region for a CgG protein of about 415 amino acids, denoted herein as nCgG.sub.1248 and represented by SEQ ID NO:9, assuming a start codon spanning about nucleotides 3698-3700 and a stop codon spanning about nucleotides 4943-4945 of SEQ ID NO:1; and a partial coding region for a CgD protein of about 119 amino acids, denoted herein as nCgD.sub.357 and represented by SEQ ID NO:11, assuming a start codon spanning about nucleotides 5137-5139. The amino acid sequences of the respective encoded proteins PCPK.sub.400, PCgG.sub.415, and PCgD.sub.119 are represented by SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12.
SEQ ID NO:17 and SEQ ID NO:19 represent the deduced nucleic acid sequences of the two complementary strands of nCUS9.sub.579. SEQ ID NO:17 includes a coding region for a CUS9 protein of about 149 amino acids, denoted herein as nCUS9.sub.450 and represented by SEQ ID NO:20, assuming a start codon spanning about nucleotides 54-56 and a stop codon spanning about nucleotides 501-503 of SEQ ID NO:17. The amino acid sequence of the encoded protein PCUS9.sub.149 is represented by SEQ ID NO:18.
SEQ ID NO:29 and SEQ ID NO:31 represent the deduced nucleic acid sequences of the two complementary strands of nCgI.sub.161. SEQ ID NO:29 includes a partial coding region for a CgI protein of about 53 amino acids, denoted herein as nCgI.sub.159 and represented by SEQ ID NO:32, assuming a first in-frame codon spanning about nucleotides 3-5 of SEQ ID NO:29. The amino acid sequence of the encoded protein PCgI.sub.53 is represented by SEQ ID NO:30.
Example 5
This Example describes the nucleic acid sequencing of additional nucleic acid molecules of the present invention.
Nucleic acid molecule nCTK.sub.280, produced as described in Example 1, was submitted to DNA sequence analysis to obtain the following sequences. SEQ ID NO:35 and SEQ ID NO:37 represent the deduced nucleic acid sequences of the two complementary strands of nCTK.sub.280. SEQ ID NO:35 includes a partial coding region for a CTK protein of about 93 amino acids, denoted herein as nCTK.sub.279 and represented by SEQ ID NO:38, assuming a first in-frame codon spanning about nucleotides 2-4 of SEQ ID NO:35. The amino acid sequence of the encoded protein PCTK.sub.93 is represented by SEQ ID NO:36.
Example 6
This Example discloses the production of a recombinant CHV genome and recombinant CHV of the present invention. A cassette including the human CMV immediate early promoter and the poly-adenylation signal from bovine growth hormone separated by a polylinker was PCR amplified from plasmid pcDNA3 (available from Invitrogen) using forward primer EJH058 having nucleic acid sequence 5' TCCCCCGGGGGCGCGCCTTGACATTGATTATTGAC 3', denoted SEQ ID NO:49, and reverse primer EJH059 having nucleic acid sequence 5' GCCCTTAAGGGGCGCGCCAATGCGATGCAATTTCC 3', denoted SEQ ID NO:50. EJH058 has SmaI and AscI sites attached to the 5' end of pcDNA3 homologous sequences, and EJH059 has AflII and AscI sites attached to the 5' end of pcDNA3 homologous sequences. The resultant PCR amplified fragment of about 930 nucleotides was digested with SmaI and AflII and ligated into the SnaBI and AflII sites of plasmid pLitmus 38. This cloning procedure eliminated the entire polylinker region of pLitmus38. The resulting recombinant plasmid, denoted herein as pAscCMV/BGH, contains the CMV promoter--BGH polyadenylation signal cassette, with its original polylinker, in a plasmid such that the entire cassette can be excised with enzyme AscI. This cassette plasmid can also be prepared with other rare-cutting enzyme sites flanking the cassette.
Plasmid pAscCMV/BGH allows for the insertion of heterologous nucleic acid molecules between the CMV promoter and the BGH polyadenylation signal. The resulting heterologous nucleic acid molecule-containing cassette was excised from the plasmid for insertion into a CHV genome. For example, a heterologous nucleic acid molecule containing a lacZ gene was inserted into the polylinker region of pAscCMV/BGH such that the lacZ gene is expressed by the CMV promoter in a eukaryotic system. The cassette containing the lacZ gene, referred to herein as AscCMV/lacZ/BGH is then excised from the plasmid by AscI digestion and gel purified by standard methods.
About 5-10 .mu.g of CHV DNA is digested with AscI, resulting in three fragments as disclosed herein. The DNA fragments are dephosphorylated with calf intestine alkaline phosphatase (available from BMB) for 10 minutes at 37.degree. C.; the enzyme is then inactivated for by incubation for 10 minutes at 65.degree. C. The phosphatase-treated digested CHV DNA is then subjected to extraction with phenol and phenol/chloroform and precipitated with ethanol.
The phosphatase-treated digested CHV genomic DNA is mixed with the gel-purified AscCMV/lacZ/BGH cassette at a molar ratio of approximately 1:2 under standard ligation conditions. Since the viral DNA is dephosphorylated, it should not be able to self ligate; thus all resultant ligated viral molecules should contain two copies of the inserted cassette. The ligated DNA is then subjected to phenol extraction and ethanol precipitated.
The precipitated ligated DNA is resuspended in hepes-buffered saline and submitted to standard viral transfection conditions, such as that described by Graham et al., ibid., along with appropriate controls (e.g., undigested viral DNA, digested and dephosphorylated viral DNA that was self-ligated, and no DNA). Resultant viral plaques are screened under an X-gal overlay for expression of .beta.-galactosidase.
Example 7
This Example discloses the production of another recombinant CHV genome and recombinant CHV of the present invention.
A recombinant, or transfer, vector to be used in the production of a recombinant CHV having a heterologous nucleic acid molecule in a TK gene of the CHV genome is constructed as follows. A CHV TK nucleic acid molecule of the present invention (e.g., nCTK.sub.280) is ligated into a pLitmus plasmid to produce a pCTK-Litmus plasmid. An expression cassette including a heterologous nucleic acid molecule (e.g., a lacZ gene or a nucleic acid molecule encoding an antigen isolated from a pathogenic organism) ligated to a CMV immediate early promoter and a BHV polyadenylation site in such a manner that the heterologous nucleic acid molecule is expressed in a eukaryotic cell is inserted into the CTK nucleic acid molecule within pCTK-Litmus such that there are CTK flanking sequences on either side of the expression cassette (e.g., into a restriction site internal to nCTK.sub.280).
A recombinant CHV is produced by co-transfecting the recombinant vector and CHV DNA into canine MDCK cells using previously described methods; see, for example, Graham et al, ibid. Recombinant TK negative CHV are selected for by passage in bromodeoxyuridine; see, for example, Kit et al., 1983, Virology 130, 381-389. If the heterologous nucleic acid molecule is the lacZ gene, such recombinant CHV can also be selected as described in Example 6.
Example 8
This Example discloses the production of another recombinant CHV genome and recombinant CHV of the present invention.
A recombinant, or transfer, vector to be used in the production of a recombinant CHV having a heterologous nucleic acid molecule in a dUTPase gene of the CHV genome is constructed as follows. A CHV dUTPase nucleic acid molecule of the present invention (e.g., nCdUTP.sub.459) is ligated into a pLitmus plasmid to produce a pCdUTP-Litmus plasmid. An expression cassette including a heterologous nucleic acid molecule (e.g., a lacZ gene or a nucleic acid molecule encoding an antigen isolated from a pathogenic organism) ligated to a CMV immediate early promoter and a BHV polyadenylation site in such a manner that the heterologous nucleic acid molecule is expressed in a eukaryotic cell is inserted into the CdUTP nucleic acid molecule within pCdUTP-Litmus such that there are CdUTPase flanking sequences on either side of the expression cassette (e.g., into a restriction site internal to nCdUTP.sub.459).
A recombinant CHV is produced by co-transfecting the recombinant vector and CHV DNA into canine MDCK cells as described in Example 7. Recombinant dUTPase negative CHV are selected for by passage in mercurithio analogs of deoxyuridine; see, for example, Holliday et al, 1991, Antiviral Research 16, 197-203. If the heterologous nucleic acid molecule is the lacZ gene, such recombinant CHV can also be selected as described in Example 6. Recombinant virus carrying the foreign DNA of interest can also be selected by either by plaque hybridizations, or by dot-blot hybridizations of infected cell cultures. Verification of the proper insert within the CHV genome is conducted by Southern hybridization analysis.
Example 9
This Example discloses the production of a recombinant CHV by co-transfection of a set of overlapping cosmid clones comprising the entire viral CHV genome.
A library of CHV cosmid clones is created in the cosmid vector SuperCos (available from Stratagene Cloning Systems, La Jolla, Calif.) according to manufacturer's specifications, except that the vector is modified to contain one or more restriction sites not present in CHV genomic DNA (e.g., Sse83871, I-Sce-I, or NotI) so that the cosmid inserts can be excised prior to cotransfection. A heterologous nucleic acid molecule in an expression cassette, such as one of those described in Examples 6-8, is inserted into a cosmid clone using standard procedures. A recombinant CHV is produced by co-transfection of a set of overlapping cosmid clones comprising the entire viral CHV genome, including the cosmid comprising a heterologous nucleic acid molecule, using techniques as described in van Zihl et al., 1988, J. Virol. 62, 2191-2195.
Example 10
This Example describes the nucleic acid sequencing of additional nucleic acid molecules of the present invention.
Nucleic acid molecules nCAsc.sub.9300 and nCAsc.sub.1000, produced as described in Example 4, were submitted to additional DNA sequence analysis. The resultant nucleic acid sequences were compiled to produce SEQ ID NO:51 and SEQ ID NO:52. SEQ ID NO:51 and SEQ ID NO:52 represent the deduced nucleic acid sequences of the two complementary strands of a nucleic acid molecule referred to herein as nCUS.sub.10592. Nucleic acid molecule nCUS.sub.10592 includes the entire US region of CHV plus terminal repeat and internal repeat sequences. Analysis of SEQ ID NO:51 indicates that the US region spans from nucleotides about 2047 through about 9724 of SEQ ID NO:51, whereas the terminal repeat sequences and inverted repeat sequences span from nucleotides about 1 through about 2046 and from nucleotides about 9725 through about 10592, respectively, of SEQ ID NO:51.
Translation of SEQ ID NO:51 and SEQ ID NO:52 indicates that nucleic acid molecule nCUS.sub.10592 contains at least the following open reading frames: CIR6, CUS2, CPK, CgG, CgD, CgI, CgE, CUS8.5 and CUS9. The relative locations of these open reading frames is shown in FIG. 4.
Specifically, SEQ ID NO:52 includes: the coding strand of nCIR6.sub.552 (having SEQ ID NO:3) which encodes a CIR6 protein of about 183 amino acids, assuming a start codon spanning about nucleotides 9672-9674 and a stop codon spanning about nucleotides 10221-10223 of SEQ ID NO:52; and the coding strand of nCUS2.sub.1176 (having SEQ ID NO:5) which encodes a CUS2 protein of about 391 amino acids, assuming a start codon spanning about nucleotides 8338-8340 and a stop codon spanning about nucleotides 9511-9513 of SEQ ID NO:52. Nucleic acid molecules nCIR6.sub.552 and nCUS2.sub.1176 are also described in Example 4 in relation to nCUS.sub.5495, as are the corresponding nucleic acid sequences and amino acid sequences they encode.
SEQ ID NO:51 includes: the coding strand of nCPK.sub.1203 (having SEQ ID NO:7) which encodes a CPK protein of about 400 amino acids, assuming a start codon spanning about nucleotides 2375-2377 and a stop codon spanning about nucleotides 3575-3577 of SEQ ID NO:51; the coding strand of nCgG.sub.1248 (having SEQ ID NO:9) which encodes a CgG protein of about 415 amino acids, assuming a start codon spanning about nucleotides 3689-3691 and a stop codon spanning about nucleotides 4934-4936 of SEQ ID NO:51; the coding strand of nCgD.sub.1038 (having SEQ ID NO:53, and including SEQ ID NO:11) which encodes a CgD protein of about 345 amino acids, assuming a start codon spanning about nucleotides 5128-5130 and a stop codon spanning about nucleotides 6163-6165 of SEQ ID NO:51; the coding strand of nCgI.sub.1095 (having SEQ ID NO:55, and including SEQ ID NO:29) which encodes a CgI protein of about 364 amino acids, assuming a start codon spanning about nucleotides 6225-6227 and a stop codon spanning about nucleotides 7317-7319 of SEQ ID NO:51; the coding strand of nCgE.sub.1569 (having SEQ ID NO:57) which encodes a CgE protein of about 522 amino acids, assuming a start codon spanning about nucleotides 7467-7469 and a stop codon spanning about nucleotides 9033-9035 of SEQ ID NO:51; the coding strand of nCUS8.5.sub.237 (having SEQ ID NO:59) which encodes a CUS8.5 protein of about 78 amino acids, assuming a start codon spanning about nucleotides 9028-9030 and a stop codon spanning about nucleotides 9262-9264 of SEQ ID NO:51; and the coding strand of nCUS9.sub.360 (having SEQ ID NO:61) which encodes a CUS9 protein of about 119 amino acids, assuming a start codon spanning about nucleotides 9376-9378 and a stop codon spanning about nucleotides 9733-9735 of SEQ ID NO:51. SEQ ID NO:61 differs from the coding region reported for CUS9 in Example 4 (e.g., SEQ ID NO:20), in that additional sequence analysis indicated that SEQ ID NO:17 included a sequencing error resulting in a frameshift, leading to a longer deduced open reading frame. Nucleic acid molecules nCPK.sub.1203 and nCgG.sub.1248 are also described in Example 4 in relation to nCUS5495 as are the corresponding nucleic acid sequences and amino acid sequences they encode. The amino acid sequences of the respective encoded proteins PCgD.sub.345, PCgI.sub.364, PCgE.sub.522, PCUS8.5.sub.78, and PCUS9.sub.119 are represented by SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60 and SEQ ID NO:62, respectively.
Example 11
This Example describes the nucleic acid sequencing of additional nucleic acid molecules of the present invention.
Nucleic acid molecules nCHin.sub.3000, and nCHin.sub.1900, produced as described in Example 3, were submitted to additional DNA sequence analysis. Also submitted to additional nucleic acid sequence analysis was nucleic acid molecule nCHin.sub.8500, a HindIII fragment shown to include the 3' end of CUL48 as well as CgC and CUL45. The resultant nucleic acid sequences were compiled to produce SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:85, and SEQ ID NO:86. SEQ ID NO:63 and SEQ ID NO:63 represent the deduced nucleic acid sequences of the two complementary strands of a nucleic acid molecule referred to herein as nCUL49/CUL48.sub.2044. Translation of SEQ ID NO:63 and SEQ ID NO:64 indicates that nucleic acid molecule nCUL49/CUL48.sub.2044 contains at least the following open reading frames: CUL48 and the 3' end of CUL49. SEQ ID NO:77 and SEQ ID NO:78 represent the deduced nucleic acid sequences of the two complementary strands of a nucleic acid molecule referred to herein as nCUL.sub.1823. Translation of SEQ ID NO:77 and SEQ ID NO:78 indicates that nucleic acid molecule nCUL.sub.1823 contains at least the following open reading frames: CUL51, CdUTPase, CUL49.5, and the 5' end of CUL49. SEQ ID NO:85 and SEQ ID NO:86 represent the deduced nucleic acid sequences of the two complementary strands of a nucleic acid molecule referred to herein as nCUL52.sub.749. Translation of SEQ ID NO:85 and SEQ ID NO:86 indicates that nucleic acid molecule nCUL52.sub.749 contains a partial open reading frame for CUL52, the 3' end of which is included in SEQ ID NO:28. The relative location of each of these open reading frames is shown in FIG. 5.
Specifically, SEQ ID NO:63 includes: the coding strand of nCUL49.sub.420 (having SEQ ID NO:65) which encodes a non-full length CUL49 protein of about 139 amino acids, assuming a stop codon spanning about nucleotides 419-421 of SEQ ID NO:63; and the coding strand of nCUL48.sub.1269 (having SEQ ID NO:67, and including SEQ ID NO:24) which encodes a CUL48 protein of about 422 amino acids, assuming a start codon spanning about nucleotides 541-543 and a stop codon spanning about nucleotides 1807-1809 of SEQ ID NO:63. The amino acid sequences of the respective encoded proteins PCUL49.sub.139 and PCUL48.sub.422 are represented by SEQ ID NO:66 and SEQ ID NO:68, respectively.
SEQ ID NO:77 includes the coding strand of nCdUTP.sub.918 (having SEQ ID NO:79 and including SEQ ID NO:15) which encodes a CdUTPase protein of about 305 amino acids, assuming a start codon spanning about nucleotides 624-626 and a stop codon spanning about nucleotides 1539-1541 of SEQ ID NO:77. The amino acid sequence of the respective encoded protein PCdUTP.sub.305 is represented by SEQ ID NO:80.
SEQ ID NO:78 includes: the coding strand of nCUL51.sub.261 (having SEQ ID NO:33) which encodes a non-full length CUL51 protein of about 86 amino acids, assuming translation begins at about nucleotide 1 and a stop codon spanning about nucleotides 259-261 of SEQ ID NO:78; the coding strand of nCUL49.5.sub.261 (having SEQ ID NO:81) which encodes a CUL49.5 protein of about 86 amino acids, assuming a start codon spanning about nucleotides 1175-1177 and a stop codon spanning about nucleotides 1433-1435 of SEQ ID NO:78; and the coding strand of nCUL49.sub.255 (having SEQ ID NO:83) which encodes a non-full length CUL49 protein of about 85 amino acids, assuming a start codon spanning about nucleotides 1586-1588 of SEQ ID NO:78. The amino acid sequence of the respective encoded proteins PCUL51.sub.86, PCUL49.5.sub.86. and PCUL49.sub.85 are represented by SEQ ID NO:34, SEQ ID NO:82 and SEQ ID NO: 84, respectively.
SEQ ID NO:85 includes the coding strand of nCUL52.sub.747 (having SEQ ID NO:87) which encodes a non-full length CUL52 protein of about 249 amino acids, assuming translation begins at about nucleotide 1 of SEQ ID NO:85. The amino acid sequence of the respective encoded protein PCUL52.sub.249 is represented by SEQ ID NO:88.
Example 12
This Example discloses the production of another recombinant CHV genome and recombinant CHV of the present invention.
A 3.2 kb fragment containing the entire CdUTPase sequence was amplified from CHV genomic DNA using forward primer RSF009 having nucleic acid sequence 5' GCCGGTACCAGGCTTTGGACGAGATTTAGG 3', denoted SEQ ID NO:89, and reverse primer RSF008 having nucleic acid sequence 5' GCCGAATTCAATATAATTAATAAACTCTC3', denoted SEQ ID NO:90. RSF009 has an Asp718 site attached to the 5' end of CHV homologous sequences, and RSF008 has an EcoRI site attached to the 5' end of CHV homologous sequences. The resultant PCR-amplified fragment of about 3.2 kb, referred to herein as nCdUTP.sub.3200, was digested with Asp718 and EcoRI and ligated into plitmus28 (available from New England Biolabs). The resultant recombinant plasmid, denoted herein as p28CdUTP.sub.3200, was verified by end-sequencing and restriction mapping. Plasmid p28CdUTP.sub.3200 was then digested with HindIII and XbaI, releasing an 858 base-pair fragment, referred to herein as nCdUTP.sub.858, containing all of the dUTPase open reading frame except 108 bp at the 3' end. The XbaI site was found to be 49 nucleotides upstream of the start codon of the dUTPase ORF (open reading frame), and is also 70 nucleotides into the UL49.5 ORF on the opposite strand, which overlaps the dUTPase ORF. Previous studies have shown that the UL49.5 ORF in other herpesviruses encodes a membrane protein, and is nonessential for growth in tissue culture (e.g., Liang et al, ibid.).
The cohesive ends on the remaining 2.3 kb fragment of p28CdUTP.sub.32001 minus the 858 bp HindIII/XbaI fragment, were filled in using Klenow fragment and dNTPs according to standard methods. The resulting blunt-ended fragment was gel purified by standard methods. A heterologous nucleic acid sequence operatively linked to transcription control regions, in this case an AscCMV/lacZ/BGH cassette described in Example 6, was isolated from its plasmid by digestion with AscI, and the cohesive ends were filled in by Klenow fragment and dNTPs. This cassette was ligated to the HindIII and XbaI-digested p28CdUTP.sub.3200 fragment described above by standard methods resulting in a plasmid containing flanking regions to the CHV dUTPase gene and with the lacZ gene, operatively linked to transcription control regions, inserted into a deletion of the dUTPase gene, herein denoted as pdUTP/lacZ.
A recombinant CHV is produced by co-transfecting the plasmid with the deleted dUTPase gene and the inserted heterologous nucleic acid molecule, in this case pdUTP/lacZ, and CHV DNA into canine cells using previously described methods; see, for example, Graham et al, ibid.). Alternatively, a recombinant CHV is produced by transfecting canine cells with the aforementioned plasmid as described, and then infecting the cells with CHV. Recombinant dUTPase-negative CHV are selected for by passage in mercurithio analogs of deoxyuridine as described in Example 8. If the heterologous nucleic acid molecule is the lacZ gene, such a recombinant CHV can be selected as described in Example 6.
Example 13
This example discloses a method for obtaining higher plaque forming efficiencies to facilitate the production of recombinant CHV genomes and recombinant CHV of the present invention. The method involves the expression of the CHV alpha-tif gene in the presence of CHV genomes introduced into canine cells during CHV production.
The alpha-tif gene of CHV (denoted herein as nCUL48.sub.1269) was identified to lie on two CHV clones described herein: namely, nCHin.sub.3000 and nCHin.sub.8500 Nucleotide sequencing from the ends of these two fragments using universal primers and internal primers designed based on previous sequences was used to determine the entire sequence. A single fragment including the complete alpha-tif gene was PCR amplified from CHV viral DNA using forward primer RSF014 having nucleic acid sequence 540 CCGGAATTCGCTTAGTGAGAGTATAAAC 3', denoted SEQ ID NO 91, and reverse primer RSF016 having nucleic acid sequence 5' CCGGAATTCCCTCATATTATATACTAAC 3', denoted SEQ ID NO:92. Both primers have EcoRI sites attached to the 5' end of the CHV homologous sequences. The resultant PCR amplified fragment of about 1351 base pairs was digested with EcoRI and ligated into EcoRI-digested pCDNA3 (available from Invitrogen, described in Example 6). This plasmid contains a neomycin-resistance gene for selection of stably transformed cell lines by techniques well known to those skilled in the art. Resulting plasmids were checked for the proper orientation by digestion with HindIII. A plasmid consisting of pcDNA3 with the alpha-tif gene inserted in the proper orientation for expression was found, and is designated herein as pATIF.sub.1351 Expression of CHV alpha-tif from pATIF.sub.135 was verified by cell-free transcription/translation using T7 RNA polymerase and a rabbit reticulocyte lysate system. These techniques are readily apparent to those skilled in the art, and are available in kit form, for example, from Amersham. Improved CHV DNA infectivity is then achieved by cotransfection of pATIF.sub.1351 with from about 1 to about 5 .mu.g of CHV DNA by methods such as described in Examples 6-9 and Example 12.
Alternatively, cell lines that stably express CHV alpha-tif are derived. Three canine cell lines, A72, D17 and CF2Th (all available from ATCC) were transfected with pATIF.sub.1351 by standard methods, see, for example, Graham et al, ibid. The cells are then subjected to selection using varying amounts of the antibiotic G418 (available from BMB), determined empirically for each cell line. Cloned G418-resistant cell lines are then derived by standard dilution methods. Cell lines stably expressing CHV alpha-tif are then used for standard CHV DNA transfections or co-transfections such as those described in Examples 6-9 and Example 12.
Example 14
This Example describes the identification and sequencing of additional CHV nucleic acid molecules of the present invention.
CHV nucleic acid molecule nCHin.sub.5500, a CHV HindIII fragment derived as described in Example 2, was submitted to nucleic acid sequence analysis. Sequences derived from the sequence analysis include SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:73 and SEQ ID NO:74. Translation of these sequences indicated that nCHin.sub.5500 includes at least a portion of the CgL and CICP4 coding regions. The nucleic acid molecule also apparently contains the CICP0 coding region.
SEQ ID NO:69 and SEQ ID NO:70 represent the deduced nucleic acid sequences of the two complementary strands of a CHV ICP4 nucleic acid molecule referred to herein as nCICP4.sub.626. Translation of SEQ ID NO:69 indicates that nCICP4.sub.626 encodes a non-full length CICP4 protein of about 208 amino acids, denoted herein as PCICP4.sub.208, having an amino acid sequence represented by SEQ ID NO:72. The coding region for PCICP4.sub.208 is denoted herein as nCICP4.sub.624, having nucleic acid sequence SEQ D NO:71.
SEQ ID NO:73 and SEQ ID NO:74 represent the deduced nucleic acid sequences of the two complementary strands of a CHV gL nucleic acid molecule referred to herein as nCgL.sub.655. Translation of SEQ ID NO:74 indicates that nCgL.sub.655 encodes a non-full length CgL protein of about 171 amino acids, denoted herein as PCgL.sub.171, having an amino acid sequence represented by SEQ ID NO:76. The coding region for PCgL.sub.171 is denoted herein as nCgL.sub.516, having nucleic acid sequence SEQ D NO:75, assuming that the open reading frame spans about nucleotides 1 through 516 of SEQ ID NO:74, with a stop codon spanning about nucleotides 514-516.
Example 15
This example describes the mapping of messenger RNA molecules transcribed from nucleic acid molecules of the present invention. These transcripts are useful for verifying expression (or lack of expression) of various genes.
Total RNA was prepared from CHV-infected cells using a phenol/guanidine extraction method familiar to those skilled in the art. See, for example, Chomczynski et al, 1987, Anal. Biochem. 162, 156-159. Multiple samples of RNA were separated on formaldehyde/agarose gels and transferred to nitrocellulose by standard methods. Based on the sequences of nCUS.sub.10592 designated SEQ ID NO:51 and SEQ ID NO:52, nucleic acid fragments were isolated for use as probes, such that they would hybridize to sequences homologous to the open reading frames nCPK.sub.1203 (SEQ ID NO:7), nCgG.sub.1248 (SEQ ID NO:9), nCgD.sub.1038 (SEQ ID NO:53), nCgI.sub.1095 (SEQ ID NO:55), nCgE.sub.1569 (SEQ ID NO:57), nCUS8.5237 (SEQ ID NO:59), nCUS9.sub.360 (SEQ ID NO:61), nCIR6.sub.552 (SEQ ID NO:3), and nCUS2.sub.1176 (SEQ ID NO:5). The probes were as follows: to hybridize with an nCIR6.sub.552 (SEQ ID NO:3) transcript, a PstI-HindIII restriction fragment extending from about nucleotide 1 to about nucleotide 685 in nCUS.sub.10592 herein denoted as probe A; to hybridize with an nCUS2.sub.1176 (SEQ ID NO:5) transcript, a PCR-amplified fragment extending from about nucleotide 2056 to about nucleotide 2273 in nCUS.sub.10592 herein denoted as probe B; to hybridize with an nCPK.sub.1203 (SEQ ID NO:7) transcript, a PstI-DraI restriction fragment extending from about nucleotide 2326 to about nucleotide 2788 in nCUS.sub.10592 herein denoted as probe C; to hybridize with an nCgG.sub.1248 (SEQ ID NO:9) transcript, a BamHI-PstI restriction fragment extending from about nucleotide 3766 to about nucleotide 4494 in nCUS.sub.10592 herein denoted as probe D; to hybridize with an nCgD.sub.1038 (SEQ ID NO:53) transcript, either a BglII--BglII restriction fragment extending from about nucleotide 5728 to about nucleotide 6561 in nCUS.sub.10592 (this piece slightly overlaps nCgI.sub.1095) herein denoted as probe E, or a PCR-amplified fragment that will extend from about nucleotide 5295 to about nucleotide 5885 in nCUS.sub.10592 herein denoted as probe F; to hybridize with an nCgI.sub.1095 (SEQ ID NO:55) transcript, a BglII--BglII restriction fragment extending from about nucleotide 6561 to about nucleotide 7263 in nCUS.sub.10592 herein denoted as probe G; to hybridize with an nCgE.sub.1569 (SEQ ID NO:57) transcript, a deletion subclone extending from about nucleotide 7667 to about nucleotide 8425 in nCUS.sub.10592 herein denoted as probe H; to hybridize with a putative ncus85237 (SEQ ID NO:59) transcript, a PCR-amplified fragment extending from about nucleotide 9023 to about nucleotide 9242 in nCUS.sub.10592 herein denoted as probe I; to hybridize to an nCUS9.sub.360 (SEQ ID NO:61) transcript, a PCR-amplified fragment extending from about nucleotide 9447 to about nucleotide 9715 in nCUS.sub.10592 herein denoted as probe J. These probes are shown graphically in FIG. 4. The probes were labelled with .sup.32 P DATP using random priming, a technique well known to those skilled in the art. Hybridization of the probes to the RNA samples on nitrocellulose and washing at stringent temperatures were done according to well known methods.
The main transcript sizes that hybridized to the various probes were as follows: probe A hybridized strongly to a transcript of about 0.7 kb, but also hybridized weakly to transcripts of about 1.7, 2.2 and 2.6 kb; probe B hybridized with a transcript of about 2.2 kb; probe C hybridized to a transcript of about 2.6 kb; probe D hybridized to two transcripts of about 1.9 kb and 2.6 kb; probe E hybridized to two transcripts of about 4.2 kb and 3.2 kb; probe G hybridized to two transcripts of about 4.2 kb and 3.2 kb; probe H hybridized to three transcripts of about 1.9 kb, 3.2 kb, and 4.2 kb; probe I hybridized to the same three transcripts as probe H; probe J hybridized to a transcript of about 2.1 kb. These data suggest that the transcripts of US2, US9, and IR6, although starting at different points, terminated in a common general area in the inverted repeats, since probe A hybridized to transcripts that were generally the same size as the US2 and US9 transcripts. Furthermore, these data suggest that the PK and gG transcripts overlapped, probably terminating at a common 3' terminus, since probe C hybridized to only a 2.6 kb transcript but probe D hybridized with both the 2.6 kb transcript and the 1.4 kb transcript. This result was even more likely because only one polyadenylation consensus sequence (AATAAA) was found downstream of the gG ORF, but before the gD ORF. This polyadenylation signal was found from nucleotide 4935-4940 of nCUS.sub.10592. Similarly, these data indicate the gI and gE transcripts overlapped, probably terminating at a common 3' terminus since probe G hybridized to a transcript of 2.6 kb, while probe H hybridized both to the 2.6 kb transcript and the 1.9 kb transcript. Probes E, G, and H also all hybridized to a 4.2 kb transcript, suggesting that the gD transcript also overlapped the gI and gE transcripts, probably terminating at a common 3' terminus. Verification of this result is if probe F hybridizes only to the 4.2 kb transcript. Probe I hybridized to only the 4.2, 2.6 and 2.9 kb transcripts suggesting two things; first, that these three transcripts probably terminated at polyadenylation signals at about 9186-9181, 9256-9261 or 9260-9265 of nCUS.sub.10592, also that the putative US8.5 open reading frame is not transcribed to levels detectable by Northern analysis.
SEQUENCE LISTING
The following Sequence Listing is submitted pursuant to 37 CFR .sctn.1.821. A copy in computer readable form is also submitted herewith.
Applicants assert pursuant to 37 CFR .sctn.1.821(f) that the content of the paper and computer readable copies of SEQ ID NO:1 through SEQ ID NO:92 submitted herewith are the same.
__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 92- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5495 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- CTGCAGTGTA TTTAAAAAAT AAAATCTATG AATGAAATCT ATGAATGAAA TC - #TATGAATG 60- AAATCTATGA ATGAAATCTA TGAATGAAAT CTATGAATGA AATCTATGAA TG - #AAATCTAT 120- GAATGAAATC TATGAATGAA ATCTATGAAT GAAATCTATG AATGAAATCT AT - #GAATGAAA 180- TCTATGAATG AAATCTATGA ATGAAATCTA TGAATGAAAT CTATGAATGA AA - #TCTATGAA 240- TGAAATCTAT GAATGAAATC TATGAATGAA ATCTATGAAT GAAATCTATG AA - #TGAAATCT 300- ATGAGACAAG TATTTTAAAA ATATTTTAAA TTTATAAGGT TAAGTACAGT AG - #GCGGTTGG 360- GTAAACATTT TTAGTTTTTC AAGTTTTTAG TTTTTCTGGT ATCCTACCCA AC - #ACAAATGC 420- ATCTTCGGAT ACATTTATTT TAAGAGAGTA ATCACTTTTT AGAATATATC TT - #ATTGGTGG 480- TACATTTATA AATTTTGGAC CATCCCAATA ACACTTCGAT TCCACAAGCG AA - #GAAGGTAC 540- TTCCATAAGC TGAGAAGCGT TTACTTGATT GTAGGGAGAA CTTGGCGTTT CA - #AAATCCTT 600- TAGAACGTAT AGTCTGCAAT ACATAGGTTC AATATCATCT TCATACCTCT CA - #TCAGGATA 660- TGAAAATGGA AGTTTCACAA AGGTTCCATC ACGAAGCTTT TTGAAGAATC GT - #ACATCCGT 720- AGGTGGTGTA GGAACAATAG TGAAGGCGTG CGGTTCACCC TGGTTTTTCA CA - #CGTGCAAG 780- CGCTGGTGTG GTTTTAGGGC GAACTGGAAA ATAACCAGGC GGAACTTGTG CG - #TAGAATCC 840- TTCATTAAGT TCTCCACGAC AGCGTCTGAA GTATGATGGC ATATTAGCTT GA - #TCGGAGTT 900- GTTATCAAAT AGAGCAAATG AAGCACTCAT TTTAAAACTT TTTAGTTAAG CT - #TTAAAAAC 960- AAGTGAAGAT TTAAAAATGT AGGATAAAAT GCCAGTTTAT ATACAGTAAG AA - #TATGGGAG1020- TGGTTCACAT AAAAAACCAG AATTTCAGGT TTACATCTAC TGTTTATTCA CA - #ACAAATAT1080- AAACAAACTT AGTTTCCACA TAAACATGAA CTAAATAGAG ATGAACGTTG AG - #CGTTGGTA1140- GGTTGTGTAG AAGACATACC ATCGTTTTCA TTTTTGGTTA TTGTTTTGGC GC - #GCCTTGAA1200- AATAATCGTT TAAAAATATT TGGTTTGGAT AGCCTTTTCA TAGGTTTCAC CC - #CATGCAAG1260- TCATCCTCTT CTGGTTCAGG AATTTCTTCA TAACCATTAT GGGATATTAT TG - #CACACATA1320- AATGATTCGA TTACCGGGGG GGCAGAACGT GTCTCATTTA TATAAAGAGA AT - #CACATACA1380- TCGCTTATAG AACATGTAGA ACTGTCAGAA TCCTCTTTAA AACTATTTTT AA - #TTTCACAA1440- TTAGTTTCTT CTAGTTCATT ATCCACCATC GCATTAGCGT ATTTCCAAAT AT - #CATTCTCT1500- GAGGAATAAT GAGATGCAGA GCATGAAGAA GAGGATGAGG AGGAGGAGGA TG - #AAGATGAG1560- GATATAGAGG GACATCTTGG AGAGCTTTCA AAGTTGAATG GAGTATTAAA TG - #TTGTACCA1620- TAAAAAATGT CACTTAACAT AGGGGGTACT TTAAAGGAGG ACAGAAAGGT GT - #CTAATACA1680- GGTACCCATA TAAACGAGGG GCAATAAACA CTCCCAGAAT CATCGATATG TT - #TTACATTA1740- TTTTTGGAAA TCTCAAGACA CTCAGGTTTC CAGGATGGTT CCGGCCATTC AC - #ATGATACA1800- TATGCATAAA TTAGTCGCTT TGGTCCTGGG ATATTAGAAA TGACTGGCTC AC - #ATAAATCC1860- GCTGCACCGA AAACCCATAG ATTAAGAGGA TAGTTTCCAA ATATACCAGA GT - #TTAGATAG1920- TTATACCCCG AAACAGCCGA TTTCCATTCG ATGCTAGCCC CAGGTTTATC CT - #CATAAAAT1980- AAAAAGTCCT CCTCCTCCCC CTCCGTTGGT TTTAAAAATT TACTATTAGA GG - #TTGATGTT2040- CTTACTATAG GCCTTGAAAC TCTAGGTAGA TGTTTTATAG AGTCCATAAA AT - #AACATAAG2100- TTTGCAGATC GTAATATTAT AGGCATAGCC AATCGTGTGA GAGAAAGGAT AT - #AGCATTGT2160- CTAGCCATAA AACACCAAAG ATCAGGATGA ACATCTTGGG AGTTTCCTGG TA - #ACGCCCCA2220- TTTTTGTCAA TAAACGTAAC AATATTAACT TCAACCACAC CCATAATTAA AT - #TTTATGTA2280- TGAATCCAAT AAAGGTTAAT ACACACCTAA TTTATGTTAT AATTTTAGAA GA - #AGCTGCAG2340- TTGATGAGTT GATATTAACA TAACAATTTC ACAATTACCT GATATGGCAA AG - #TGTACCAC2400- CGAAAAGTTT TGTTGTATCA GCGTGAATAG AGAATCTTCT GTCGATCCAG AA - #GACTTCTA2460- TAAACCGGTT CCTCTAACTT CAGATTTGAT TGAAGAGGAT AACCTACATC AA - #GACAAAAT2520- AATGGATGAG GATTTATACT CGGATTTTAG TGATGATGAC TTTATGGATT AT - #ACAAAAAA2580- TCCAACTGAA AGTGAAAATG AAAGAGAAAG TGACGAAGAA GTTGAAGAAA GT - #TATGAAAG2640- TGATGAAGAT AAAAAAAGTT TATCTCCTAC TAAAAGCGAA GGAATTGAAG CG - #GCTGAAGC2700- GCTAAAGTTT TCTGTTGTTA AATCGTTAAC GCCTGGGTCA GAAGGAAGAG TT - #TTTATTGC2760- TCTTAAAAAA GATAAAGATA CAAGCTATAA GGTAATTTTA AAAATTGGAC AA - #AGGGGAAA2820- CACGCTTGTG GAATCGTTAA TTTTGAGAAA TATTAGTCAC CAATCTATAA TT - #AAACTTCA2880- AGACACTCTT TTTTATAAAG AGTTAACATG TTTGGTGTTA CCGTATTATA AA - #TATGATCT2940- ATATAATTTT TTAATGGATC ATGGGAAATC TCTGTCTTTT GAATCTGTAA TT - #AAAATTGA3000- AAAACAAATA TTAACTGGAC TTCAATATAT TCATGGAAAA AAAATTATTC AT - #CGAGATAT3060- AAAAACTGAA AATATTTTCT TGGATAATGA CTCTAATGTT TGTATAGGTG AT - #TTTGGGGC3120- TTCTCAATTT CCTGTTTCCT CACCAGATTA TTTGGGAATT GCGGGGACTA TT - #GAAACTAA3180- TGCTCCTGAA GTTCTATCAA AGGATGCGTA CAACTGTAAA GCTGATATTT GG - #AGTGCTGG3240- TATAATTTTA TTTGAAATGC TTGCATATCC TAATGTTTTG TTTGAGGAGG AA - #GAAAGAGA3300- TAGTAGCGAT TTAATAAACA ATTGTAATCT TCATCTTATA AAAATTATAT CA - #ACTCTGAA3360- GATTAACCCA AATGAATTTC CATCTGATTT GGAATCTAAT CTAGTAAAAC AT - #TTTATAAA3420- ATATGCTAAT AATGATAGAC CTCCATTTAC ACGATATAAT CGTCTAAATA AC - #CTTAAATT3480- ACATCTCGAT GGTGAATTTT TAATTCATAA AATGCTAACA TTTGATGCAT CT - #CTACGACC3540- AAGTGCGGAA GAACTATTAT CCTATCAGAT TTTTAGTAAA CAATAAATTT CA - #TAAAAATG3600- GGCGTGGAAT TTTTTATTGT TTTATATAAA ACGGGTGTTT GAAAGCTCTT TT - #TTATTAAT3660- TTTATTTTTA CATCCTAGCT ACAATATTAT AGTTATCATG TTGTATACGC TG - #TTTTTTGT3720- TTTTTATTTT AAGGTAGTTT TATCTCGCAT AGCTCCGCTA GAGTTGTGTT AT - #GCGGATCC3780- TAAAGAAAAT ACAACTGAAC CTACACAACT TCCTACAGGG GAACAATCTA AG - #ACTCTTAT3840- TCCCGTGGTA ACAAACGGAT ATGTTGAATA CTCTAAAGGA TGTGAACTAC GA - #TTACTAGA3900- TACATATGTA AATGTATCTT CACGACCAGA AAAAAAGGTT AATGCTACAA TT - #GGATGGTC3960- ATTTGATCTT GGTTGTCAAA TTCCTTTAAT TTATAGAGAA TATTATAATT GT - #ACTGGTAA4020- TATAATACCA TCACCAGAAA CTTGTGATGG TTATTCTTTA ACTTTGGTAA AA - #TCTGAAAG4080- TATATCATCT TATGCACTTG TTAATGTTAG TTTGCTTATT CAACCAGGAA TT - #TTTGATTC4140- TGGTAGATAT TTATACTCAC TTGTTTTTGG AAACGATAGT TATAACGGAA GA - #ATTGAAGT4200- TCGAGTGGAT AATGAGACAG ACTATCCATG TTTTATGATG CATGGATTGA CT - #GTAAAAAA4260- GGGTGATAAA CTTCATATTC CTTATAAACC ATCCACAAAT CCTAATCATA AA - #CGATATAG4320- AGGTTGTTTT CCAATATCAA ATACTGAGCT ATGGAATAAT ATTAGTGATG AA - #AGTGTTGG4380- TAGATATTCA TATGATGAAG AATATGAAGA ATATGAAGAA GAAAACGAAG AT - #TTTGAAGA4440- TCTACAATCA AAAGATTGCC GCAAATCCAA TCTTTTTGAT ATGAAGAAGA CT - #TTTAATTT4500- GGCTGCAGGT TCTCAAAGTT TATTGATTGC TAGTTTGGGT AAATCAATTT CA - #GAACAACC4560- GTGGTCATTT AAAATTAATG AAAGTTATGA ACTTTTTAAT AATTTGTCTA TC - #ACCCTTCA4620- ATCGGAAGAA GATTCTAATA TACTGAATCC TGAAATTGTA ACGTTTACCA CA - #CCACCACC4680- TACTGAAAAT ACACATATGT TTATGTCAAA TAATGAAACT ATGTATGAAG AA - #GAAAGTGT4740- TTTAAGCATT ATTCAATTGT TTAACAATGG TTATAATAAT TGTAATACCC AT - #ATAAAGGT4800- AATTGGATTT GGAACAATTA TCTTTATTAT TTTATTTTTT GTTGCTGTGT TT - #TTTTGTGG4860- ATATACTTGT GTATTAAACT CTCGTATTAA AATGATTAAC CATGCTTATA TA - #CAACCCCA4920- GAAATTAAAT TTTTATGATA TTTAATAAAA CTATTATGAA ACTTCTTATA AC - #TTATTTGT4980- TTTTATTAAA TGGGTTGGGT TGGTTTTAAA ATTACATACG TGTATTAAGA AT - #TAACATCA5040- TAAAGGACAC ACCCATGAAA AACATTTAAA TTCTATTAAT TTGAACGGAT TA - #AACATTTT5100- CTCATTTTAA GAGTTGCTAC GACTTTTGAT AGTAAAATGA TTAAACTTCT AT - #TTATCTTA5160- TTTTATTTTA ACCCAATAAC TGGATATAAA TGGGTAGACC CTCCTCGTAG GT - #ATAATTAC5220- ACCGTTTTAA GAATGATTCC AGATATTCCA AATCCAATGG ATCCTTCTAA AA - #ACGCTGAA5280- GTTCGGTATG TAACTTCTAC TGACCCATGT GATATGGTTG CTTTGATTTC TA - #ATCCAAAT5340- ATAGAATCTA CAATTAAAAC GATTCAATTT GTGCAAAAGA AAAAATTTTA CA - #ATGCATCT5400- CTTAGTTGGT TTAAAGTTGG AGATGATTGT ACATATCCAA TATATTTAAT TC - #AATATTTT5460# 5495 GAGA ATTTGGCATA TGTTT- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5495 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- AAACATATGC CAAATTCTCT TTGAGGATCA CAATCAAAAT ATTGAATTAA AT - #ATATTGGA 60- TATGTACAAT CATCTCCAAC TTTAAACCAA CTAAGAGATG CATTGTAAAA TT - #TTTTCTTT 120- TGCACAAATT GAATCGTTTT AATTGTAGAT TCTATATTTG GATTAGAAAT CA - #AAGCAACC 180- ATATCACATG GGTCAGTAGA AGTTACATAC CGAACTTCAG CGTTTTTAGA AG - #GATCCATT 240- GGATTTGGAA TATCTGGAAT CATTCTTAAA ACGGTGTAAT TATACCTACG AG - #GAGGGTCT 300- ACCCATTTAT ATCCAGTTAT TGGGTTAAAA TAAAATAAGA TAAATAGAAG TT - #TAATCATT 360- TTACTATCAA AAGTCGTAGC AACTCTTAAA ATGAGAAAAT GTTTAATCCG TT - #CAAATTAA 420- TAGAATTTAA ATGTTTTTCA TGGGTGTGTC CTTTATGATG TTAATTCTTA AT - #ACACGTAT 480- GTAATTTTAA AACCAACCCA ACCCATTTAA TAAAAACAAA TAAGTTATAA GA - #AGTTTCAT 540- AATAGTTTTA TTAAATATCA TAAAAATTTA ATTTCTGGGG TTGTATATAA GC - #ATGGTTAA 600- TCATTTTAAT ACGAGAGTTT AATACACAAG TATATCCACA AAAAAACACA GC - #AACAAAAA 660- ATAAAATAAT AAAGATAATT GTTCCAAATC CAATTACCTT TATATGGGTA TT - #ACAATTAT 720- TATAACCATT GTTAAACAAT TGAATAATGC TTAAAACACT TTCTTCTTCA TA - #CATAGTTT 780- CATTATTTGA CATAAACATA TGTGTATTTT CAGTAGGTGG TGGTGTGGTA AA - #CGTTACAA 840- TTTCAGGATT CAGTATATTA GAATCTTCTT CCGATTGAAG GGTGATAGAC AA - #ATTATTAA 900- AAAGTTCATA ACTTTCATTA ATTTTAAATG ACCACGGTTG TTCTGAAATT GA - #TTTACCCA 960- AACTAGCAAT CAATAAACTT TGAGAACCTG CAGCCAAATT AAAAGTCTTC TT - #CATATCAA1020- AAAGATTGGA TTTGCGGCAA TCTTTTGATT GTAGATCTTC AAAATCTTCG TT - #TTCTTCTT1080- CATATTCTTC ATATTCTTCA TCATATGAAT ATCTACCAAC ACTTTCATCA CT - #AATATTAT1140- TCCATAGCTC AGTATTTGAT ATTGGAAAAC AACCTCTATA TCGTTTATGA TT - #AGGATTTG1200- TGGATGGTTT ATAAGGAATA TGAAGTTTAT CACCCTTTTT TACAGTCAAT CC - #ATGCATCA1260- TAAAACATGG ATAGTCTGTC TCATTATCCA CTCGAACTTC AATTCTTCCG TT - #ATAACTAT1320- CGTTTCCAAA AACAAGTGAG TATAAATATC TACCAGAATC AAAAATTCCT GG - #TTGAATAA1380- GCAAACTAAC ATTAACAAGT GCATAAGATG ATATACTTTC AGATTTTACC AA - #AGTTAAAG1440- AATAACCATC ACAAGTTTCT GGTGATGGTA TTATATTACC AGTACAATTA TA - #ATATTCTC1500- TATAAATTAA AGGAATTTGA CAACCAAGAT CAAATGACCA TCCAATTGTA GC - #ATTAACCT1560- TTTTTTCTGG TCGTGAAGAT ACATTTACAT ATGTATCTAG TAATCGTAGT TC - #ACATCCTT1620- TAGAGTATTC AACATATCCG TTTGTTACCA CGGGAATAAG AGTCTTAGAT TG - #TTCCCCTG1680- TAGGAAGTTG TGTAGGTTCA GTTGTATTTT CTTTAGGATC CGCATAACAC AA - #CTCTAGCG1740- GAGCTATGCG AGATAAAACT ACCTTAAAAT AAAAAACAAA AAACAGCGTA TA - #CAACATGA1800- TAACTATAAT ATTGTAGCTA GGATGTAAAA ATAAAATTAA TAAAAAAGAG CT - #TTCAAACA1860- CCCGTTTTAT ATAAAACAAT AAAAAATTCC ACGCCCATTT TTATGAAATT TA - #TTGTTTAC1920- TAAAAATCTG ATAGGATAAT AGTTCTTCCG CACTTGGTCG TAGAGATGCA TC - #AAATGTTA1980- GCATTTTATG AATTAAAAAT TCACCATCGA GATGTAATTT AAGGTTATTT AG - #ACGATTAT2040- ATCGTGTAAA TGGAGGTCTA TCATTATTAG CATATTTTAT AAAATGTTTT AC - #TAGATTAG2100- ATTCCAAATC AGATGGAAAT TCATTTGGGT TAATCTTCAG AGTTGATATA AT - #TTTTATAA2160- GATGAAGATT ACAATTGTTT ATTAAATCGC TACTATCTCT TTCTTCCTCC TC - #AAACAAAA2220- CATTAGGATA TGCAAGCATT TCAAATAAAA TTATACCAGC ACTCCAAATA TC - #AGCTTTAC2280- AGTTGTACGC ATCCTTTGAT AGAACTTCAG GAGCATTAGT TTCAATAGTC CC - #CGCAATTC2340- CCAAATAATC TGGTGAGGAA ACAGGAAATT GAGAAGCCCC AAAATCACCT AT - #ACAAACAT2400- TAGAGTCATT ATCCAAGAAA ATATTTTCAG TTTTTATATC TCGATGAATA AT - #TTTTTTTC2460- CATGAATATA TTGAAGTCCA GTTAATATTT GTTTTTCAAT TTTAATTACA GA - #TTCAAAAG2520- ACAGAGATTT CCCATGATCC ATTAAAAAAT TATATAGATC ATATTTATAA TA - #CGGTAACA2580- CCAAACATGT TAACTCTTTA TAAAAAAGAG TGTCTTGAAG TTTAATTATA GA - #TTGGTGAC2640- TAATATTTCT CAAAATTAAC GATTCCACAA GCGTGTTTCC CCTTTGTCCA AT - #TTTTAAAA2700- TTACCTTATA GCTTGTATCT TTATCTTTTT TAAGAGCAAT AAAAACTCTT CC - #TTCTGACC2760- CAGGCGTTAA CGATTTAACA ACAGAAAACT TTAGCGCTTC AGCCGCTTCA AT - #TCCTTCGC2820- TTTTAGTAGG AGATAAACTT TTTTTATCTT CATCACTTTC ATAACTTTCT TC - #AACTTCTT2880- CGTCACTTTC TCTTTCATTT TCACTTTCAG TTGGATTTTT TGTATAATCC AT - #AAAGTCAT2940- CATCACTAAA ATCCGAGTAT AAATCCTCAT CCATTATTTT GTCTTGATGT AG - #GTTATCCT3000- CTTCAATCAA ATCTGAAGTT AGAGGAACCG GTTTATAGAA GTCTTCTGGA TC - #GACAGAAG3060- ATTCTCTATT CACGCTGATA CAACAAAACT TTTCGGTGGT ACACTTTGCC AT - #ATCAGGTA3120- ATTGTGAAAT TGTTATGTTA ATATCAACTC ATCAACTGCA GCTTCTTCTA AA - #ATTATAAC3180- ATAAATTAGG TGTGTATTAA CCTTTATTGG ATTCATACAT AAAATTTAAT TA - #TGGGTGTG3240- GTTGAAGTTA ATATTGTTAC GTTTATTGAC AAAAATGGGG CGTTACCAGG AA - #ACTCCCAA3300- GATGTTCATC CTGATCTTTG GTGTTTTATG GCTAGACAAT GCTATATCCT TT - #CTCTCACA3360- CGATTGGCTA TGCCTATAAT ATTACGATCT GCAAACTTAT GTTATTTTAT GG - #ACTCTATA3420- AAACATCTAC CTAGAGTTTC AAGGCCTATA GTAAGAACAT CAACCTCTAA TA - #GTAAATTT3480- TTAAAACCAA CGGAGGGGGA GGAGGAGGAC TTTTTATTTT ATGAGGATAA AC - #CTGGGGCT3540- AGCATCGAAT GGAAATCGGC TGTTTCGGGG TATAACTATC TAAACTCTGG TA - #TATTTGGA3600- AACTATCCTC TTAATCTATG GGTTTTCGGT GCAGCGGATT TATGTGAGCC AG - #TCATTTCT3660- AATATCCCAG GACCAAAGCG ACTAATTTAT GCATATGTAT CATGTGAATG GC - #CGGAACCA3720- TCCTGGAAAC CTGAGTGTCT TGAGATTTCC AAAAATAATG TAAAACATAT CG - #ATGATTCT3780- GGGAGTGTTT ATTGCCCCTC GTTTATATGG GTACCTGTAT TAGACACCTT TC - #TGTCCTCC3840- TTTAAAGTAC CCCCTATGTT AAGTGACATT TTTTATGGTA CAACATTTAA TA - #CTCCATTC3900- AACTTTGAAA GCTCTCCAAG ATGTCCCTCT ATATCCTCAT CTTCATCCTC CT - #CCTCCTCA3960- TCCTCTTCTT CATGCTCTGC ATCTCATTAT TCCTCAGAGA ATGATATTTG GA - #AATACGCT4020- AATGCGATGG TGGATAATGA ACTAGAAGAA ACTAATTGTG AAATTAAAAA TA - #GTTTTAAA4080- GAGGATTCTG ACAGTTCTAC ATGTTCTATA AGCGATGTAT GTGATTCTCT TT - #ATATAAAT4140- GAGACACGTT CTGCCCCCCC GGTAATCGAA TCATTTATGT GTGCAATAAT AT - #CCCATAAT4200- GGTTATGAAG AAATTCCTGA ACCAGAAGAG GATGACTTGC ATGGGGTGAA AC - #CTATGAAA4260- AGGCTATCCA AACCAAATAT TTTTAAACGA TTATTTTCAA GGCGCGCCAA AA - #CAATAACC4320- AAAAATGAAA ACGATGGTAT GTCTTCTACA CAACCTACCA ACGCTCAACG TT - #CATCTCTA4380- TTTAGTTCAT GTTTATGTGG AAACTAAGTT TGTTTATATT TGTTGTGAAT AA - #ACAGTAGA4440- TGTAAACCTG AAATTCTGGT TTTTTATGTG AACCACTCCC ATATTCTTAC TG - #TATATAAA4500- CTGGCATTTT ATCCTACATT TTTAAATCTT CACTTGTTTT TAAAGCTTAA CT - #AAAAAGTT4560- TTAAAATGAG TGCTTCATTT GCTCTATTTG ATAACAACTC CGATCAAGCT AA - #TATGCCAT4620- CATACTTCAG ACGCTGTCGT GGAGAACTTA ATGAAGGATT CTACGCACAA GT - #TCCGCCTG4680- GTTATTTTCC AGTTCGCCCT AAAACCACAC CAGCGCTTGC ACGTGTGAAA AA - #CCAGGGTG4740- AACCGCACGC CTTCACTATT GTTCCTACAC CACCTACGGA TGTACGATTC TT - #CAAAAAGC4800- TTCGTGATGG AACCTTTGTG AAACTTCCAT TTTCATATCC TGATGAGAGG TA - #TGAAGATG4860- ATATTGAACC TATGTATTGC AGACTATACG TTCTAAAGGA TTTTGAAACG CC - #AAGTTCTC4920- CCTACAATCA AGTAAACGCT TCTCAGCTTA TGGAAGTACC TTCTTCGCTT GT - #GGAATCGA4980- AGTGTTATTG GGATGGTCCA AAATTTATAA ATGTACCACC AATAAGATAT AT - #TCTAAAAA5040- GTGATTACTC TCTTAAAATA AATGTATCCG AAGATGCATT TGTGTTGGGT AG - #GATACCAG5100- AAAAACTAAA AACTTGAAAA ACTAAAAATG TTTACCCAAC CGCCTACTGT AC - #TTAACCTT5160- ATAAATTTAA AATATTTTTA AAATACTTGT CTCATAGATT TCATTCATAG AT - #TTCATTCA5220- TAGATTTCAT TCATAGATTT CATTCATAGA TTTCATTCAT AGATTTCATT CA - #TAGATTTC5280- ATTCATAGAT TTCATTCATA GATTTCATTC ATAGATTTCA TTCATAGATT TC - #ATTCATAG5340- ATTTCATTCA TAGATTTCAT TCATAGATTT CATTCATAGA TTTCATTCAT AG - #ATTTCATT5400- CATAGATTTC ATTCATAGAT TTCATTCATA GATTTCATTC ATAGATTTCA TT - #CATAGATT5460# 5495 TTTT TTAAATACAC TGCAG- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 552 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..552- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- ATG AGT GCT TCA TTT GCT CTA TTT GAT AAC AA - #C TCC GAT CAA GCT AAT 48Met Ser Ala Ser Phe Ala Leu Phe Asp Asn As - #n Ser Asp Gln Ala Asn# 15- ATG CCA TCA TAC TTC AGA CGC TGT CGT GGA GA - #A CTT AAT GAA GGA TTC 96Met Pro Ser Tyr Phe Arg Arg Cys Arg Gly Gl - #u Leu Asn Glu Gly Phe# 30- TAC GCA CAA GTT CCG CCT GGT TAT TTT CCA GT - #T CGC CCT AAA ACC ACA 144Tyr Ala Gln Val Pro Pro Gly Tyr Phe Pro Va - #l Arg Pro Lys Thr Thr# 45- CCA GCG CTT GCA CGT GTG AAA AAC CAG GGT GA - #A CCG CAC GCC TTC ACT 192Pro Ala Leu Ala Arg Val Lys Asn Gln Gly Gl - #u Pro His Ala Phe Thr# 60- ATT GTT CCT ACA CCA CCT ACG GAT GTA CGA TT - #C TTC AAA AAG CTT CGT 240Ile Val Pro Thr Pro Pro Thr Asp Val Arg Ph - #e Phe Lys Lys Leu Arg# 80- GAT GGA ACC TTT GTG AAA CTT CCA TTT TCA TA - #T CCT GAT GAG AGG TAT 288Asp Gly Thr Phe Val Lys Leu Pro Phe Ser Ty - #r Pro Asp Glu Arg Tyr# 95- GAA GAT GAT ATT GAA CCT ATG TAT TGC AGA CT - #A TAC GTT CTA AAG GAT 336Glu Asp Asp Ile Glu Pro Met Tyr Cys Arg Le - #u Tyr Val Leu Lys Asp# 110- TTT GAA ACG CCA AGT TCT CCC TAC AAT CAA GT - #A AAC GCT TCT CAG CTT 384Phe Glu Thr Pro Ser Ser Pro Tyr Asn Gln Va - #l Asn Ala Ser Gln Leu# 125- ATG GAA GTA CCT TCT TCG CTT GTG GAA TCG AA - #G TGT TAT TGG GAT GGT 432Met Glu Val Pro Ser Ser Leu Val Glu Ser Ly - #s Cys Tyr Trp Asp Gly# 140- CCA AAA TTT ATA AAT GTA CCA CCA ATA AGA TA - #T ATT CTA AAA AGT GAT 480Pro Lys Phe Ile Asn Val Pro Pro Ile Arg Ty - #r Ile Leu Lys Ser Asp145 1 - #50 1 - #55 1 -#60- TAC TCT CTT AAA ATA AAT GTA TCC GAA GAT GC - #A TTT GTG TTG GGT AGG 528Tyr Ser Leu Lys Ile Asn Val Ser Glu Asp Al - #a Phe Val Leu Gly Arg# 175# 552TA AAA ACT TGAIle Pro Glu Lys Leu Lys Thr * 180- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 183 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- Met Ser Ala Ser Phe Ala Leu Phe Asp Asn As - #n Ser Asp Gln Ala Asn# 15- Met Pro Ser Tyr Phe Arg Arg Cys Arg Gly Gl - #u Leu Asn Glu Gly Phe# 30- Tyr Ala Gln Val Pro Pro Gly Tyr Phe Pro Va - #l Arg Pro Lys Thr Thr# 45- Pro Ala Leu Ala Arg Val Lys Asn Gln Gly Gl - #u Pro His Ala Phe Thr# 60- Ile Val Pro Thr Pro Pro Thr Asp Val Arg Ph - #e Phe Lys Lys Leu Arg# 80- Asp Gly Thr Phe Val Lys Leu Pro Phe Ser Ty - #r Pro Asp Glu Arg Tyr# 95- Glu Asp Asp Ile Glu Pro Met Tyr Cys Arg Le - #u Tyr Val Leu Lys Asp# 110- Phe Glu Thr Pro Ser Ser Pro Tyr Asn Gln Va - #l Asn Ala Ser Gln Leu# 125- Met Glu Val Pro Ser Ser Leu Val Glu Ser Ly - #s Cys Tyr Trp Asp Gly# 140- Pro Lys Phe Ile Asn Val Pro Pro Ile Arg Ty - #r Ile Leu Lys Ser Asp145 1 - #50 1 - #55 1 -#60- Tyr Ser Leu Lys Ile Asn Val Ser Glu Asp Al - #a Phe Val Leu Gly Arg# 175- Ile Pro Glu Lys Leu Lys Thr 180- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1176 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1176- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- ATG GGT GTG GTT GAA GTT AAT ATT GTT ACG TT - #T ATT GAC AAA AAT GGG 48Met Gly Val Val Glu Val Asn Ile Val Thr Ph - #e Ile Asp Lys Asn Gly# 15- GCG TTA CCA GGA AAC TCC CAA GAT GTT CAT CC - #T GAT CTT TGG TGT TTT 96Ala Leu Pro Gly Asn Ser Gln Asp Val His Pr - #o Asp Leu Trp Cys Phe# 30- ATG GCT AGA CAA TGC TAT ATC CTT TCT CTC AC - #A CGA TTG GCT ATG CCT 144Met Ala Arg Gln Cys Tyr Ile Leu Ser Leu Th - #r Arg Leu Ala Met Pro# 45- ATA ATA TTA CGA TCT GCA AAC TTA TGT TAT TT - #T ATG GAC TCT ATA AAA 192Ile Ile Leu Arg Ser Ala Asn Leu Cys Tyr Ph - #e Met Asp Ser Ile Lys# 60- CAT CTA CCT AGA GTT TCA AGG CCT ATA GTA AG - #A ACA TCA ACC TCT AAT 240His Leu Pro Arg Val Ser Arg Pro Ile Val Ar - #g Thr Ser Thr Ser Asn# 80- AGT AAA TTT TTA AAA CCA ACG GAG GGG GAG GA - #G GAG GAC TTT TTA TTT 288Ser Lys Phe Leu Lys Pro Thr Glu Gly Glu Gl - #u Glu Asp Phe Leu Phe# 95- TAT GAG GAT AAA CCT GGG GCT AGC ATC GAA TG - #G AAA TCG GCT GTT TCG 336Tyr Glu Asp Lys Pro Gly Ala Ser Ile Glu Tr - #p Lys Ser Ala Val Ser# 110- GGG TAT AAC TAT CTA AAC TCT GGT ATA TTT GG - #A AAC TAT CCT CTT AAT 384Gly Tyr Asn Tyr Leu Asn Ser Gly Ile Phe Gl - #y Asn Tyr Pro Leu Asn# 125- CTA TGG GTT TTC GGT GCA GCG GAT TTA TGT GA - #G CCA GTC ATT TCT AAT 432Leu Trp Val Phe Gly Ala Ala Asp Leu Cys Gl - #u Pro Val Ile Ser Asn# 140- ATC CCA GGA CCA AAG CGA CTA ATT TAT GCA TA - #T GTA TCA TGT GAA TGG 480Ile Pro Gly Pro Lys Arg Leu Ile Tyr Ala Ty - #r Val Ser Cys Glu Trp145 1 - #50 1 - #55 1 -#60- CCG GAA CCA TCC TGG AAA CCT GAG TGT CTT GA - #G ATT TCC AAA AAT AAT 528Pro Glu Pro Ser Trp Lys Pro Glu Cys Leu Gl - #u Ile Ser Lys Asn Asn# 175- GTA AAA CAT ATC GAT GAT TCT GGG AGT GTT TA - #T TGC CCC TCG TTT ATA 576Val Lys His Ile Asp Asp Ser Gly Ser Val Ty - #r Cys Pro Ser Phe Ile# 190- TGG GTA CCT GTA TTA GAC ACC TTT CTG TCC TC - #C TTT AAA GTA CCC CCT 624Trp Val Pro Val Leu Asp Thr Phe Leu Ser Se - #r Phe Lys Val Pro Pro# 205- ATG TTA AGT GAC ATT TTT TAT GGT ACA ACA TT - #T AAT ACT CCA TTC AAC 672Met Leu Ser Asp Ile Phe Tyr Gly Thr Thr Ph - #e Asn Thr Pro Phe Asn# 220- TTT GAA AGC TCT CCA AGA TGT CCC TCT ATA TC - #C TCA TCT TCA TCC TCC 720Phe Glu Ser Ser Pro Arg Cys Pro Ser Ile Se - #r Ser Ser Ser Ser Ser225 2 - #30 2 - #35 2 -#40- TCC TCC TCA TCC TCT TCT TCA TGC TCT GCA TC - #T CAT TAT TCC TCA GAG 768Ser Ser Ser Ser Ser Ser Ser Cys Ser Ala Se - #r His Tyr Ser Ser Glu# 255- AAT GAT ATT TGG AAA TAC GCT AAT GCG ATG GT - #G GAT AAT GAA CTA GAA 816Asn Asp Ile Trp Lys Tyr Ala Asn Ala Met Va - #l Asp Asn Glu Leu Glu# 270- GAA ACT AAT TGT GAA ATT AAA AAT AGT TTT AA - #A GAG GAT TCT GAC AGT 864Glu Thr Asn Cys Glu Ile Lys Asn Ser Phe Ly - #s Glu Asp Ser Asp Ser# 285- TCT ACA TGT TCT ATA AGC GAT GTA TGT GAT TC - #T CTT TAT ATA AAT GAG 912Ser Thr Cys Ser Ile Ser Asp Val Cys Asp Se - #r Leu Tyr Ile Asn Glu# 300- ACA CGT TCT GCC CCC CCG GTA ATC GAA TCA TT - #T ATG TGT GCA ATA ATA 960Thr Arg Ser Ala Pro Pro Val Ile Glu Ser Ph - #e Met Cys Ala Ile Ile305 3 - #10 3 - #15 3 -#20- TCC CAT AAT GGT TAT GAA GAA ATT CCT GAA CC - #A GAA GAG GAT GAC TTG1008Ser His Asn Gly Tyr Glu Glu Ile Pro Glu Pr - #o Glu Glu Asp Asp Leu# 335- CAT GGG GTG AAA CCT ATG AAA AGG CTA TCC AA - #A CCA AAT ATT TTT AAA1056His Gly Val Lys Pro Met Lys Arg Leu Ser Ly - #s Pro Asn Ile Phe Lys# 350- CGA TTA TTT TCA AGG CGC GCC AAA ACA ATA AC - #C AAA AAT GAA AAC GAT1104Arg Leu Phe Ser Arg Arg Ala Lys Thr Ile Th - #r Lys Asn Glu Asn Asp# 365- GGT ATG TCT TCT ACA CAA CCT ACC AAC GCT CA - #A CGT TCA TCT CTA TTT1152Gly Met Ser Ser Thr Gln Pro Thr Asn Ala Gl - #n Arg Ser Ser Leu Phe# 380# 1176GT GGA AAC TAASer Ser Cys Leu Cys Gly Asn *385 3 - #90- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 391 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Met Gly Val Val Glu Val Asn Ile Val Thr Ph - #e Ile Asp Lys Asn Gly# 15- Ala Leu Pro Gly Asn Ser Gln Asp Val His Pr - #o Asp Leu Trp Cys Phe# 30- Met Ala Arg Gln Cys Tyr Ile Leu Ser Leu Th - #r Arg Leu Ala Met Pro# 45- Ile Ile Leu Arg Ser Ala Asn Leu Cys Tyr Ph - #e Met Asp Ser Ile Lys# 60- His Leu Pro Arg Val Ser Arg Pro Ile Val Ar - #g Thr Ser Thr Ser Asn# 80- Ser Lys Phe Leu Lys Pro Thr Glu Gly Glu Gl - #u Glu Asp Phe Leu Phe# 95- Tyr Glu Asp Lys Pro Gly Ala Ser Ile Glu Tr - #p Lys Ser Ala Val Ser# 110- Gly Tyr Asn Tyr Leu Asn Ser Gly Ile Phe Gl - #y Asn Tyr Pro Leu Asn# 125- Leu Trp Val Phe Gly Ala Ala Asp Leu Cys Gl - #u Pro Val Ile Ser Asn# 140- Ile Pro Gly Pro Lys Arg Leu Ile Tyr Ala Ty - #r Val Ser Cys Glu Trp145 1 - #50 1 - #55 1 -#60- Pro Glu Pro Ser Trp Lys Pro Glu Cys Leu Gl - #u Ile Ser Lys Asn Asn# 175- Val Lys His Ile Asp Asp Ser Gly Ser Val Ty - #r Cys Pro Ser Phe Ile# 190- Trp Val Pro Val Leu Asp Thr Phe Leu Ser Se - #r Phe Lys Val Pro Pro# 205- Met Leu Ser Asp Ile Phe Tyr Gly Thr Thr Ph - #e Asn Thr Pro Phe Asn# 220- Phe Glu Ser Ser Pro Arg Cys Pro Ser Ile Se - #r Ser Ser Ser Ser Ser225 2 - #30 2 - #35 2 -#40- Ser Ser Ser Ser Ser Ser Ser Cys Ser Ala Se - #r His Tyr Ser Ser Glu# 255- Asn Asp Ile Trp Lys Tyr Ala Asn Ala Met Va - #l Asp Asn Glu Leu Glu# 270- Glu Thr Asn Cys Glu Ile Lys Asn Ser Phe Ly - #s Glu Asp Ser Asp Ser# 285- Ser Thr Cys Ser Ile Ser Asp Val Cys Asp Se - #r Leu Tyr Ile Asn Glu# 300- Thr Arg Ser Ala Pro Pro Val Ile Glu Ser Ph - #e Met Cys Ala Ile Ile305 3 - #10 3 - #15 3 -#20- Ser His Asn Gly Tyr Glu Glu Ile Pro Glu Pr - #o Glu Glu Asp Asp Leu# 335- His Gly Val Lys Pro Met Lys Arg Leu Ser Ly - #s Pro Asn Ile Phe Lys# 350- Arg Leu Phe Ser Arg Arg Ala Lys Thr Ile Th - #r Lys Asn Glu Asn Asp# 365- Gly Met Ser Ser Thr Gln Pro Thr Asn Ala Gl - #n Arg Ser Ser Leu Phe# 380- Ser Ser Cys Leu Cys Gly Asn385 3 - #90- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1203 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1203- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- ATG GCA AAG TGT ACC ACC GAA AAG TTT TGT TG - #T ATC AGC GTG AAT AGA 48Met Ala Lys Cys Thr Thr Glu Lys Phe Cys Cy - #s Ile Ser Val Asn Arg# 15- GAA TCT TCT GTC GAT CCA GAA GAC TTC TAT AA - #A CCG GTT CCT CTA ACT 96Glu Ser Ser Val Asp Pro Glu Asp Phe Tyr Ly - #s Pro Val Pro Leu Thr# 30- TCA GAT TTG ATT GAA GAG GAT AAC CTA CAT CA - #A GAC AAA ATA ATG GAT 144Ser Asp Leu Ile Glu Glu Asp Asn Leu His Gl - #n Asp Lys Ile Met Asp# 45- GAG GAT TTA TAC TCG GAT TTT AGT GAT GAT GA - #C TTT ATG GAT TAT ACA 192Glu Asp Leu Tyr Ser Asp Phe Ser Asp Asp As - #p Phe Met Asp Tyr Thr# 60- AAA AAT CCA ACT GAA AGT GAA AAT GAA AGA GA - #A AGT GAC GAA GAA GTT 240Lys Asn Pro Thr Glu Ser Glu Asn Glu Arg Gl - #u Ser Asp Glu Glu Val# 80- GAA GAA AGT TAT GAA AGT GAT GAA GAT AAA AA - #A AGT TTA TCT CCT ACT 288Glu Glu Ser Tyr Glu Ser Asp Glu Asp Lys Ly - #s Ser Leu Ser Pro Thr# 95- AAA AGC GAA GGA ATT GAA GCG GCT GAA GCG CT - #A AAG TTT TCT GTT GTT 336Lys Ser Glu Gly Ile Glu Ala Ala Glu Ala Le - #u Lys Phe Ser Val Val# 110- AAA TCG TTA ACG CCT GGG TCA GAA GGA AGA GT - #T TTT ATT GCT CTT AAA 384Lys Ser Leu Thr Pro Gly Ser Glu Gly Arg Va - #l Phe Ile Ala Leu Lys# 125- AAA GAT AAA GAT ACA AGC TAT AAG GTA ATT TT - #A AAA ATT GGA CAA AGG 432Lys Asp Lys Asp Thr Ser Tyr Lys Val Ile Le - #u Lys Ile Gly Gln Arg# 140- GGA AAC ACG CTT GTG GAA TCG TTA ATT TTG AG - #A AAT ATT AGT CAC CAA 480Gly Asn Thr Leu Val Glu Ser Leu Ile Leu Ar - #g Asn Ile Ser His Gln145 1 - #50 1 - #55 1 -#60- TCT ATA ATT AAA CTT CAA GAC ACT CTT TTT TA - #T AAA GAG TTA ACA TGT 528Ser Ile Ile Lys Leu Gln Asp Thr Leu Phe Ty - #r Lys Glu Leu Thr Cys# 175- TTG GTG TTA CCG TAT TAT AAA TAT GAT CTA TA - #T AAT TTT TTA ATG GAT 576Leu Val Leu Pro Tyr Tyr Lys Tyr Asp Leu Ty - #r Asn Phe Leu Met Asp# 190- CAT GGG AAA TCT CTG TCT TTT GAA TCT GTA AT - #T AAA ATT GAA AAA CAA 624His Gly Lys Ser Leu Ser Phe Glu Ser Val Il - #e Lys Ile Glu Lys Gln# 205- ATA TTA ACT GGA CTT CAA TAT ATT CAT GGA AA - #A AAA ATT ATT CAT CGA 672Ile Leu Thr Gly Leu Gln Tyr Ile His Gly Ly - #s Lys Ile Ile His Arg# 220- GAT ATA AAA ACT GAA AAT ATT TTC TTG GAT AA - #T GAC TCT AAT GTT TGT 720Asp Ile Lys Thr Glu Asn Ile Phe Leu Asp As - #n Asp Ser Asn Val Cys225 2 - #30 2 - #35 2 -#40- ATA GGT GAT TTT GGG GCT TCT CAA TTT CCT GT - #T TCC TCA CCA GAT TAT 768Ile Gly Asp Phe Gly Ala Ser Gln Phe Pro Va - #l Ser Ser Pro Asp Tyr# 255- TTG GGA ATT GCG GGG ACT ATT GAA ACT AAT GC - #T CCT GAA GTT CTA TCA 816Leu Gly Ile Ala Gly Thr Ile Glu Thr Asn Al - #a Pro Glu Val Leu Ser# 270- AAG GAT GCG TAC AAC TGT AAA GCT GAT ATT TG - #G AGT GCT GGT ATA ATT 864Lys Asp Ala Tyr Asn Cys Lys Ala Asp Ile Tr - #p Ser Ala Gly Ile Ile# 285- TTA TTT GAA ATG CTT GCA TAT CCT AAT GTT TT - #G TTT GAG GAG GAA GAA 912Leu Phe Glu Met Leu Ala Tyr Pro Asn Val Le - #u Phe Glu Glu Glu Glu# 300- AGA GAT AGT AGC GAT TTA ATA AAC AAT TGT AA - #T CTT CAT CTT ATA AAA 960Arg Asp Ser Ser Asp Leu Ile Asn Asn Cys As - #n Leu His Leu Ile Lys305 3 - #10 3 - #15 3 -#20- ATT ATA TCA ACT CTG AAG ATT AAC CCA AAT GA - #A TTT CCA TCT GAT TTG1008Ile Ile Ser Thr Leu Lys Ile Asn Pro Asn Gl - #u Phe Pro Ser Asp Leu# 335- GAA TCT AAT CTA GTA AAA CAT TTT ATA AAA TA - #T GCT AAT AAT GAT AGA1056Glu Ser Asn Leu Val Lys His Phe Ile Lys Ty - #r Ala Asn Asn Asp Arg# 350- CCT CCA TTT ACA CGA TAT AAT CGT CTA AAT AA - #C CTT AAA TTA CAT CTC1104Pro Pro Phe Thr Arg Tyr Asn Arg Leu Asn As - #n Leu Lys Leu His Leu# 365- GAT GGT GAA TTT TTA ATT CAT AAA ATG CTA AC - #A TTT GAT GCA TCT CTA1152Asp Gly Glu Phe Leu Ile His Lys Met Leu Th - #r Phe Asp Ala Ser Leu# 380- CGA CCA AGT GCG GAA GAA CTA TTA TCC TAT CA - #G ATT TTT AGT AAA CAA1200Arg Pro Ser Ala Glu Glu Leu Leu Ser Tyr Gl - #n Ile Phe Ser Lys Gln385 3 - #90 3 - #95 4 -#00# 1203 *- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 400 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Met Ala Lys Cys Thr Thr Glu Lys Phe Cys Cy - #s Ile Ser Val Asn Arg# 15- Glu Ser Ser Val Asp Pro Glu Asp Phe Tyr Ly - #s Pro Val Pro Leu Thr# 30- Ser Asp Leu Ile Glu Glu Asp Asn Leu His Gl - #n Asp Lys Ile Met Asp# 45- Glu Asp Leu Tyr Ser Asp Phe Ser Asp Asp As - #p Phe Met Asp Tyr Thr# 60- Lys Asn Pro Thr Glu Ser Glu Asn Glu Arg Gl - #u Ser Asp Glu Glu Val# 80- Glu Glu Ser Tyr Glu Ser Asp Glu Asp Lys Ly - #s Ser Leu Ser Pro Thr# 95- Lys Ser Glu Gly Ile Glu Ala Ala Glu Ala Le - #u Lys Phe Ser Val Val# 110- Lys Ser Leu Thr Pro Gly Ser Glu Gly Arg Va - #l Phe Ile Ala Leu Lys# 125- Lys Asp Lys Asp Thr Ser Tyr Lys Val Ile Le - #u Lys Ile Gly Gln Arg# 140- Gly Asn Thr Leu Val Glu Ser Leu Ile Leu Ar - #g Asn Ile Ser His Gln145 1 - #50 1 - #55 1 -#60- Ser Ile Ile Lys Leu Gln Asp Thr Leu Phe Ty - #r Lys Glu Leu Thr Cys# 175- Leu Val Leu Pro Tyr Tyr Lys Tyr Asp Leu Ty - #r Asn Phe Leu Met Asp# 190- His Gly Lys Ser Leu Ser Phe Glu Ser Val Il - #e Lys Ile Glu Lys Gln# 205- Ile Leu Thr Gly Leu Gln Tyr Ile His Gly Ly - #s Lys Ile Ile His Arg# 220- Asp Ile Lys Thr Glu Asn Ile Phe Leu Asp As - #n Asp Ser Asn Val Cys225 2 - #30 2 - #35 2 -#40- Ile Gly Asp Phe Gly Ala Ser Gln Phe Pro Va - #l Ser Ser Pro Asp Tyr# 255- Leu Gly Ile Ala Gly Thr Ile Glu Thr Asn Al - #a Pro Glu Val Leu Ser# 270- Lys Asp Ala Tyr Asn Cys Lys Ala Asp Ile Tr - #p Ser Ala Gly Ile Ile# 285- Leu Phe Glu Met Leu Ala Tyr Pro Asn Val Le - #u Phe Glu Glu Glu Glu# 300- Arg Asp Ser Ser Asp Leu Ile Asn Asn Cys As - #n Leu His Leu Ile Lys305 3 - #10 3 - #15 3 -#20- Ile Ile Ser Thr Leu Lys Ile Asn Pro Asn Gl - #u Phe Pro Ser Asp Leu# 335- Glu Ser Asn Leu Val Lys His Phe Ile Lys Ty - #r Ala Asn Asn Asp Arg# 350- Pro Pro Phe Thr Arg Tyr Asn Arg Leu Asn As - #n Leu Lys Leu His Leu# 365- Asp Gly Glu Phe Leu Ile His Lys Met Leu Th - #r Phe Asp Ala Ser Leu# 380- Arg Pro Ser Ala Glu Glu Leu Leu Ser Tyr Gl - #n Ile Phe Ser Lys Gln385 3 - #90 3 - #95 4 -#00- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1248 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1248- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:- ATG TTG TAT ACG CTG TTT TTT GTT TTT TAT TT - #T AAG GTA GTT TTA TCT 48Met Leu Tyr Thr Leu Phe Phe Val Phe Tyr Ph - #e Lys Val Val Leu Ser# 15- CGC ATA GCT CCG CTA GAG TTG TGT TAT GCG GA - #T CCT AAA GAA AAT ACA 96Arg Ile Ala Pro Leu Glu Leu Cys Tyr Ala As - #p Pro Lys Glu Asn Thr# 30- ACT GAA CCT ACA CAA CTT CCT ACA GGG GAA CA - #A TCT AAG ACT CTT ATT 144Thr Glu Pro Thr Gln Leu Pro Thr Gly Glu Gl - #n Ser Lys Thr Leu Ile# 45- CCC GTG GTA ACA AAC GGA TAT GTT GAA TAC TC - #T AAA GGA TGT GAA CTA 192Pro Val Val Thr Asn Gly Tyr Val Glu Tyr Se - #r Lys Gly Cys Glu Leu# 60- CGA TTA CTA GAT ACA TAT GTA AAT GTA TCT TC - #A CGA CCA GAA AAA AAG 240Arg Leu Leu Asp Thr Tyr Val Asn Val Ser Se - #r Arg Pro Glu Lys Lys# 80- GTT AAT GCT ACA ATT GGA TGG TCA TTT GAT CT - #T GGT TGT CAA ATT CCT 288Val Asn Ala Thr Ile Gly Trp Ser Phe Asp Le - #u Gly Cys Gln Ile Pro# 95- TTA ATT TAT AGA GAA TAT TAT AAT TGT ACT GG - #T AAT ATA ATA CCA TCA 336Leu Ile Tyr Arg Glu Tyr Tyr Asn Cys Thr Gl - #y Asn Ile Ile Pro Ser# 110- CCA GAA ACT TGT GAT GGT TAT TCT TTA ACT TT - #G GTA AAA TCT GAA AGT 384Pro Glu Thr Cys Asp Gly Tyr Ser Leu Thr Le - #u Val Lys Ser Glu Ser# 125- ATA TCA TCT TAT GCA CTT GTT AAT GTT AGT TT - #G CTT ATT CAA CCA GGA 432Ile Ser Ser Tyr Ala Leu Val Asn Val Ser Le - #u Leu Ile Gln Pro Gly# 140- ATT TTT GAT TCT GGT AGA TAT TTA TAC TCA CT - #T GTT TTT GGA AAC GAT 480Ile Phe Asp Ser Gly Arg Tyr Leu Tyr Ser Le - #u Val Phe Gly Asn Asp145 1 - #50 1 - #55 1 -#60- AGT TAT AAC GGA AGA ATT GAA GTT CGA GTG GA - #T AAT GAG ACA GAC TAT 528Ser Tyr Asn Gly Arg Ile Glu Val Arg Val As - #p Asn Glu Thr Asp Tyr# 175- CCA TGT TTT ATG ATG CAT GGA TTG ACT GTA AA - #A AAG GGT GAT AAA CTT 576Pro Cys Phe Met Met His Gly Leu Thr Val Ly - #s Lys Gly Asp Lys Leu# 190- CAT ATT CCT TAT AAA CCA TCC ACA AAT CCT AA - #T CAT AAA CGA TAT AGA 624His Ile Pro Tyr Lys Pro Ser Thr Asn Pro As - #n His Lys Arg Tyr Arg# 205- GGT TGT TTT CCA ATA TCA AAT ACT GAG CTA TG - #G AAT AAT ATT AGT GAT 672Gly Cys Phe Pro Ile Ser Asn Thr Glu Leu Tr - #p Asn Asn Ile Ser Asp# 220- GAA AGT GTT GGT AGA TAT TCA TAT GAT GAA GA - #A TAT GAA GAA TAT GAA 720Glu Ser Val Gly Arg Tyr Ser Tyr Asp Glu Gl - #u Tyr Glu Glu Tyr Glu225 2 - #30 2 - #35 2 -#40- GAA GAA AAC GAA GAT TTT GAA GAT CTA CAA TC - #A AAA GAT TGC CGC AAA 768Glu Glu Asn Glu Asp Phe Glu Asp Leu Gln Se - #r Lys Asp Cys Arg Lys# 255- TCC AAT CTT TTT GAT ATG AAG AAG ACT TTT AA - #T TTG GCT GCA GGT TCT 816Ser Asn Leu Phe Asp Met Lys Lys Thr Phe As - #n Leu Ala Ala Gly Ser# 270- CAA AGT TTA TTG ATT GCT AGT TTG GGT AAA TC - #A ATT TCA GAA CAA CCG 864Gln Ser Leu Leu Ile Ala Ser Leu Gly Lys Se - #r Ile Ser Glu Gln Pro# 285- TGG TCA TTT AAA ATT AAT GAA AGT TAT GAA CT - #T TTT AAT AAT TTG TCT 912Trp Ser Phe Lys Ile Asn Glu Ser Tyr Glu Le - #u Phe Asn Asn Leu Ser# 300- ATC ACC CTT CAA TCG GAA GAA GAT TCT AAT AT - #A CTG AAT CCT GAA ATT 960Ile Thr Leu Gln Ser Glu Glu Asp Ser Asn Il - #e Leu Asn Pro Glu Ile305 3 - #10 3 - #15 3 -#20- GTA ACG TTT ACC ACA CCA CCA CCT ACT GAA AA - #T ACA CAT ATG TTT ATG1008Val Thr Phe Thr Thr Pro Pro Pro Thr Glu As - #n Thr His Met Phe Met# 335- TCA AAT AAT GAA ACT ATG TAT GAA GAA GAA AG - #T GTT TTA AGC ATT ATT1056Ser Asn Asn Glu Thr Met Tyr Glu Glu Glu Se - #r Val Leu Ser Ile Ile# 350- CAA TTG TTT AAC AAT GGT TAT AAT AAT TGT AA - #T ACC CAT ATA AAG GTA1104Gln Leu Phe Asn Asn Gly Tyr Asn Asn Cys As - #n Thr His Ile Lys Val# 365- ATT GGA TTT GGA ACA ATT ATC TTT ATT ATT TT - #A TTT TTT GTT GCT GTG1152Ile Gly Phe Gly Thr Ile Ile Phe Ile Ile Le - #u Phe Phe Val Ala Val# 380- TTT TTT TGT GGA TAT ACT TGT GTA TTA AAC TC - #T CGT ATT AAA ATG ATT1200Phe Phe Cys Gly Tyr Thr Cys Val Leu Asn Se - #r Arg Ile Lys Met Ile385 3 - #90 3 - #95 4 -#00- AAC CAT GCT TAT ATA CAA CCC CAG AAA TTA AA - #T TTT TAT GAT ATT TAA1248Asn His Ala Tyr Ile Gln Pro Gln Lys Leu As - #n Phe Tyr Asp Ile *# 415- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 415 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:- Met Leu Tyr Thr Leu Phe Phe Val Phe Tyr Ph - #e Lys Val Val Leu Ser# 15- Arg Ile Ala Pro Leu Glu Leu Cys Tyr Ala As - #p Pro Lys Glu Asn Thr# 30- Thr Glu Pro Thr Gln Leu Pro Thr Gly Glu Gl - #n Ser Lys Thr Leu Ile# 45- Pro Val Val Thr Asn Gly Tyr Val Glu Tyr Se - #r Lys Gly Cys Glu Leu# 60- Arg Leu Leu Asp Thr Tyr Val Asn Val Ser Se - #r Arg Pro Glu Lys Lys# 80- Val Asn Ala Thr Ile Gly Trp Ser Phe Asp Le - #u Gly Cys Gln Ile Pro# 95- Leu Ile Tyr Arg Glu Tyr Tyr Asn Cys Thr Gl - #y Asn Ile Ile Pro Ser# 110- Pro Glu Thr Cys Asp Gly Tyr Ser Leu Thr Le - #u Val Lys Ser Glu Ser# 125- Ile Ser Ser Tyr Ala Leu Val Asn Val Ser Le - #u Leu Ile Gln Pro Gly# 140- Ile Phe Asp Ser Gly Arg Tyr Leu Tyr Ser Le - #u Val Phe Gly Asn Asp145 1 - #50 1 - #55 1 -#60- Ser Tyr Asn Gly Arg Ile Glu Val Arg Val As - #p Asn Glu Thr Asp Tyr# 175- Pro Cys Phe Met Met His Gly Leu Thr Val Ly - #s Lys Gly Asp Lys Leu# 190- His Ile Pro Tyr Lys Pro Ser Thr Asn Pro As - #n His Lys Arg Tyr Arg# 205- Gly Cys Phe Pro Ile Ser Asn Thr Glu Leu Tr - #p Asn Asn Ile Ser Asp# 220- Glu Ser Val Gly Arg Tyr Ser Tyr Asp Glu Gl - #u Tyr Glu Glu Tyr Glu225 2 - #30 2 - #35 2 -#40- Glu Glu Asn Glu Asp Phe Glu Asp Leu Gln Se - #r Lys Asp Cys Arg Lys# 255- Ser Asn Leu Phe Asp Met Lys Lys Thr Phe As - #n Leu Ala Ala Gly Ser# 270- Gln Ser Leu Leu Ile Ala Ser Leu Gly Lys Se - #r Ile Ser Glu Gln Pro# 285- Trp Ser Phe Lys Ile Asn Glu Ser Tyr Glu Le - #u Phe Asn Asn Leu Ser# 300- Ile Thr Leu Gln Ser Glu Glu Asp Ser Asn Il - #e Leu Asn Pro Glu Ile305 3 - #10 3 - #15 3 -#20- Val Thr Phe Thr Thr Pro Pro Pro Thr Glu As - #n Thr His Met Phe Met# 335- Ser Asn Asn Glu Thr Met Tyr Glu Glu Glu Se - #r Val Leu Ser Ile Ile# 350- Gln Leu Phe Asn Asn Gly Tyr Asn Asn Cys As - #n Thr His Ile Lys Val# 365- Ile Gly Phe Gly Thr Ile Ile Phe Ile Ile Le - #u Phe Phe Val Ala Val# 380- Phe Phe Cys Gly Tyr Thr Cys Val Leu Asn Se - #r Arg Ile Lys Met Ile385 3 - #90 3 - #95 4 -#00- Asn His Ala Tyr Ile Gln Pro Gln Lys Leu As - #n Phe Tyr Asp Ile# 415- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 357 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..357- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:- ATG ATT AAA CTT CTA TTT ATC TTA TTT TAT TT - #T AAC CCA ATA ACT GGA 48Met Ile Lys Leu Leu Phe Ile Leu Phe Tyr Ph - #e Asn Pro Ile Thr Gly# 15- TAT AAA TGG GTA GAC CCT CCT CGT AGG TAT AA - #T TAC ACC GTT TTA AGA 96Tyr Lys Trp Val Asp Pro Pro Arg Arg Tyr As - #n Tyr Thr Val Leu Arg# 30- ATG ATT CCA GAT ATT CCA AAT CCA ATG GAT CC - #T TCT AAA AAC GCT GAA 144Met Ile Pro Asp Ile Pro Asn Pro Met Asp Pr - #o Ser Lys Asn Ala Glu# 45- GTT CGG TAT GTA ACT TCT ACT GAC CCA TGT GA - #T ATG GTT GCT TTG ATT 192Val Arg Tyr Val Thr Ser Thr Asp Pro Cys As - #p Met Val Ala Leu Ile# 60- TCT AAT CCA AAT ATA GAA TCT ACA ATT AAA AC - #G ATT CAA TTT GTG CAA 240Ser Asn Pro Asn Ile Glu Ser Thr Ile Lys Th - #r Ile Gln Phe Val Gln# 80- AAG AAA AAA TTT TAC AAT GCA TCT CTT AGT TG - #G TTT AAA GTT GGA GAT 288Lys Lys Lys Phe Tyr Asn Ala Ser Leu Ser Tr - #p Phe Lys Val Gly Asp# 95- GAT TGT ACA TAT CCA ATA TAT TTA ATT CAA TA - #T TTT GAT TGT GAT CCT 336Asp Cys Thr Tyr Pro Ile Tyr Leu Ile Gln Ty - #r Phe Asp Cys Asp Pro# 110# 357 ATA TGTGln Arg Glu Phe Gly Ile Cys 115- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 119 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- Met Ile Lys Leu Leu Phe Ile Leu Phe Tyr Ph - #e Asn Pro Ile Thr Gly# 15- Tyr Lys Trp Val Asp Pro Pro Arg Arg Tyr As - #n Tyr Thr Val Leu Arg# 30- Met Ile Pro Asp Ile Pro Asn Pro Met Asp Pr - #o Ser Lys Asn Ala Glu# 45- Val Arg Tyr Val Thr Ser Thr Asp Pro Cys As - #p Met Val Ala Leu Ile# 60- Ser Asn Pro Asn Ile Glu Ser Thr Ile Lys Th - #r Ile Gln Phe Val Gln# 80- Lys Lys Lys Phe Tyr Asn Ala Ser Leu Ser Tr - #p Phe Lys Val Gly Asp# 95- Asp Cys Thr Tyr Pro Ile Tyr Leu Ile Gln Ty - #r Phe Asp Cys Asp Pro# 110- Gln Arg Glu Phe Gly Ile Cys 115- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 743 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:- CGAAGCGGGA GGAGGATGCT GGTTATGATA TACCATCTCC AAATTTAGTT CA - #AATAAAAC 60- CGGGATATAG TTACCTTTTT TGTCTTCCTA TTTTTCAATT AGAAATGAAA AA - #CCCACCAA 120- TCGCTTGTAT TTTTGGTAGA TCATCCTTAA ATTCAAGCGG AATAATTGTT CT - #TCCAACTA 180- TATGGAAACC AAAAACAATT TGTCAATTTT TTATTAAAAA TATATCCTCT AA - #AACTGTAA 240- CTATAGAAAA AGGTCAGAGA ATAGCTCAGT TAGTTCTTTT AAAAAACAAT CA - #ACCACTAT 300- GGTTACAACC ACAAATTAAT TGTCATTCTT TATTTCCAAA GTCAAACTAT TT - #AAGCTTAT 360- CAAATCGAGA ATGTGATATG TGGAAGTTTA CAGAAGATCT GAATTTTGAA GC - #ACCGAAAA 420- GTTTACGAGG AATAAATGGA TTTGGATCCA CGGGATTGTA AAATTCGTTA AT - #AAAGTTAT 480- ATTTAAAGTG CCAAACTTTC ACGTGTCATT TTTTTGGGAC CGTTTCTTTT TT - #GTTTAGTC 540- GATAAAATAT TTTCAGTTTC CATAGAACTT ATTAGAGGTT CTGTATCTAG TA - #TATCTGTA 600- GAATTATTTT CATCATATTT AACGGTTTGA AGAGATAAGG GTTTTGTTGT AT - #TAGAATCT 660- ATACCAAGGG TTTTTTCTAA AACCGCTACA TCTGCCATAA CAATATTATT TT - #CTGAAGTC 720# 743CACC ACC- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 743 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:- GGTGGTGCCC AAGCCATAAA AATGACTTCA GAAAATAATA TTGTTATGGC AG - #ATGTAGCG 60- GTTTTAGAAA AAACCCTTGG TATAGATTCT AATACAACAA AACCCTTATC TC - #TTCAAACC 120- GTTAAATATG ATGAAAATAA TTCTACAGAT ATACTAGATA CAGAACCTCT AA - #TAAGTTCT 180- ATGGAAACTG AAAATATTTT ATCGACTAAA CAAAAAAGAA ACGGTCCCAA AA - #AAATGACA 240- CGTGAAAGTT TGGCACTTTA AATATAACTT TATTAACGAA TTTTACAATC CC - #GTGGATCC 300- AAATCCATTT ATTCCTCGTA AACTTTTCGG TGCTTCAAAA TTCAGATCTT CT - #GTAAACTT 360- CCACATATCA CATTCTCGAT TTGATAAGCT TAAATAGTTT GACTTTGGAA AT - #AAAGAATG 420- ACAATTAATT TGTGGTTGTA ACCATAGTGG TTGATTGTTT TTTAAAAGAA CT - #AACTGAGC 480- TATTCTCTGA CCTTTTTCTA TAGTTACAGT TTTAGAGGAT ATATTTTTAA TA - #AAAAATTG 540- ACAAATTGTT TTTGGTTTCC ATATAGTTGG AAGAACAATT ATTCCGCTTG AA - #TTTAAGGA 600- TGATCTACCA AAAATACAAG CGATTGGTGG GTTTTTCATT TCTAATTGAA AA - #ATAGGAAG 660- ACAAAAAAGG TAACTATATC CCGGTTTTAT TTGAACTAAA TTTGGAGATG GT - #ATATCATA 720# 743CGCT TCG- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 459 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..459- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- AAG CGG GAG GAG GAT GCT GGT TAT GAT ATA CC - #A TCT CCA AAT TTA GTT 48Lys Arg Glu Glu Asp Ala Gly Tyr Asp Ile Pr - #o Ser Pro Asn Leu Val# 15- CAA ATA AAA CCG GGA TAT AGT TAC CTT TTT TG - #T CTT CCT ATT TTT CAA 96Gln Ile Lys Pro Gly Tyr Ser Tyr Leu Phe Cy - #s Leu Pro Ile Phe Gln# 30- TTA GAA ATG AAA AAC CCA CCA ATC GCT TGT AT - #T TTT GGT AGA TCA TCC 144Leu Glu Met Lys Asn Pro Pro Ile Ala Cys Il - #e Phe Gly Arg Ser Ser# 45- TTA AAT TCA AGC GGA ATA ATT GTT CTT CCA AC - #T ATA TGG AAA CCA AAA 192Leu Asn Ser Ser Gly Ile Ile Val Leu Pro Th - #r Ile Trp Lys Pro Lys# 60- ACA ATT TGT CAA TTT TTT ATT AAA AAT ATA TC - #C TCT AAA ACT GTA ACT 240Thr Ile Cys Gln Phe Phe Ile Lys Asn Ile Se - #r Ser Lys Thr Val Thr# 80- ATA GAA AAA GGT CAG AGA ATA GCT CAG TTA GT - #T CTT TTA AAA AAC AAT 288Ile Glu Lys Gly Gln Arg Ile Ala Gln Leu Va - #l Leu Leu Lys Asn Asn# 95- CAA CCA CTA TGG TTA CAA CCA CAA ATT AAT TG - #T CAT TCT TTA TTT CCA 336Gln Pro Leu Trp Leu Gln Pro Gln Ile Asn Cy - #s His Ser Leu Phe Pro# 110- AAG TCA AAC TAT TTA AGC TTA TCA AAT CGA GA - #A TGT GAT ATG TGG AAG 384Lys Ser Asn Tyr Leu Ser Leu Ser Asn Arg Gl - #u Cys Asp Met Trp Lys# 125- TTT ACA GAA GAT CTG AAT TTT GAA GCA CCG AA - #A AGT TTA CGA GGA ATA 432Phe Thr Glu Asp Leu Asn Phe Glu Ala Pro Ly - #s Ser Leu Arg Gly Ile# 140# 459 CC ACG GGA TTG TAAAsn Gly Phe Gly Ser Thr Gly Leu *145 1 - #50- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 152 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:- Lys Arg Glu Glu Asp Ala Gly Tyr Asp Ile Pr - #o Ser Pro Asn Leu Val# 15- Gln Ile Lys Pro Gly Tyr Ser Tyr Leu Phe Cy - #s Leu Pro Ile Phe Gln# 30- Leu Glu Met Lys Asn Pro Pro Ile Ala Cys Il - #e Phe Gly Arg Ser Ser# 45- Leu Asn Ser Ser Gly Ile Ile Val Leu Pro Th - #r Ile Trp Lys Pro Lys# 60- Thr Ile Cys Gln Phe Phe Ile Lys Asn Ile Se - #r Ser Lys Thr Val Thr# 80- Ile Glu Lys Gly Gln Arg Ile Ala Gln Leu Va - #l Leu Leu Lys Asn Asn# 95- Gln Pro Leu Trp Leu Gln Pro Gln Ile Asn Cy - #s His Ser Leu Phe Pro# 110- Lys Ser Asn Tyr Leu Ser Leu Ser Asn Arg Gl - #u Cys Asp Met Trp Lys# 125- Phe Thr Glu Asp Leu Asn Phe Glu Ala Pro Ly - #s Ser Leu Arg Gly Ile# 140- Asn Gly Phe Gly Ser Thr Gly Leu145 1 - #50- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 579 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 54..503- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:- AATTATTACT CTAAATCTCA CTTCATTATA CTTATATAAT AATATAAAAC CT - #T ATG 56# Met# 1- TTT GTC ATT ATT AAC TTA ACA CTA GAT GGT AC - #T ATA AAG CTA ACT TAC 104Phe Val Ile Ile Asn Leu Thr Leu Asp Gly Th - #r Ile Lys Leu Thr Tyr# 15- AAT ATA AAT AGT AAG ATT AGT TTA TAT AAA TT - #A CAT TTA ATG GCT TTA 152Asn Ile Asn Ser Lys Ile Ser Leu Tyr Lys Le - #u His Leu Met Ala Leu# 30- CCA GAT AAC GTT TTT AGT ATT ATT AAT GAA AA - #T TAT ATC GAT GGA ATT 200Pro Asp Asn Val Phe Ser Ile Ile Asn Glu As - #n Tyr Ile Asp Gly Ile# 45- TTA ACT ATG AAA ATG GGT GAA GAA ATA GAA AG - #C TCA TCA CCA TTA AAT 248Leu Thr Met Lys Met Gly Glu Glu Ile Glu Se - #r Ser Ser Pro Leu Asn# 65- GAA ACA AAT GTT AAT ATA GAT CAA CAT ACA AT - #A GAT ATT TTT GAT TAC 296Glu Thr Asn Val Asn Ile Asp Gln His Thr Il - #e Asp Ile Phe Asp Tyr# 80- GAT TCA GAT AAT GGA TGT TAT TAT AGT GAA AG - #A GAT AAT GAA ACC GCA 344Asp Ser Asp Asn Gly Cys Tyr Tyr Ser Glu Ar - #g Asp Asn Glu Thr Ala# 95- ACT CTT TTT TTA AAA CGT GTT GGT TAT AGA GA - #A ACC TCA AAA AAG CGT 392Thr Leu Phe Leu Lys Arg Val Gly Tyr Arg Gl - #u Thr Ser Lys Lys Arg# 110- AAA CGG ATT TGT GGA TTT ATT GTT TTA GCA AT - #T TTT ATG GTT ATT ATA 440Lys Arg Ile Cys Gly Phe Ile Val Leu Ala Il - #e Phe Met Val Ile Ile# 125- TTA TGT TTT TTA TCA ATA ATT TTG GGA GTT TT - #T ATA GCG CCT CAT ATT 488Leu Cys Phe Leu Ser Ile Ile Leu Gly Val Ph - #e Ile Ala Pro His Ile130 1 - #35 1 - #40 1 -#45- TAT AAA GGC CTA TAG TAAGAACATC AACCTCTAAT AGGTAAATT - #T TTAAAACCAA 543Tyr Lys Gly Leu * 150# 579 GGAC TTTTTATTTT ATGAGA- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 149 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:- Met Phe Val Ile Ile Asn Leu Thr Leu Asp Gl - #y Thr Ile Lys Leu Thr# 15- Tyr Asn Ile Asn Ser Lys Ile Ser Leu Tyr Ly - #s Leu His Leu Met Ala# 30- Leu Pro Asp Asn Val Phe Ser Ile Ile Asn Gl - #u Asn Tyr Ile Asp Gly# 45- Ile Leu Thr Met Lys Met Gly Glu Glu Ile Gl - #u Ser Ser Ser Pro Leu# 60- Asn Glu Thr Asn Val Asn Ile Asp Gln His Th - #r Ile Asp Ile Phe Asp# 80- Tyr Asp Ser Asp Asn Gly Cys Tyr Tyr Ser Gl - #u Arg Asp Asn Glu Thr# 95- Ala Thr Leu Phe Leu Lys Arg Val Gly Tyr Ar - #g Glu Thr Ser Lys Lys# 110- Arg Lys Arg Ile Cys Gly Phe Ile Val Leu Al - #a Ile Phe Met Val Ile# 125- Ile Leu Cys Phe Leu Ser Ile Ile Leu Gly Va - #l Phe Ile Ala Pro His# 140- Ile Tyr Lys Gly Leu145- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 579 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:- TCTCATAAAA TAAAAAGTCC TCCTCCTCCC CCTCCGTTGG TTTTAAAAAT TT - #ACCTATTA 60- GAGGTTGATG TTCTTACTAT AGGCCTTTAT AAATATGAGG CGCTATAAAA AC - #TCCCAAAA 120- TTATTGATAA AAAACATAAT ATAATAACCA TAAAAATTGC TAAAACAATA AA - #TCCACAAA 180- TCCGTTTACG CTTTTTTGAG GTTTCTCTAT AACCAACACG TTTTAAAAAA AG - #AGTTGCGG 240- TTTCATTATC TCTTTCACTA TAATAACATC CATTATCTGA ATCGTAATCA AA - #AATATCTA 300- TTGTATGTTG ATCTATATTA ACATTTGTTT CATTTAATGG TGATGAGCTT TC - #TATTTCTT 360- CACCCATTTT CATAGTTAAA ATTCCATCGA TATAATTTTC ATTAATAATA CT - #AAAAACGT 420- TATCTGGTAA AGCCATTAAA TGTAATTTAT ATAAACTAAT CTTACTATTT AT - #ATTGTAAG 480- TTAGCTTTAT AGTACCATCT AGTGTTAAGT TAATAATGAC AAACATAAGG TT - #TTATATTA 540# 579 AAGT GAGATTTAGA GTAATAATT- (2) INFORMATION FOR SEQ ID NO:20:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 450 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:- ATGTTTGTCA TTATTAACTT AACACTAGAT GGTACTATAA AGCTAACTTA CA - #ATATAAAT 60- AGTAAGATTA GTTTATATAA ATTACATTTA ATGGCTTTAC CAGATAACGT TT - #TTAGTATT 120- ATTAATGAAA ATTATATCGA TGGAATTTTA ACTATGAAAA TGGGTGAAGA AA - #TAGAAAGC 180- TCATCACCAT TAAATGAAAC AAATGTTAAT ATAGATCAAC ATACAATAGA TA - #TTTTTGAT 240- TACGATTCAG ATAATGGATG TTATTATAGT GAAAGAGATA ATGAAACCGC AA - #CTCTTTTT 300- TTAAAACGTG TTGGTTATAG AGAAACCTCA AAAAAGCGTA AACGGATTTG TG - #GATTTATT 360- GTTTTAGCAA TTTTTATGGT TATTATATTA TGTTTTTTAT CAATAATTTT GG - #GAGTTTTT 420# 450 ATAA AGGCCTATAG- (2) INFORMATION FOR SEQ ID NO:21:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 294 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3..293- (ix) FEATURE:#A or G (A) NAME/KEY: R = (B) LOCATION: 49- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:- TC CAA AGT GTT TTT GTT TCA TTG TCT TAT TCT - # TGG AGC CAC CGA CGA 47#Ser Trp Ser His Arg Arger Leu Ser Tyr# 15- CRG TTT GAG TGT ATA TTT CAT CCA ATT TTA TT - #T AAT CAT GGT ATT GTG 95Xaa Phe Glu Cys Ile Phe His Pro Ile Leu Ph - #e Asn His Gly Ile Val# 30- AAT TTG GAA AAT AAC CCT TTG ACA TTT AAG GA - #A CTA CAA AAA ATA AAT 143Asn Leu Glu Asn Asn Pro Leu Thr Phe Lys Gl - #u Leu Gln Lys Ile Asn# 45- TAT AGA CGT CAT ATT CTT GGT TTA CCA TTG AT - #T AGA GCT GGA TTG GTA 191Tyr Arg Arg His Ile Leu Gly Leu Pro Leu Il - #e Arg Ala Gly Leu Val# 60- GAA GAA GAT AAT CAA CCT TTA ATG ATA CCT CC - #A GAG TTT TCC AGT AAA 239Glu Glu Asp Asn Gln Pro Leu Met Ile Pro Pr - #o Glu Phe Ser Ser Lys# 75- CTA CCT CGA ACA ATA GGA TTT TTA ACT CAA CA - #A ATT AGA GCC AAA ATG 287Leu Pro Arg Thr Ile Gly Phe Leu Thr Gln Gl - #n Ile Arg Ala Lys Met# 95# 294Glu Ala- (2) INFORMATION FOR SEQ ID NO:22:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 97 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (ix) FEATURE:#Arg or GlnA) NAME/KEY: Xaa = (B) LOCATION: 16- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:- Gln Ser Val Phe Val Ser Leu Ser Tyr Ser Tr - #p Ser His Arg Arg Xaa# 15- Phe Glu Cys Ile Phe His Pro Ile Leu Phe As - #n His Gly Ile Val Asn# 30- Leu Glu Asn Asn Pro Leu Thr Phe Lys Glu Le - #u Gln Lys Ile Asn Tyr# 45- Arg Arg His Ile Leu Gly Leu Pro Leu Ile Ar - #g Ala Gly Leu Val Glu# 60- Glu Asp Asn Gln Pro Leu Met Ile Pro Pro Gl - #u Phe Ser Ser Lys Leu# 80- Pro Arg Thr Ile Gly Phe Leu Thr Gln Gln Il - #e Arg Ala Lys Met Glu# 95- Ala- (2) INFORMATION FOR SEQ ID NO:23:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 294 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:- AAGCTTCCAT TTTGGCTCTA ATTTGTTGAG TTAAAAATCC TATTGTTCGA GG - #TAGTTTAC 60- TGGAAAACTC TGGAGGTATC ATTAAAGGTT GATTATCTTC TTCTACCAAT CC - #AGCTCTAA 120- TCAATGGTAA ACCAAGAATA TGACGTCTAT AATTTATTTT TTGTAGTTCC TT - #AAATGTCA 180- AAGGGTTATT TTCCAAATTC ACAATACCAT GATTAAATAA AATTGGATGA AA - #TATACACT 240- CAAACYGTCG TCGGTGGCTC CAAGAATAAG ACAATGAAAC AAAAACACTT TG - #GA 294- (2) INFORMATION FOR SEQ ID NO:24:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 291 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:- CAAAGTGTTT TTGTTTCATT GTCTTATTCT TGGAGCCACC GACGACRGTT TG - #AGTGTATA 60- TTTCATCCAA TTTTATTTAA TCATGGTATT GTGAATTTGG AAAATAACCC TT - #TGACATTT 120- AAGGAACTAC AAAAAATAAA TTATAGACGT CATATTCTTG GTTTACCATT GA - #TTAGAGCT 180- GGATTGGTAG AAGAAGATAA TCAACCTTTA ATGATACCTC CAGAGTTTTC CA - #GTAAACTA 240# 291GATTTTT AACTCAACAA ATTAGAGCCA AAATGGAAGC T- (2) INFORMATION FOR SEQ ID NO:25:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 146 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..146- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:- CTA GAA GAT TAT ATA ACA CAT CGA ATT AAT GC - #C GAT ATT TCA GAG GTT 48Leu Glu Asp Tyr Ile Thr His Arg Ile Asn Al - #a Asp Ile Ser Glu Val# 15- GGT GTA TTG AGA AAT TAT ATT TCT GCT GAT AG - #A CAG AGT TTA AAA GTT 96Gly Val Leu Arg Asn Tyr Ile Ser Ala Asp Ar - #g Gln Ser Leu Lys Val# 30- TCT GAT AGA GAG TTT ATT AAT TAT ATT TAC TT - #G GCA CAT TTT GAA AGC TT 146Ser Asp Arg Glu Phe Ile Asn Tyr Ile Tyr Le - #u Ala His Phe Glu Ser# 45- (2) INFORMATION FOR SEQ ID NO:26:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 48 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:- Leu Glu Asp Tyr Ile Thr His Arg Ile Asn Al - #a Asp Ile Ser Glu Val# 15- Gly Val Leu Arg Asn Tyr Ile Ser Ala Asp Ar - #g Gln Ser Leu Lys Val# 30- Ser Asp Arg Glu Phe Ile Asn Tyr Ile Tyr Le - #u Ala His Phe Glu Ser# 45- (2) INFORMATION FOR SEQ ID NO:27:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 146 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:- AAGCTTTCAA AATGTGCCAA GTAAATATAA TTAATAAACT CTCTATCAGA AA - #CTTTTAAA 60- CTCTGTCTAT CAGCAGAAAT ATAATTTCTC AATACACCAA CCTCTGAAAT AT - #CGGCATTA 120# 146 AATC TTCTAG- (2) INFORMATION FOR SEQ ID NO:28:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 144 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:- CTAGAAGATT ATATAACACA TCGAATTAAT GCCGATATTT CAGAGGTTGG TG - #TATTGAGA 60- AATTATATTT CTGCTGATAG ACAGAGTTTA AAAGTTTCTG ATAGAGAGTT TA - #TTAATTAT 120# 144TTGA AAGC- (2) INFORMATION FOR SEQ ID NO:29:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 161 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3..161- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:- TT ATG TCA GTG GAC GTT ATA TTT CTC GAT GAC - # CAA CAT CTG TCA GTA 47#Asp Gln His Leu Ser Valle Phe Leu Asp# 15- AAT AAT TAT AGC GGA ACT ATT GAG TTT ATT CA - #T TTT AAT AAC TCT TGT 95Asn Asn Tyr Ser Gly Thr Ile Glu Phe Ile Hi - #s Phe Asn Asn Ser Cys# 30- TAT ACC GTT TAT CAA ACT ATT GAA TAT TTT TC - #T TGT CCT CGC ATT TTT 143Tyr Thr Val Tyr Gln Thr Ile Glu Tyr Phe Se - #r Cys Pro Arg Ile Phe# 45# 161 GA TCTAsn Asn Ala Phe Arg Ser 50- (2) INFORMATION FOR SEQ ID NO:30:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 53 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:- Met Ser Val Asp Val Ile Phe Leu Asp Asp Gl - #n His Leu Ser Val Asn# 15- Asn Tyr Ser Gly Thr Ile Glu Phe Ile His Ph - #e Asn Asn Ser Cys Tyr# 30- Thr Val Tyr Gln Thr Ile Glu Tyr Phe Ser Cy - #s Pro Arg Ile Phe Asn# 45- Asn Ala Phe Arg Ser 50- (2) INFORMATION FOR SEQ ID NO:31:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 161 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:- AGATCTAAAA GCATTATTAA AAATGCGAGG ACAAGAAAAA TATTCAATAG TT - #TGATAAAC 60- GGTATAACAA GAGTTATTAA AATGAATAAA CTCAATAGTT CCGCTATAAT TA - #TTTACTGA 120# 161 AGAA ATATAACGTC CACTGACATA A- (2) INFORMATION FOR SEQ ID NO:32:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 159 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:- ATGTCAGTGG ACGTTATATT TCTCGATGAC CAACATCTGT CAGTAAATAA TT - #ATAGCGGA 60- ACTATTGAGT TTATTCATTT TAATAACTCT TGTTATACCG TTTATCAAAC TA - #TTGAATAT 120# 159 TTTT TAATAATGCT TTTAGATCT- (2) INFORMATION FOR SEQ ID NO:33:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 261 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..261- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:- GGT GGT GCC CAA GCC ATA AAA ATG ACT TCA GA - #A AAT AAT ATT GTT ATG 48Gly Gly Ala Gln Ala Ile Lys Met Thr Ser Gl - #u Asn Asn Ile Val Met# 15- GCA GAT GTA GCG GTT TTA GAA AAA ACC CTT GG - #T ATA GAT TCT AAT ACA 96Ala Asp Val Ala Val Leu Glu Lys Thr Leu Gl - #y Ile Asp Ser Asn Thr# 30- ACA AAA CCC TTA TCT CTT CAA ACC GTT AAA TA - #T GAT GAA AAT AAT TCT 144Thr Lys Pro Leu Ser Leu Gln Thr Val Lys Ty - #r Asp Glu Asn Asn Ser# 45- ACA GAT ATA CTA GAT ACA GAA CCT CTA ATA AG - #T TCT ATG GAA ACT GAA 192Thr Asp Ile Leu Asp Thr Glu Pro Leu Ile Se - #r Ser Met Glu Thr Glu# 60- AAT ATT TTA TCG ACT AAA CAA AAA AGA AAC GG - #T CCC AAA AAA ATG ACA 240Asn Ile Leu Ser Thr Lys Gln Lys Arg Asn Gl - #y Pro Lys Lys Met Thr# 80# 261 CTT TAAArg Glu Ser Leu Ala Leu * 85- (2) INFORMATION FOR SEQ ID NO:34:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 86 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:- Gly Gly Ala Gln Ala Ile Lys Met Thr Ser Gl - #u Asn Asn Ile Val Met# 15- Ala Asp Val Ala Val Leu Glu Lys Thr Leu Gl - #y Ile Asp Ser Asn Thr# 30- Thr Lys Pro Leu Ser Leu Gln Thr Val Lys Ty - #r Asp Glu Asn Asn Ser# 45- Thr Asp Ile Leu Asp Thr Glu Pro Leu Ile Se - #r Ser Met Glu Thr Glu# 60- Asn Ile Leu Ser Thr Lys Gln Lys Arg Asn Gl - #y Pro Lys Lys Met Thr# 80- Arg Glu Ser Leu Ala Leu 85- (2) INFORMATION FOR SEQ ID NO:35:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 280 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..280- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:#AAT CCA GTA TAT TAT 46 GAA AAA AAT Ala Leu Asn Phe Ile Lys Leu Glu Lys A - #sn Asn Pro Val Tyr Tyr# 15- TTT CCG GAA CCT ATG GCA TTC TGG CGT ATC AT - #C CTA GAA ACA GAT ATT 94Phe Pro Glu Pro Met Ala Phe Trp Arg Ile Il - #e Leu Glu Thr Asp Ile# 30- GTG CAA GGT ATA TAC TCA GTA CAA GAC CGG AA - #G CTG CGT GGT GAA TTA 142Val Gln Gly Ile Tyr Ser Val Gln Asp Arg Ly - #s Leu Arg Gly Glu Leu# 45- AGC CTA AAT GAT GCG TCA TTA ATT ACA GCT CA - #A CTT CAA ACT AAA TTT 190Ser Leu Asn Asp Ala Ser Leu Ile Thr Ala Gl - #n Leu Gln Thr Lys Phe# 60- TCT ACG CCA TAT ATT TTA CTT CAT TCC AAT GT - #A TCC AAA TTT TTT GGA 238Ser Thr Pro Tyr Ile Leu Leu His Ser Asn Va - #l Ser Lys Phe Phe Gly# 75- GAA AAT GTA ACA TTT GGA ATT CCG GAA GTA AT - #A TTT ATT TTT# 280Glu Asn Val Thr Phe Gly Ile Pro Glu Val Il - #e Phe Ile Phe# 90- (2) INFORMATION FOR SEQ ID NO:36:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 93 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:- Ala Leu Asn Phe Ile Lys Leu Glu Lys Asn As - #n Pro Val Tyr Tyr Phe# 15- Pro Glu Pro Met Ala Phe Trp Arg Ile Ile Le - #u Glu Thr Asp Ile Val# 30- Gln Gly Ile Tyr Ser Val Gln Asp Arg Lys Le - #u Arg Gly Glu Leu Ser# 45- Leu Asn Asp Ala Ser Leu Ile Thr Ala Gln Le - #u Gln Thr Lys Phe Ser# 60- Thr Pro Tyr Ile Leu Leu His Ser Asn Val Se - #r Lys Phe Phe Gly Glu# 80- Asn Val Thr Phe Gly Ile Pro Glu Val Ile Ph - #e Ile Phe# 90- (2) INFORMATION FOR SEQ ID NO:37:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 280 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:- AAAAATAAAT ATTACTTCCG GAATTCCAAA TGTTACATTT TCTCCAAAAA AT - #TTGGATAC 60- ATTGGAATGA AGTAAAATAT ATGGCGTAGA AAATTTAGTT TGAAGTTGAG CT - #GTAATTAA 120- TGACGCATCA TTTAGGCTTA ATTCACCACG CAGCTTCCGG TCTTGTACTG AG - #TATATACC 180- TTGCACAATA TCTGTTTCTA GGATGATACG CCAGAATGCC ATAGGTTCCG GA - #AAATAATA 240# 280 TCTA ATTTAATAAA ATTTAATGCA- (2) INFORMATION FOR SEQ ID NO:38:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 279 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:- GCATTAAATT TTATTAAATT AGAAAAAAAT AATCCAGTAT ATTATTTTCC GG - #AACCTATG 60- GCATTCTGGC GTATCATCCT AGAAACAGAT ATTGTGCAAG GTATATACTC AG - #TACAAGAC 120- CGGAAGCTGC GTGGTGAATT AAGCCTAAAT GATGCGTCAT TAATTACAGC TC - #AACTTCAA 180- ACTAAATTTT CTACGCCATA TATTTTACTT CATTCCAATG TATCCAAATT TT - #TTGGAGAA 240# 279 TTCC GGAAGTAATA TTTATTTTT- (2) INFORMATION FOR SEQ ID NO:39:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..27#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 11- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 17- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 20- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:# 27 NGAN GARGAYG- (2) INFORMATION FOR SEQ ID NO:40:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 24 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..24#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 11- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 16- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 22- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:# 24CCYA ANCC- (2) INFORMATION FOR SEQ ID NO:41:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 26 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..26#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 18- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 24- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:# 26 SNCA YGTNTA- (2) INFORMATION FOR SEQ ID NO:42:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..30#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 16- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 19- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 24- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 25- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 28- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:# 30 SWNG GDANNSWNGT- (2) INFORMATION FOR SEQ ID NO:43:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 23 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..20#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 12- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 18- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 21- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:# 23SNAC NRC- (2) INFORMATION FOR SEQ ID NO:44:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..20#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 15- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:# 20 KRTC- (2) INFORMATION FOR SEQ ID NO:45:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..30#/label= labelOTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:# 30 TAAG TCAAAATGAG- (2) INFORMATION FOR SEQ ID NO:46:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..29#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:# 29 ACAA AAAGTAATG- (2) INFORMATION FOR SEQ ID NO:47:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..26#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 11- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 20- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:# 28 HYTN ATHGARGG- (2) INFORMATION FOR SEQ ID NO:48:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..29#/label= primerTHER INFORMATION:- (ix) FEATURE:#Inosine (A) NAME/KEY: N = (B) LOCATION: 21- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:# 29 ARTT NGTRTGYTT- (2) INFORMATION FOR SEQ ID NO:49:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..35#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:# 35 CTTG ACATTGATTA TTGAC- (2) INFORMATION FOR SEQ ID NO:50:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..35#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:# 35 CCAA TGCGATGCAA TTTCC- (2) INFORMATION FOR SEQ ID NO:51:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 10592 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:- CTGCAGTGTA TTTAAAAAAT AAAAATCTAT GAATGAAATC TATGAATGAA AT - #CTATGAAT 60- GAAATCTATG AATGAAATCT ATGAATGAAA TCTATGAATG AAATCTATGA AT - #GAAATCTA 120- TGAATGAAAT CTATGAATGA AATCTATGAA TGAAATCTAT GAATGAAATC TA - #TGAATGAA 180- ATCTATGAAT GAAATCTATG AATGAAATCT ATGAATGAAA TCTATGAATG AA - #ATCTATGA 240- ATGAAATCTA TGAATGAAAT CTATGAATGA AATCTATGAA TGAAATCTAT GA - #GACAAAGT 300- AATTTTTAAA AATATTTTAA ATTTTATTAA GAGTATAGGT TACAAGGTTT AA - #TGCGTTGG 360- GTAAACATTT TAGTTTTCAA GTTTTAGTTT TCTGGTATCT ACCAACACAA AT - #GCATCTTC 420- GGATACATTA TTTAGAGAGT AATCACTTTT TAGAATATAT CTTATTGGTG GT - #ACATTTAT 480- AAATTTTGGA CCATCCCAAT AACACTTCGA TTCCACAAGC GAAGAAGGTA CT - #TCCATAAG 540- CTGAGAAGCG TTTACTTGAT TGTAGGGAGA ACTTGGCGTT TCAAAATCCT TT - #AGAACGTA 600- TAGTCTGCAA TACATAGGTT CAATATCATC TTCATACCTC TCATCAGGAT AT - #GAAAATGG 660- AAGTTTCACA AAGGTTCCAT CACGAAGCTT TTTGAAGAAT CGTACATCCG TA - #GGTGGTGT 720- AGGAACAATA GTGAAGGCGT GCGGTTCACC CTGGTTTTTC ACACGTGCAA GC - #GCTGGTGT 780- GGTTTTAGGG CGAACTGGAA AATAACCAGG CGGAACTTGT GCGTAGAATC CT - #TCATTAAG 840- TTCTCCACGA CAGCGTCTGA AGTATGATGG CATATTAGCT TGATCGGAGT TG - #TTATCAAA 900- TAGAGCAAAT GAAGCACTCA TTTTAAAACT TTTTAGTTAA GCTTTAAAAA CA - #AGTGAAGA 960- TTTAAAAATG TAGGATAAAA TGCCAGTTTA TATACAGTAA GAATATGGGA GT - #GGTTCACA1020- TAAAAAACCA GAATTTCAGG TTTACATCTA CTGTTTATTC ACAACAAATA TA - #AACAAACT1080- TAGTTTCCAC ATAAACATGA ACTAAATAGA GATGAACGTT GAGCGTTGGT AG - #GTTGTGTA1140- GAAGACATAC CATCGTTTTC ATTTTTGGTT ATTGTTTTGG CGCGCCTTGA AA - #ATAATCGT1200- TTAAAAATAT TTGGTTTGGA TAGCCTTTTC ATAGGTTTCA CCCCATGCAA GT - #CATCCTCT1260- TCTGGTTCAG GAATTTCTTC ATAACCATTA TGGGATATTA TTGCACACAT AA - #ATGATTCG1320- ATTACCGGGG GGGCAGAACG TGTCTCATTT ATATAAAGAG AATCACATAC AT - #CGCTTATA1380- GAACATGTAG AACTGTCAGA ATCCTCTTTA AAACTATTTT TAATTTCACA AT - #TAGTTTCT1440- TCTAGTTCAT TATCCACCAT CGCATTAGCG TATTTCCAAA TATCATTCTC TG - #AGGAATAA1500- TGAGATGCAG AGCATGAAGA AGAGGATGAG GAGGAGGAGG ATGAAGATGA GG - #ATATAGAG1560- GGACATCTTG GAGAGCTTTC AAAGTTGAAT GGAGTATTAA ATGTTGTACC AT - #AAAAAATG1620- TCACTTAACA TAGGGGGTAC TTTAAAGGAG GACAGAAAGG TGTCTAATAC AG - #GTACCCAT1680- ATAAACGAGG GGCAATAAAC ACTCCCAGAA TCATCGATAT GTTTTACATT AT - #TTTTGGAA1740- ATCTCAAGAC ACTCAGGTTT CCAGGATGGT TCCGGCCATT CACATGATAC AT - #ATGCATAA1800- ATTAGTCGCT TTGGTCCTGG GATATTAGAA ATGACTGGCT CACATAAATC CG - #CTGCACCG1860- AAAACCCATA GATTAAGAGG ATAGTTTCCA AATATACCAG AGTTTAGATA GT - #TATACCCC1920- GAAACAGCCG ATTTCCATTC GATGCTAGCC CCAGGTTTAT CCTCATAAAA TA - #AAAAGTCC1980- TCCTCCTCCC CCTCCGTTGG TTTTAAAAAT TTACTATTAG AGGTTGATGT TC - #TTACTATA2040- GGCCTTGAAA CTCTAGGTAG ATGTTTTATA GAGTCCATAA AATAACATAA GT - #TTGCAGAT2100- CGTAATATTA TAGGCATAGC CAATCGTGTG AGAGAAAGGA TATAGCATTG TC - #TAGCCATA2160- AAACACCAAA GATCAGGATG AACATCTTGG GAGTTTCCTG GTAACGCCCC AT - #TTTTGTCA2220- ATAAACGTAA CAATATTAAC TTCAACCACA CCCATAATTA AATTTTATGT AT - #GAATCCAA2280- TAAAGGTTAA TACACACCTA ATTTATGTTA TAATTTTAGA AGAAGCTGCA GT - #TGATGAGT2340- TGATATTAAC ATAACAATTT CACAATTACC TGATATGGCA AAGTGTACCA CC - #GAAAAGTT2400- TTGTTGTATC AGCGTGAATA GAGAATCTTC TGTCGATCCA GAAGACTTCT AT - #AAACCGGT2460- TCCTCTAACT TCAGATTTGA TTGAAGAGGA TAACCTACAT CAAGACAAAA TA - #ATGGATGA2520- GGATTTATAC TCGGATTTTA GTGATGATGA CTTTATGGAT TATACAAAAA AT - #CCAACTGA2580- AAGTGAAAAT GAAAGAGAAA GTGACGAAGA AGTTGAAGAA AGTTATGAAA GT - #GATGAAGA2640- TAAAAAAAGT TTATCTCCTA CTAAAAGCGA AGGAATTGAA GCGGCTGAAG CG - #CTAAAGTT2700- TTCTGTTGTT AAATCGTTAA CGCCTGGGTC AGAAGGAAGA GTTTTTATTG CT - #CTTAAAAA2760- AGATAAAGAT ACAAGCTATA AGGTAATTTT AAAAATTGGA CAAAGGGGAA AC - #ACGCTTGT2820- GGAATCGTTA ATTTTGAGAA ATATTAGTCA CCAATCTATA ATTAAACTTC AA - #GACACTCT2880- TTTTTATAAA GAGTTAACAT GTTTGGTGTT ACCGTATTAT AAATATGATC TA - #TATAATTT2940- TTTAATGGAT CATGGGAAAT CTCTGTCTTT TGAATCTGTA ATTAAAATTG AA - #AAACAAAT3000- ATTAACTGGA CTTCAATATA TTCATGGAAA AAAAATTATT CATCGAGATA TA - #AAAACTGA3060- AAATATTTTC TTGGATAATG ACTCTAATGT TTGTATAGGT GATTTTGGGG CT - #TCTCAATT3120- TCCTGTTTCC TCACCAGATT ATTTGGGAAT TGCGGGGACT ATTGAAACTA AT - #GCTCCTGA3180- AGTTCTATCA AAGGATGCGT ACAACTGTAA AGCTGATATT TGGAGTGCTG GT - #ATAATTTT3240- ATTTGAAATG CTTGCATATC CTAATGTTTT GTTTGAGGAG GAAGAAAGAG AT - #AGTAGCGA3300- TTTAATAAAC AATTGTAATC TTCATCTTAT AAAAATTATA TCAACTCTGA AG - #ATTAACCC3360- AAATGAATTT CCATCTGATT TGGAATCTAA TCTAGTAAAA CATTTTATAA AA - #TATGCTAA3420- TAATGATAGA CCTCCATTTA CACGATATAA TCGTCTAAAT AACCTTAAAT TA - #CATCTCGA3480- TGGTGAATTT TTAATTCATA AAATGCTAAC ATTTGATGCA TCTCTACGAC CA - #AGTGCGGA3540- AGAACTATTA TCCTATCAGA TTTTTAGTAA ACAATAAATT TCATAAAAAT GG - #GCGTGGAA3600- TTTTTTATTG TTTTATATAA AACGGGTGTT TGAAAGCTCT TTTTTATTAA TT - #TTATTTTT3660- ACATCCTAGC TACAATATTA TAGTTATCAT GTTGTATACG CTGTTTTTTG TT - #TTTTATTT3720- TAAGGTAGTT TTATCTCGCA TAGCTCCGCT AGAGTTGTGT TATGCGGATC CT - #AAAGAAAA3780- TACAACTGAA CCTACACAAC TTCCTACAGG GGAACAATCT AAGACTCTTA TT - #CCCGTGGT3840- AACAAACGGA TATGTTGAAT ACTCTAAAGG ATGTGAACTA CGATTACTAG AT - #ACATATGT3900- AAATGTATCT TCACGACCAG AAAAAAAGGT TAATGCTACA ATTGGATGGT CA - #TTTGATCT3960- TGGTTGTCAA ATTCCTTTAA TTTATAGAGA ATATTATAAT TGTACTGGTA AT - #ATAATACC4020- ATCACCAGAA ACTTGTGATG GTTATTCTTT AACTTTGGTA AAATCTGAAA GT - #ATATCATC4080- TTATGCACTT GTTAATGTTA GTTTGCTTAT TCAACCAGGA ATTTTTGATT CT - #GGTAGATA4140- TTTATACTCA CTTGTTTTTG GAAACGATAG TTATAACGGA AGAATTGAAG TT - #CGAGTGGA4200- TAATGAGACA GACTATCCAT GTTTTATGAT GCATGGATTG ACTGTAAAAA AG - #GGTGATAA4260- ACTTCATATT CCTTATAAAC CATCCACAAA TCCTAATCAT AAACGATATA GA - #GGTTGTTT4320- TCCAATATCA AATACTGAGC TATGGAATAA TATTAGTGAT GAAAGTGTTG GT - #AGATATTC4380- ATATGATGAA GAATATGAAG AATATGAAGA AGAAAACGAA GATTTTGAAG AT - #CTACAATC4440- AAAAGATTGC CGCAAATCCA ATCTTTTTGA TATGAAGAAG ACTTTTAATT TG - #GCTGCAGG4500- TTCTCAAAGT TTATTGATTG CTAGTTTGGG TAAATCAATT TCAGAACAAC CG - #TGGTCATT4560- TAAAATTAAT GAAAGTTATG AACTTTTTAA TAATTTGTCT ATCACCCTTC AA - #TCGGAAGA4620- AGATTCTAAT ATACTGAATC CTGAAATTGT AACGTTTACC ACACCACCAC CT - #ACTGAAAA4680- TACACATATG TTTATGTCAA ATAATGAAAC TATGTATGAA GAAGAAAGTG TT - #TTAAGCAT4740- TATTCAATTG TTTAACAATG GTTATAATAA TTGTAATACC CATATAAAGG TA - #ATTGGATT4800- TGGAACAATT ATCTTTATTA TTTTATTTTT TGTTGCTGTG TTTTTTTGTG GA - #TATACTTG4860- TGTATTAAAC TCTCGTATTA AAATGATTAA CCATGCTTAT ATACAACCCC AG - #AAATTAAA4920- TTTTTATGAT ATTTAATAAA ACTATTATGA AACTTCTTAT AACTTATTTG TT - #TTTATTAA4980- ATGGGTTGGG TTGGTTTTAA AATTACATAC GTGTATTAAG AATTAACATC AT - #AAAGGACA5040- CACCCATGAA AAACATTTAA ATTCTATTAA TTTGAACGGA TTAAACATTT TC - #TCATTTTA5100- AGAGTTGCTA CGACTTTTGA TAGTAAAATG ATTAAACTTC TATTTATCTT AT - #TTTATTTT5160- AACCCAATAA CTGGATATAA ATGGGTAGAC CCTCCTCGTA GGTATAATTA CA - #CCGTTTTA5220- AGAATGATTC CAGATATTCC AAATCCAATG GATCCTTCTA AAAACGCTGA AG - #TTCGGTAT5280- GTAACTTCTA CTGACCCATG TGATATGGTT GCTTTGATTT CTAATCCAAA TA - #TAGAATCT5340- ACAATTAAAA CGATTCAATT TGTGCAAAAG AAAAAATTTT ACAATGCATC TC - #TTAGTTGG5400- TTTAAAGTTG GAGATGATTG TACATATCCA ATATATTTAA TTCAATATTT TG - #ATTGTGAT5460- CCTCAAAGAG AATTTGGCAT ATGTTTAAAA AGATCTCCAG ATTTTTGGAA AC - #CATCGTTA5520- GTTGGTTACA CATTTTTAAC TGATGATGAA TTGGGATTAG TTTTAGCTGC CC - #CCGCTCCA5580- TTTAATCAAG GTCAATATAG ACGGGTTATT CAAATTGAAA ATGAAGTTTT TT - #ATACTGAT5640- TTTATGGTTC AATTACCACG AGAAACTTGT TATTTTTCTA AAGAAGATAA AT - #TTGAACCA5700- ACTTTTATGG AATGGTGTAA GGAATCTAGA TCTGTAGGAG CATCAAAAGT TG - #ACGATGAA5760- CTTTTTTATC TAAATAGAGC TGGTCCCCAA ACCCTGCTTA AATATTATGT TA - #TTAAAGAT5820- TTTTATAGAC TTAACGGTAG AGAACCTCCA ATAAAATTTA AAGAAGCTCT TA - #GATACGAT5880- ATACCATATA AAGTGAATGA TAAATTTGAT GATGAATTAC CATCGAGGCC AC - #ATATTAGT5940- AATACTATTA ATAAAACTAT TAAAGAAATT GTAAATCTTG AAGATTATTT TA - #AAAATACA6000- AATGTTATAG ATACTACTAC CCCAACACCA ATAAATAATA CCCCAAAAAA TA - #TAACCGTG6060- GGAATTGTTA TAATTATATT AATAATACTA TTTATAATTG GATTTTTTGT TT - #ATAAAAGA6120- CAAAAAATAT ATAATAATTA TAAAAAATTA ACAACAAATG TTTAGCCTTT AT - #AAATTAAT6180- TTACAGAATA AACAACTGGG CGGTCTTTTG TTTAATAAAA ATTCATGTAC CT - #ACAACTTT6240- TATTCACTTG CAAGAGGGTT GAGACCAGAT TACTTATAAC TATGTTTCTA CC - #TATTTTAT6300- TTCTTTTTTT ATATGGTGTA AATGGATTTG TTTACAAAGG TACGTATATA AG - #TATGTTTT6360- TAAATACTAG TTCTGGCTTT TCTATTTTTC CCGATGATAA ATTTATTGTC AG - #TGGACGTT6420- TATTATTTCT CGATGACCAA CATCTGTCAG TAAATAATTA TAGCGGAACT AT - #TGAGTTTA6480- TTCATTTTAA TAACTCTTGT TATACCGTTT ATCAAACTAT TGAATATTTT TC - #TTGTCCTC6540- GCATTTTTAA TAATGCTTTT AGATCTTGTT TAAAAAAGGT ATCAAAACAT CA - #TGAAAGTC6600- AACTTCGGAT AAATTCATCT ATAGAAAACG GTGTTTTGTT GGAAATTACA AA - #TCCTAAAC6660- CAAATGATTC AGGTGTTTAT TTTATACGAG TTCAATTGGA AAATAATAAA AC - #AGATGTGT6720- TTGGAATACC TGCATTTATT TATTCCTTTA ATATGTCAAA CGAAGTAAAT AA - #ATCAAACT6780- TCGATGATGT TACTACATCT TTATATACCT CATCACACCC TTCTTCCCAA AC - #TATTACAC6840- CTATCTATTT AAATGAAAAA CACGAACCGA TATGTCATAC TGTAAAAAAG GA - #TGAAAATG6900- TGTATGAACT TTTACTAGGT TTGCATGGAA ATATAACTGA TGATATTTTT CT - #CGATGAGG6960- ATTCTGAATT GCTTAAAAGA GTAAATATAC CTACAACGAC AAATAATTAT AT - #ATTTAAGC7020- CTTACCTAGA CCAACGTAAT AGAAAATTTT TAATTATTGT AATTTCGATT TC - #GATAATTT7080- TACTTATTCT TTTGGTATTA ATTGGATCAA TTATTAACAA TATTATTCGT AG - #ACACTTTT7140- CTTCTTCTAG GCGTATTTAT CGTCCTAAAG GTAACTCGGA ATCTGAAAAT AT - #AGAACTGA7200- CATGTGGGGA AAACTCAGTA AACAAAAATA ATCCATTACC AAAAAAACCT AA - #CCGCCAAA7260- AAAGATCTTC AACTATTCAA AGGGAGACAT CTCTTGAAAC TATTAAGGAA GA - #AGTATAAT7320- TTTAAAAATA TTTACCTACG TAGGTTGATG ACGACTTGTA TGACTAAAAA TT - #AGAATTTA7380- AATGATGAAA ATTTTTTAAA AATAATATAG TATTCCAAAG AGCCTTTTAG GA - #AAATCATC7440- AAGTCTCCAT TTCTCCAATC TTTACGATGT TTCGTTTATT TTTTTTAATC GC - #GTCTACAT7500- TATGTTCGGT AAGATTTGGT TTTTCAACAA TTCGTAATGT TATTGTTTCT GA - #AAAATCTG7560- GATTTGTAAT TGATGGTTAT AGTACTAACC CACCATTTAA TGAGACTAAA AA - #ATTTACTA7620- GAGGATGGGT ATTTTTACAA ACCCCCCCTT CTTATTGTAA AGATGGGATA TC - #AATATCTA7680- ATATATGCAT TGAACGTAAT ATTTGTGAAG AAGATATTTT TTTGAATAAA CG - #ATGTACAA7740- TTAAAACTAT TAATTATCCC TTAGCTGTAG CAGATTTTGA GATTAGTAAT AA - #TACTATTA7800- AAAAAATAAA TGATGTTTAT TTTGTTAATG ATAGTGTTTT TCCAATAATA AC - #TACAAATA7860- AAAGTGGTAT CCATATCACA AATGTGACTA TAAATAATTC TGGAATTTAT AC - #ATTGTATG7920- AAAATAATGA TAAGTGGAGT CATCAATCAA AAATCTTGGT AACTATAAAG AA - #AAAAGAAA7980- CAGTAATTAC TAAACCTAAA GTATATATAA AAAAACATGG TGGATTTTTT CA - #TGTAAAAA8040- ATTATCACTC TCATGTATTT GTACCAAATG ATTCATTTAA AATTGAACTT AA - #TCTTGAAT8100- CGGAAATTTA TGATTCTGAA TTTTCAGCAA GTATTGATTG GTATTATATG AA - #AACTAGCT8160- CGGAATGTTC AGTGTTTCAT ATATATGAAA CTTGTATATT TCACCCTCAT GC - #AAACTCTT8220- GTTTGAATCC AATAAACCCA TTGTGTAGTT TTACTTCCCC TTTGAGGGCA AC - #ATCACTAA8280- TTAATAGATT TTATTTTAGA TGTAAACCTG AAGGTAAAAA CTGGACAACT GA - #TTGTATAA8340- ACACCTTTTC TATTAATGCA GATAAACATA TTAAACAGCA TTCAAATAAT GT - #AGATTTGA8400- TTTTTTTAAA TACTCCAACT AATGCATCTG GTTTGTATGT TTTTATTCTT AA - #GTATAATG8460- GTCATCCAGA GGCTTGGACA TATACTTTGG TTTCAACGGT TAAAAATTTT AT - #GAATGTAA8520- TTAAGGATAT GACACGCCCC CTTTTGTCAA ATAATAAAAT GAAAAAACCT GA - #GCATTCTA8580- CTCAACCACC AACCATAACC AACATAACAC CTGGCTTTAA ATCTAAAAAT TG - #GGTAGATA8640- AATATATAAT TTCAGTAGCG GTGGTTTCTT GTATTACTAT TGTTATATTG AT - #TGTGGTAA8700- TAACCTTTTG TGTTCATCAA TGTATCGGTT TAAATCGTAA ACCATATGAA AT - #TATAAACC8760- CATTTAATAC AGCTTATAAA AGTATACCTA CAAATGAAAA AAATATTCTT CA - #TTTTGCTG8820- AAGTAACAGA ATCTGATTAT TCCTCCGACG AATCCTTCGA CAGTGACTCA GA - #AGAGCTAA8880- ATCAACGAGG TGAAACAATA CAACAAGGGA AAAAGGAACA ATCTGGATAT AC - #TATTTGGT8940- TTAATGAAGA TTTAGAAGAA TCCGTCTCCA AAAAACTTAA CCAACCAAAC TA - #TTCAAAAA9000- TAATTAATAG CTTAAAATCA ATCCAGAATG AATAAATCTA AACTCTCATT TA - #AAGAAAAA9060- AACGCTATAT ATGAATTTAA AAATATTTTA TCAAACACTT CATTGTCAAC TT - #TTCCTGTA9120- TTATCGTTTA ATGAGGAGCC AAAATCCAGA TTTTTTAAAA TGTTTAAAAA TA - #TTTTACTG9180- GAAAAAATAA AAAAAACTTC AATGGATTAT TTAATTTATT GTACTCTAAA AA - #TCTCACTT9240- TCATTTATAC TTTATAATAA ATAAAATTAT TAAAAAAACT TTATTGTTTT GT - #CATTATTA9300- ACTTTAACAC TAGATGGTAC TATAAAGCTA ACTTACAATA TAAATAGTAA GA - #TTAGTTTA9360- TATAAATTAC ATTTAATGGC TTTACCAGAT AACGTTTTTA GTATTATTAA TG - #AAAATTAT9420- ATCGATGGAA TTTTAACTAT GAAAATGGGT GAAGAAATAG AAAGCTCATC AC - #CATTAAAT9480- GAAACAAATG TTAATATAGA TCAACATACA ATAGATATTT TTGATTACGA TT - #CAGATAAT9540- GGATGTTATT ATAGTGAAAG AGATAATGAA ACCGCAACTC TTTTTTTAAA AC - #GTGTTGGT9600- TATAGAGAAA CCTCAAAAAA GCGTAAACGG ATTTGTGGAT TTATTGTTTT AG - #CAATTTTT9660- ATGGTTATTA TATTATGTTT TTTATCAATA ATTTTGGGAG TTTTTATAGC GC - #CTCATATT9720- TATAAAGGCC TATAGTAAGA ACATCAACCT CTAATAGTAA ATTTTTAAAA CC - #AACGGAGG9780- GGGAGGAGGA GGACTTTTTA TTTTATGAGG ATAAACCTGG GGCTAGCATC GA - #ATGGAAAT9840- CGGCTGTTTC GGGGTATAAC TATCTAAACT CTGGTATATT TGGAAACTAT CC - #TCTTAATC9900- TATGGGTTTT CGGTGCAGCG GATTTATGTG AGCCAGTCAT TTCTAATATC CC - #AGGACCAA9960- AGCGACTAAT TTATGCATAT GTATCATGTG AATGGCCGGA ACCATCCTGG AA - #ACCTGAGT10020- GTCTTGAGAT TTCCAAAAAT AATGTAAAAC ATATCGATGA TTCTGGGAGT GT - #TTATTGCC10080- CCTCGTTTAT ATGGGTACCT GTATTAGACA CCTTTCTGTC CTCCTTTAAA GT - #ACCCCCTA10140- TGTTAAGTGA CATTTTTTAT GGTACAACAT TTAATACTCC ATTCAACTTT GA - #AAGCTCTC10200- CAAGATGTCC CTCTATATCC TCATCTTCAT CCTCCTCCTC CTCATCCTCT TC - #TTCATGCT10260- CTGCATCTCA TTATTCCTCA GAGAATGATA TTTGGAAATA CGCTAATGCG AT - #GGTGGATA10320- ATGAACTAGA AGAAACTAAT TGTGAAATTA AAAATAGTTT TAAAGAGGAT TC - #TGACAGTT10380- CTACATGTTC TATAAGCGAT GTATGTGATT CTCTTTATAT AAATGAGACA CG - #TTCTGCCC10440- CCCCGGTAAT CGAATCATTT ATGTGTGCAA TAATATCCCA TAATGGTTAT GA - #AGAAATTC10500- CTGAACCAGA AGAGGATGAC TTGCATGGGG TGAAACCTAT GAAAAGGCTA TC - #CAAACCAA10560# 10592 ATTT TCAAGGCGCG CC- (2) INFORMATION FOR SEQ ID NO:52:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 10592 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:- GGCGCGCCTT GAAAATAATC GTTTAAAAAT ATTTGGTTTG GATAGCCTTT TC - #ATAGGTTT 60- CACCCCATGC AAGTCATCCT CTTCTGGTTC AGGAATTTCT TCATAACCAT TA - #TGGGATAT 120- TATTGCACAC ATAAATGATT CGATTACCGG GGGGGCAGAA CGTGTCTCAT TT - #ATATAAAG 180- AGAATCACAT ACATCGCTTA TAGAACATGT AGAACTGTCA GAATCCTCTT TA - #AAACTATT 240- TTTAATTTCA CAATTAGTTT CTTCTAGTTC ATTATCCACC ATCGCATTAG CG - #TATTTCCA 300- AATATCATTC TCTGAGGAAT AATGAGATGC AGAGCATGAA GAAGAGGATG AG - #GAGGAGGA 360- GGATGAAGAT GAGGATATAG AGGGACATCT TGGAGAGCTT TCAAAGTTGA AT - #GGAGTATT 420- AAATGTTGTA CCATAAAAAA TGTCACTTAA CATAGGGGGT ACTTTAAAGG AG - #GACAGAAA 480- GGTGTCTAAT ACAGGTACCC ATATAAACGA GGGGCAATAA ACACTCCCAG AA - #TCATCGAT 540- ATGTTTTACA TTATTTTTGG AAATCTCAAG ACACTCAGGT TTCCAGGATG GT - #TCCGGCCA 600- TTCACATGAT ACATATGCAT AAATTAGTCG CTTTGGTCCT GGGATATTAG AA - #ATGACTGG 660- CTCACATAAA TCCGCTGCAC CGAAAACCCA TAGATTAAGA GGATAGTTTC CA - #AATATACC 720- AGAGTTTAGA TAGTTATACC CCGAAACAGC CGATTTCCAT TCGATGCTAG CC - #CCAGGTTT 780- ATCCTCATAA AATAAAAAGT CCTCCTCCTC CCCCTCCGTT GGTTTTAAAA AT - #TTACTATT 840- AGAGGTTGAT GTTCTTACTA TAGGCCTTTA TAAATATGAG GCGCTATAAA AA - #CTCCCAAA 900- ATTATTGATA AAAAACATAA TATAATAACC ATAAAAATTG CTAAAACAAT AA - #ATCCACAA 960- ATCCGTTTAC GCTTTTTTGA GGTTTCTCTA TAACCAACAC GTTTTAAAAA AA - #GAGTTGCG1020- GTTTCATTAT CTCTTTCACT ATAATAACAT CCATTATCTG AATCGTAATC AA - #AAATATCT1080- ATTGTATGTT GATCTATATT AACATTTGTT TCATTTAATG GTGATGAGCT TT - #CTATTTCT1140- TCACCCATTT TCATAGTTAA AATTCCATCG ATATAATTTT CATTAATAAT AC - #TAAAAACG1200- TTATCTGGTA AAGCCATTAA ATGTAATTTA TATAAACTAA TCTTACTATT TA - #TATTGTAA1260- GTTAGCTTTA TAGTACCATC TAGTGTTAAA GTTAATAATG ACAAAACAAT AA - #AGTTTTTT1320- TAATAATTTT ATTTATTATA AAGTATAAAT GAAAGTGAGA TTTTTAGAGT AC - #AATAAATT1380- AAATAATCCA TTGAAGTTTT TTTTATTTTT TCCAGTAAAA TATTTTTAAA CA - #TTTTAAAA1440- AATCTGGATT TTGGCTCCTC ATTAAACGAT AATACAGGAA AAGTTGACAA TG - #AAGTGTTT1500- GATAAAATAT TTTTAAATTC ATATATAGCG TTTTTTTCTT TAAATGAGAG TT - #TAGATTTA1560- TTCATTCTGG ATTGATTTTA AGCTATTAAT TATTTTTGAA TAGTTTGGTT GG - #TTAAGTTT1620- TTTGGAGACG GATTCTTCTA AATCTTCATT AAACCAAATA GTATATCCAG AT - #TGTTCCTT1680- TTTCCCTTGT TGTATTGTTT CACCTCGTTG ATTTAGCTCT TCTGAGTCAC TG - #TCGAAGGA1740- TTCGTCGGAG GAATAATCAG ATTCTGTTAC TTCAGCAAAA TGAAGAATAT TT - #TTTTCATT1800- TGTAGGTATA CTTTTATAAG CTGTATTAAA TGGGTTTATA ATTTCATATG GT - #TTACGATT1860- TAAACCGATA CATTGATGAA CACAAAAGGT TATTACCACA ATCAATATAA CA - #ATAGTAAT1920- ACAAGAAACC ACCGCTACTG AAATTATATA TTTATCTACC CAATTTTTAG AT - #TTAAAGCC1980- AGGTGTTATG TTGGTTATGG TTGGTGGTTG AGTAGAATGC TCAGGTTTTT TC - #ATTTTATT2040- ATTTGACAAA AGGGGGCGTG TCATATCCTT AATTACATTC ATAAAATTTT TA - #ACCGTTGA2100- AACCAAAGTA TATGTCCAAG CCTCTGGATG ACCATTATAC TTAAGAATAA AA - #ACATACAA2160- ACCAGATGCA TTAGTTGGAG TATTTAAAAA AATCAAATCT ACATTATTTG AA - #TGCTGTTT2220- AATATGTTTA TCTGCATTAA TAGAAAAGGT GTTTATACAA TCAGTTGTCC AG - #TTTTTACC2280- TTCAGGTTTA CATCTAAAAT AAAATCTATT AATTAGTGAT GTTGCCCTCA AA - #GGGGAAGT2340- AAAACTACAC AATGGGTTTA TTGGATTCAA ACAAGAGTTT GCATGAGGGT GA - #AATATACA2400- AGTTTCATAT ATATGAAACA CTGAACATTC CGAGCTAGTT TTCATATAAT AC - #CAATCAAT2460- ACTTGCTGAA AATTCAGAAT CATAAATTTC CGATTCAAGA TTAAGTTCAA TT - #TTAAATGA2520- ATCATTTGGT ACAAATACAT GAGAGTGATA ATTTTTTACA TGAAAAAATC CA - #CCATGTTT2580- TTTTATATAT ACTTTAGGTT TAGTAATTAC TGTTTCTTTT TTCTTTATAG TT - #ACCAAGAT2640- TTTTGATTGA TGACTCCACT TATCATTATT TTCATACAAT GTATAAATTC CA - #GAATTATT2700- TATAGTCACA TTTGTGATAT GGATACCACT TTTATTTGTA GTTATTATTG GA - #AAAACACT2760- ATCATTAACA AAATAAACAT CATTTATTTT TTTAATAGTA TTATTACTAA TC - #TCAAAATC2820- TGCTACAGCT AAGGGATAAT TAATAGTTTT AATTGTACAT CGTTTATTCA AA - #AAAATATC2880- TTCTTCACAA ATATTACGTT CAATGCATAT ATTAGATATT GATATCCCAT CT - #TTACAATA2940- AGAAGGGGGG GTTTGTAAAA ATACCCATCC TCTAGTAAAT TTTTTAGTCT CA - #TTAAATGG3000- TGGGTTAGTA CTATAACCAT CAATTACAAA TCCAGATTTT TCAGAAACAA TA - #ACATTACG3060- AATTGTTGAA AAACCAAATC TTACCGAACA TAATGTAGAC GCGATTAAAA AA - #AATAAACG3120- AAACATCGTA AAGATTGGAG AAATGGAGAC TTGATGATTT TCCTAAAAGG CT - #CTTTGGAA3180- TACTATATTA TTTTTAAAAA ATTTTCATCA TTTAAATTCT AATTTTTAGT CA - #TACAAGTC3240- GTCATCAACC TACGTAGGTA AATATTTTTA AAATTATACT TCTTCCTTAA TA - #GTTTCAAG3300- AGATGTCTCC CTTTGAATAG TTGAAGATCT TTTTTGGCGG TTAGGTTTTT TT - #GGTAATGG3360- ATTATTTTTG TTTACTGAGT TTTCCCCACA TGTCAGTTCT ATATTTTCAG AT - #TCCGAGTT3420- ACCTTTAGGA CGATAAATAC GCCTAGAAGA AGAAAAGTGT CTACGAATAA TA - #TTGTTAAT3480- AATTGATCCA ATTAATACCA AAAGAATAAG TAAAATTATC GAAATCGAAA TT - #ACAATAAT3540- TAAAAATTTT CTATTACGTT GGTCTAGGTA AGGCTTAAAT ATATAATTAT TT - #GTCGTTGT3600- AGGTATATTT ACTCTTTTAA GCAATTCAGA ATCCTCATCG AGAAAAATAT CA - #TCAGTTAT3660- ATTTCCATGC AAACCTAGTA AAAGTTCATA CACATTTTCA TCCTTTTTTA CA - #GTATGACA3720- TATCGGTTCG TGTTTTTCAT TTAAATAGAT AGGTGTAATA GTTTGGGAAG AA - #GGGTGTGA3780- TGAGGTATAT AAAGATGTAG TAACATCATC GAAGTTTGAT TTATTTACTT CG - #TTTGACAT3840- ATTAAAGGAA TAAATAAATG CAGGTATTCC AAACACATCT GTTTTATTAT TT - #TCCAATTG3900- AACTCGTATA AAATAAACAC CTGAATCATT TGGTTTAGGA TTTGTAATTT CC - #AACAAAAC3960- ACCGTTTTCT ATAGATGAAT TTATCCGAAG TTGACTTTCA TGATGTTTTG AT - #ACCTTTTT4020- TAAACAAGAT CTAAAAGCAT TATTAAAAAT GCGAGGACAA GAAAAATATT CA - #ATAGTTTG4080- ATAAACGGTA TAACAAGAGT TATTAAAATG AATAAACTCA ATAGTTCCGC TA - #TAATTATT4140- TACTGACAGA TGTTGGTCAT CGAGAAATAA TAAACGTCCA CTGACAATAA AT - #TTATCATC4200- GGGAAAAATA GAAAAGCCAG AACTAGTATT TAAAAACATA CTTATATACG TA - #CCTTTGTA4260- AACAAATCCA TTTACACCAT ATAAAAAAAG AAATAAAATA GGTAGAAACA TA - #GTTATAAG4320- TAATCTGGTC TCAACCCTCT TGCAAGTGAA TAAAAGTTGT AGGTACATGA AT - #TTTTATTA4380- AACAAAAGAC CGCCCAGTTG TTTATTCTGT AAATTAATTT ATAAAGGCTA AA - #CATTTGTT4440- GTTAATTTTT TATAATTATT ATATATTTTT TGTCTTTTAT AAACAAAAAA TC - #CAATTATA4500- AATAGTATTA TTAATATAAT TATAACAATT CCCACGGTTA TATTTTTTGG GG - #TATTATTT4560- ATTGGTGTTG GGGTAGTAGT ATCTATAACA TTTGTATTTT TAAAATAATC TT - #CAAGATTT4620- ACAATTTCTT TAATAGTTTT ATTAATAGTA TTACTAATAT GTGGCCTCGA TG - #GTAATTCA4680- TCATCAAATT TATCATTCAC TTTATATGGT ATATCGTATC TAAGAGCTTC TT - #TAAATTTT4740- ATTGGAGGTT CTCTACCGTT AAGTCTATAA AAATCTTTAA TAACATAATA TT - #TAAGCAGG4800- GTTTGGGGAC CAGCTCTATT TAGATAAAAA AGTTCATCGT CAACTTTTGA TG - #CTCCTACA4860- GATCTAGATT CCTTACACCA TTCCATAAAA GTTGGTTCAA ATTTATCTTC TT - #TAGAAAAA4920- TAACAAGTTT CTCGTGGTAA TTGAACCATA AAATCAGTAT AAAAAACTTC AT - #TTTCAATT4980- TGAATAACCC GTCTATATTG ACCTTGATTA AATGGAGCGG GGGCAGCTAA AA - #CTAATCCC5040- AATTCATCAT CAGTTAAAAA TGTGTAACCA ACTAACGATG GTTTCCAAAA AT - #CTGGAGAT5100- CTTTTTAAAC ATATGCCAAA TTCTCTTTGA GGATCACAAT CAAAATATTG AA - #TTAAATAT5160- ATTGGATATG TACAATCATC TCCAACTTTA AACCAACTAA GAGATGCATT GT - #AAAATTTT5220- TTCTTTTGCA CAAATTGAAT CGTTTTAATT GTAGATTCTA TATTTGGATT AG - #AAATCAAA5280- GCAACCATAT CACATGGGTC AGTAGAAGTT ACATACCGAA CTTCAGCGTT TT - #TAGAAGGA5340- TCCATTGGAT TTGGAATATC TGGAATCATT CTTAAAACGG TGTAATTATA CC - #TACGAGGA5400- GGGTCTACCC ATTTATATCC AGTTATTGGG TTAAAATAAA ATAAGATAAA TA - #GAAGTTTA5460- ATCATTTTAC TATCAAAAGT CGTAGCAACT CTTAAAATGA GAAAATGTTT AA - #TCCGTTCA5520- AATTAATAGA ATTTAAATGT TTTTCATGGG TGTGTCCTTT ATGATGTTAA TT - #CTTAATAC5580- ACGTATGTAA TTTTAAAACC AACCCAACCC ATTTAATAAA AACAAATAAG TT - #ATAAGAAG5640- TTTCATAATA GTTTTATTAA ATATCATAAA AATTTAATTT CTGGGGTTGT AT - #ATAAGCAT5700- GGTTAATCAT TTTAATACGA GAGTTTAATA CACAAGTATA TCCACAAAAA AA - #CACAGCAA5760- CAAAAAATAA AATAATAAAG ATAATTGTTC CAAATCCAAT TACCTTTATA TG - #GGTATTAC5820- AATTATTATA ACCATTGTTA AACAATTGAA TAATGCTTAA AACACTTTCT TC - #TTCATACA5880- TAGTTTCATT ATTTGACATA AACATATGTG TATTTTCAGT AGGTGGTGGT GT - #GGTAAACG5940- TTACAATTTC AGGATTCAGT ATATTAGAAT CTTCTTCCGA TTGAAGGGTG AT - #AGACAAAT6000- TATTAAAAAG TTCATAACTT TCATTAATTT TAAATGACCA CGGTTGTTCT GA - #AATTGATT6060- TACCCAAACT AGCAATCAAT AAACTTTGAG AACCTGCAGC CAAATTAAAA GT - #CTTCTTCA6120- TATCAAAAAG ATTGGATTTG CGGCAATCTT TTGATTGTAG ATCTTCAAAA TC - #TTCGTTTT6180- CTTCTTCATA TTCTTCATAT TCTTCATCAT ATGAATATCT ACCAACACTT TC - #ATCACTAA6240- TATTATTCCA TAGCTCAGTA TTTGATATTG GAAAACAACC TCTATATCGT TT - #ATGATTAG6300- GATTTGTGGA TGGTTTATAA GGAATATGAA GTTTATCACC CTTTTTTACA GT - #CAATCCAT6360- GCATCATAAA ACATGGATAG TCTGTCTCAT TATCCACTCG AACTTCAATT CT - #TCCGTTAT6420- AACTATCGTT TCCAAAAACA AGTGAGTATA AATATCTACC AGAATCAAAA AT - #TCCTGGTT6480- GAATAAGCAA ACTAACATTA ACAAGTGCAT AAGATGATAT ACTTTCAGAT TT - #TACCAAAG6540- TTAAAGAATA ACCATCACAA GTTTCTGGTG ATGGTATTAT ATTACCAGTA CA - #ATTATAAT6600- ATTCTCTATA AATTAAAGGA ATTTGACAAC CAAGATCAAA TGACCATCCA AT - #TGTAGCAT6660- TAACCTTTTT TTCTGGTCGT GAAGATACAT TTACATATGT ATCTAGTAAT CG - #TAGTTCAC6720- ATCCTTTAGA GTATTCAACA TATCCGTTTG TTACCACGGG AATAAGAGTC TT - #AGATTGTT6780- CCCCTGTAGG AAGTTGTGTA GGTTCAGTTG TATTTTCTTT AGGATCCGCA TA - #ACACAACT6840- CTAGCGGAGC TATGCGAGAT AAAACTACCT TAAAATAAAA AACAAAAAAC AG - #CGTATACA6900- ACATGATAAC TATAATATTG TAGCTAGGAT GTAAAAATAA AATTAATAAA AA - #AGAGCTTT6960- CAAACACCCG TTTTATATAA AACAATAAAA AATTCCACGC CCATTTTTAT GA - #AATTTATT7020- GTTTACTAAA AATCTGATAG GATAATAGTT CTTCCGCACT TGGTCGTAGA GA - #TGCATCAA7080- ATGTTAGCAT TTTATGAATT AAAAATTCAC CATCGAGATG TAATTTAAGG TT - #ATTTAGAC7140- GATTATATCG TGTAAATGGA GGTCTATCAT TATTAGCATA TTTTATAAAA TG - #TTTTACTA7200- GATTAGATTC CAAATCAGAT GGAAATTCAT TTGGGTTAAT CTTCAGAGTT GA - #TATAATTT7260- TTATAAGATG AAGATTACAA TTGTTTATTA AATCGCTACT ATCTCTTTCT TC - #CTCCTCAA7320- ACAAAACATT AGGATATGCA AGCATTTCAA ATAAAATTAT ACCAGCACTC CA - #AATATCAG7380- CTTTACAGTT GTACGCATCC TTTGATAGAA CTTCAGGAGC ATTAGTTTCA AT - #AGTCCCCG7440- CAATTCCCAA ATAATCTGGT GAGGAAACAG GAAATTGAGA AGCCCCAAAA TC - #ACCTATAC7500- AAACATTAGA GTCATTATCC AAGAAAATAT TTTCAGTTTT TATATCTCGA TG - #AATAATTT7560- TTTTTCCATG AATATATTGA AGTCCAGTTA ATATTTGTTT TTCAATTTTA AT - #TACAGATT7620- CAAAAGACAG AGATTTCCCA TGATCCATTA AAAAATTATA TAGATCATAT TT - #ATAATACG7680- GTAACACCAA ACATGTTAAC TCTTTATAAA AAAGAGTGTC TTGAAGTTTA AT - #TATAGATT7740- GGTGACTAAT ATTTCTCAAA ATTAACGATT CCACAAGCGT GTTTCCCCTT TG - #TCCAATTT7800- TTAAAATTAC CTTATAGCTT GTATCTTTAT CTTTTTTAAG AGCAATAAAA AC - #TCTTCCTT7860- CTGACCCAGG CGTTAACGAT TTAACAACAG AAAACTTTAG CGCTTCAGCC GC - #TTCAATTC7920- CTTCGCTTTT AGTAGGAGAT AAACTTTTTT TATCTTCATC ACTTTCATAA CT - #TTCTTCAA7980- CTTCTTCGTC ACTTTCTCTT TCATTTTCAC TTTCAGTTGG ATTTTTTGTA TA - #ATCCATAA8040- AGTCATCATC ACTAAAATCC GAGTATAAAT CCTCATCCAT TATTTTGTCT TG - #ATGTAGGT8100- TATCCTCTTC AATCAAATCT GAAGTTAGAG GAACCGGTTT ATAGAAGTCT TC - #TGGATCGA8160- CAGAAGATTC TCTATTCACG CTGATACAAC AAAACTTTTC GGTGGTACAC TT - #TGCCATAT8220- CAGGTAATTG TGAAATTGTT ATGTTAATAT CAACTCATCA ACTGCAGCTT CT - #TCTAAAAT8280- TATAACATAA ATTAGGTGTG TATTAACCTT TATTGGATTC ATACATAAAA TT - #TAATTATG8340- GGTGTGGTTG AAGTTAATAT TGTTACGTTT ATTGACAAAA ATGGGGCGTT AC - #CAGGAAAC8400- TCCCAAGATG TTCATCCTGA TCTTTGGTGT TTTATGGCTA GACAATGCTA TA - #TCCTTTCT8460- CTCACACGAT TGGCTATGCC TATAATATTA CGATCTGCAA ACTTATGTTA TT - #TTATGGAC8520- TCTATAAAAC ATCTACCTAG AGTTTCAAGG CCTATAGTAA GAACATCAAC CT - #CTAATAGT8580- AAATTTTTAA AACCAACGGA GGGGGAGGAG GAGGACTTTT TATTTTATGA GG - #ATAAACCT8640- GGGGCTAGCA TCGAATGGAA ATCGGCTGTT TCGGGGTATA ACTATCTAAA CT - #CTGGTATA8700- TTTGGAAACT ATCCTCTTAA TCTATGGGTT TTCGGTGCAG CGGATTTATG TG - #AGCCAGTC8760- ATTTCTAATA TCCCAGGACC AAAGCGACTA ATTTATGCAT ATGTATCATG TG - #AATGGCCG8820- GAACCATCCT GGAAACCTGA GTGTCTTGAG ATTTCCAAAA ATAATGTAAA AC - #ATATCGAT8880- GATTCTGGGA GTGTTTATTG CCCCTCGTTT ATATGGGTAC CTGTATTAGA CA - #CCTTTCTG8940- TCCTCCTTTA AAGTACCCCC TATGTTAAGT GACATTTTTT ATGGTACAAC AT - #TTAATACT9000- CCATTCAACT TTGAAAGCTC TCCAAGATGT CCCTCTATAT CCTCATCTTC AT - #CCTCCTCC9060- TCCTCATCCT CTTCTTCATG CTCTGCATCT CATTATTCCT CAGAGAATGA TA - #TTTGGAAA9120- TACGCTAATG CGATGGTGGA TAATGAACTA GAAGAAACTA ATTGTGAAAT TA - #AAAATAGT9180- TTTAAAGAGG ATTCTGACAG TTCTACATGT TCTATAAGCG ATGTATGTGA TT - #CTCTTTAT9240- ATAAATGAGA CACGTTCTGC CCCCCCGGTA ATCGAATCAT TTATGTGTGC AA - #TAATATCC9300- CATAATGGTT ATGAAGAAAT TCCTGAACCA GAAGAGGATG ACTTGCATGG GG - #TGAAACCT9360- ATGAAAAGGC TATCCAAACC AAATATTTTT AAACGATTAT TTTCAAGGCG CG - #CCAAAACA9420- ATAACCAAAA ATGAAAACGA TGGTATGTCT TCTACACAAC CTACCAACGC TC - #AACGTTCA9480- TCTCTATTTA GTTCATGTTT ATGTGGAAAC TAAGTTTGTT TATATTTGTT GT - #GAATAAAC9540- AGTAGATGTA AACCTGAAAT TCTGGTTTTT TATGTGAACC ACTCCCATAT TC - #TTACTGTA9600- TATAAACTGG CATTTTATCC TACATTTTTA AATCTTCACT TGTTTTTAAA GC - #TTAACTAA9660- AAAGTTTTAA AATGAGTGCT TCATTTGCTC TATTTGATAA CAACTCCGAT CA - #AGCTAATA9720- TGCCATCATA CTTCAGACGC TGTCGTGGAG AACTTAATGA AGGATTCTAC GC - #ACAAGTTC9780- CGCCTGGTTA TTTTCCAGTT CGCCCTAAAA CCACACCAGC GCTTGCACGT GT - #GAAAAACC9840- AGGGTGAACC GCACGCCTTC ACTATTGTTC CTACACCACC TACGGATGTA CG - #ATTCTTCA9900- AAAAGCTTCG TGATGGAACC TTTGTGAAAC TTCCATTTTC ATATCCTGAT GA - #GAGGTATG9960- AAGATGATAT TGAACCTATG TATTGCAGAC TATACGTTCT AAAGGATTTT GA - #AACGCCAA10020- GTTCTCCCTA CAATCAAGTA AACGCTTCTC AGCTTATGGA AGTACCTTCT TC - #GCTTGTGG10080- AATCGAAGTG TTATTGGGAT GGTCCAAAAT TTATAAATGT ACCACCAATA AG - #ATATATTC10140- TAAAAAGTGA TTACTCTCTA AATAATGTAT CCGAAGATGC ATTTGTGTTG GT - #AGATACCA10200- GAAAACTAAA ACTTGAAAAC TAAAATGTTT ACCCAACGCA TTAAACCTTG TA - #ACCTATAC10260- TCTTAATAAA ATTTAAAATA TTTTTAAAAA TTACTTTGTC TCATAGATTT CA - #TTCATAGA10320- TTTCATTCAT AGATTTCATT CATAGATTTC ATTCATAGAT TTCATTCATA GA - #TTTCATTC10380- ATAGATTTCA TTCATAGATT TCATTCATAG ATTTCATTCA TAGATTTCAT TC - #ATAGATTT10440- CATTCATAGA TTTCATTCAT AGATTTCATT CATAGATTTC ATTCATAGAT TT - #CATTCATA10500- GATTTCATTC ATAGATTTCA TTCATAGATT TCATTCATAG ATTTCATTCA TA - #GATTTCAT10560# 10592 TTTA AATACACTGC AG- (2) INFORMATION FOR SEQ ID NO:53:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1038 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1035- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:- ATG ATT AAA CTT CTA TTT ATC TTA TTT TAT TT - #T AAC CCA ATA ACT GGA 48Met Ile Lys Leu Leu Phe Ile Leu Phe Tyr Ph - #e Asn Pro Ile Thr Gly# 15- TAT AAA TGG GTA GAC CCT CCT CGT AGG TAT AA - #T TAC ACC GTT TTA AGA 96Tyr Lys Trp Val Asp Pro Pro Arg Arg Tyr As - #n Tyr Thr Val Leu Arg# 30- ATG ATT CCA GAT ATT CCA AAT CCA ATG GAT CC - #T TCT AAA AAC GCT GAA 144Met Ile Pro Asp Ile Pro Asn Pro Met Asp Pr - #o Ser Lys Asn Ala Glu# 45- GTT CGG TAT GTA ACT TCT ACT GAC CCA TGT GA - #T ATG GTT GCT TTG ATT 192Val Arg Tyr Val Thr Ser Thr Asp Pro Cys As - #p Met Val Ala Leu Ile# 60- TCT AAT CCA AAT ATA GAA TCT ACA ATT AAA AC - #G ATT CAA TTT GTG CAA 240Ser Asn Pro Asn Ile Glu Ser Thr Ile Lys Th - #r Ile Gln Phe Val Gln# 80- AAG AAA AAA TTT TAC AAT GCA TCT CTT AGT TG - #G TTT AAA GTT GGA GAT 288Lys Lys Lys Phe Tyr Asn Ala Ser Leu Ser Tr - #p Phe Lys Val Gly Asp# 95- GAT TGT ACA TAT CCA ATA TAT TTA ATT CAA TA - #T TTT GAT TGT GAT CCT 336Asp Cys Thr Tyr Pro Ile Tyr Leu Ile Gln Ty - #r Phe Asp Cys Asp Pro# 110- CAA AGA GAA TTT GGC ATA TGT TTA AAA AGA TC - #T CCA GAT TTT TGG AAA 384Gln Arg Glu Phe Gly Ile Cys Leu Lys Arg Se - #r Pro Asp Phe Trp Lys# 125- CCA TCG TTA GTT GGT TAC ACA TTT TTA ACT GA - #T GAT GAA TTG GGA TTA 432Pro Ser Leu Val Gly Tyr Thr Phe Leu Thr As - #p Asp Glu Leu Gly Leu# 140- GTT TTA GCT GCC CCC GCT CCA TTT AAT CAA GG - #T CAA TAT AGA CGG GTT 480Val Leu Ala Ala Pro Ala Pro Phe Asn Gln Gl - #y Gln Tyr Arg Arg Val145 1 - #50 1 - #55 1 -#60- ATT CAA ATT GAA AAT GAA GTT TTT TAT ACT GA - #T TTT ATG GTT CAA TTA 528Ile Gln Ile Glu Asn Glu Val Phe Tyr Thr As - #p Phe Met Val Gln Leu# 175- CCA CGA GAA ACT TGT TAT TTT TCT AAA GAA GA - #T AAA TTT GAA CCA ACT 576Pro Arg Glu Thr Cys Tyr Phe Ser Lys Glu As - #p Lys Phe Glu Pro Thr# 190- TTT ATG GAA TGG TGT AAG GAA TCT AGA TCT GT - #A GGA GCA TCA AAA GTT 624Phe Met Glu Trp Cys Lys Glu Ser Arg Ser Va - #l Gly Ala Ser Lys Val# 205- GAC GAT GAA CTT TTT TAT CTA AAT AGA GCT GG - #T CCC CAA ACC CTG CTT 672Asp Asp Glu Leu Phe Tyr Leu Asn Arg Ala Gl - #y Pro Gln Thr Leu Leu# 220- AAA TAT TAT GTT ATT AAA GAT TTT TAT AGA CT - #T AAC GGT AGA GAA CCT 720Lys Tyr Tyr Val Ile Lys Asp Phe Tyr Arg Le - #u Asn Gly Arg Glu Pro225 2 - #30 2 - #35 2 -#40- CCA ATA AAA TTT AAA GAA GCT CTT AGA TAC GA - #T ATA CCA TAT AAA GTG 768Pro Ile Lys Phe Lys Glu Ala Leu Arg Tyr As - #p Ile Pro Tyr Lys Val# 255- AAT GAT AAA TTT GAT GAT GAA TTA CCA TCG AG - #G CCA CAT ATT AGT AAT 816Asn Asp Lys Phe Asp Asp Glu Leu Pro Ser Ar - #g Pro His Ile Ser Asn# 270- ACT ATT AAT AAA ACT ATT AAA GAA ATT GTA AA - #T CTT GAA GAT TAT TTT 864Thr Ile Asn Lys Thr Ile Lys Glu Ile Val As - #n Leu Glu Asp Tyr Phe# 285- AAA AAT ACA AAT GTT ATA GAT ACT ACT ACC CC - #A ACA CCA ATA AAT AAT 912Lys Asn Thr Asn Val Ile Asp Thr Thr Thr Pr - #o Thr Pro Ile Asn Asn# 300- ACC CCA AAA AAT ATA ACC GTG GGA ATT GTT AT - #A ATT ATA TTA ATA ATA 960Thr Pro Lys Asn Ile Thr Val Gly Ile Val Il - #e Ile Ile Leu Ile Ile305 3 - #10 3 - #15 3 -#20- CTA TTT ATA ATT GGA TTT TTT GTT TAT AAA AG - #A CAA AAA ATA TAT AAT1008Leu Phe Ile Ile Gly Phe Phe Val Tyr Lys Ar - #g Gln Lys Ile Tyr Asn# 335# 1038 TA ACA ACA AAT GTT TAGAsn Tyr Lys Lys Leu Thr Thr Asn Val# 345- (2) INFORMATION FOR SEQ ID NO:54:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 345 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:- Met Ile Lys Leu Leu Phe Ile Leu Phe Tyr Ph - #e Asn Pro Ile Thr Gly# 15- Tyr Lys Trp Val Asp Pro Pro Arg Arg Tyr As - #n Tyr Thr Val Leu Arg# 30- Met Ile Pro Asp Ile Pro Asn Pro Met Asp Pr - #o Ser Lys Asn Ala Glu# 45- Val Arg Tyr Val Thr Ser Thr Asp Pro Cys As - #p Met Val Ala Leu Ile# 60- Ser Asn Pro Asn Ile Glu Ser Thr Ile Lys Th - #r Ile Gln Phe Val Gln# 80- Lys Lys Lys Phe Tyr Asn Ala Ser Leu Ser Tr - #p Phe Lys Val Gly Asp# 95- Asp Cys Thr Tyr Pro Ile Tyr Leu Ile Gln Ty - #r Phe Asp Cys Asp Pro# 110- Gln Arg Glu Phe Gly Ile Cys Leu Lys Arg Se - #r Pro Asp Phe Trp Lys# 125- Pro Ser Leu Val Gly Tyr Thr Phe Leu Thr As - #p Asp Glu Leu Gly Leu# 140- Val Leu Ala Ala Pro Ala Pro Phe Asn Gln Gl - #y Gln Tyr Arg Arg Val145 1 - #50 1 - #55 1 -#60- Ile Gln Ile Glu Asn Glu Val Phe Tyr Thr As - #p Phe Met Val Gln Leu# 175- Pro Arg Glu Thr Cys Tyr Phe Ser Lys Glu As - #p Lys Phe Glu Pro Thr# 190- Phe Met Glu Trp Cys Lys Glu Ser Arg Ser Va - #l Gly Ala Ser Lys Val# 205- Asp Asp Glu Leu Phe Tyr Leu Asn Arg Ala Gl - #y Pro Gln Thr Leu Leu# 220- Lys Tyr Tyr Val Ile Lys Asp Phe Tyr Arg Le - #u Asn Gly Arg Glu Pro225 2 - #30 2 - #35 2 -#40- Pro Ile Lys Phe Lys Glu Ala Leu Arg Tyr As - #p Ile Pro Tyr Lys Val# 255- Asn Asp Lys Phe Asp Asp Glu Leu Pro Ser Ar - #g Pro His Ile Ser Asn# 270- Thr Ile Asn Lys Thr Ile Lys Glu Ile Val As - #n Leu Glu Asp Tyr Phe# 285- Lys Asn Thr Asn Val Ile Asp Thr Thr Thr Pr - #o Thr Pro Ile Asn Asn# 300- Thr Pro Lys Asn Ile Thr Val Gly Ile Val Il - #e Ile Ile Leu Ile Ile305 3 - #10 3 - #15 3 -#20- Leu Phe Ile Ile Gly Phe Phe Val Tyr Lys Ar - #g Gln Lys Ile Tyr Asn# 335- Asn Tyr Lys Lys Leu Thr Thr Asn Val# 345- (2) INFORMATION FOR SEQ ID NO:55:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1095 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1092- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:- ATG TAC CTA CAA CTT TTA TTC ACT TGC AAG AG - #G GTT GAG ACC AGA TTA 48Met Tyr Leu Gln Leu Leu Phe Thr Cys Lys Ar - #g Val Glu Thr Arg Leu# 15- CTT ATA ACT ATG TTT CTA CCT ATT TTA TTT CT - #T TTT TTA TAT GGT GTA 96Leu Ile Thr Met Phe Leu Pro Ile Leu Phe Le - #u Phe Leu Tyr Gly Val# 30- AAT GGA TTT GTT TAC AAA GGT ACG TAT ATA AG - #T ATG TTT TTA AAT ACT 144Asn Gly Phe Val Tyr Lys Gly Thr Tyr Ile Se - #r Met Phe Leu Asn Thr# 45- AGT TCT GGC TTT TCT ATT TTT CCC GAT GAT AA - #A TTT ATT GTC AGT GGA 192Ser Ser Gly Phe Ser Ile Phe Pro Asp Asp Ly - #s Phe Ile Val Ser Gly# 60- CGT TTA TTA TTT CTC GAT GAC CAA CAT CTG TC - #A GTA AAT AAT TAT AGC 240Arg Leu Leu Phe Leu Asp Asp Gln His Leu Se - #r Val Asn Asn Tyr Ser# 80- GGA ACT ATT GAG TTT ATT CAT TTT AAT AAC TC - #T TGT TAT ACC GTT TAT 288Gly Thr Ile Glu Phe Ile His Phe Asn Asn Se - #r Cys Tyr Thr Val Tyr# 95- CAA ACT ATT GAA TAT TTT TCT TGT CCT CGC AT - #T TTT AAT AAT GCT TTT 336Gln Thr Ile Glu Tyr Phe Ser Cys Pro Arg Il - #e Phe Asn Asn Ala Phe# 110- AGA TCT TGT TTA AAA AAG GTA TCA AAA CAT CA - #T GAA AGT CAA CTT CGG 384Arg Ser Cys Leu Lys Lys Val Ser Lys His Hi - #s Glu Ser Gln Leu Arg# 125- ATA AAT TCA TCT ATA GAA AAC GGT GTT TTG TT - #G GAA ATT ACA AAT CCT 432Ile Asn Ser Ser Ile Glu Asn Gly Val Leu Le - #u Glu Ile Thr Asn Pro# 140- AAA CCA AAT GAT TCA GGT GTT TAT TTT ATA CG - #A GTT CAA TTG GAA AAT 480Lys Pro Asn Asp Ser Gly Val Tyr Phe Ile Ar - #g Val Gln Leu Glu Asn145 1 - #50 1 - #55 1 -#60- AAT AAA ACA GAT GTG TTT GGA ATA CCT GCA TT - #T ATT TAT TCC TTT AAT 528Asn Lys Thr Asp Val Phe Gly Ile Pro Ala Ph - #e Ile Tyr Ser Phe Asn# 175- ATG TCA AAC GAA GTA AAT AAA TCA AAC TTC GA - #T GAT GTT ACT ACA TCT 576Met Ser Asn Glu Val Asn Lys Ser Asn Phe As - #p Asp Val Thr Thr Ser# 190- TTA TAT ACC TCA TCA CAC CCT TCT TCC CAA AC - #T ATT ACA CCT ATC TAT 624Leu Tyr Thr Ser Ser His Pro Ser Ser Gln Th - #r Ile Thr Pro Ile Tyr# 205- TTA AAT GAA AAA CAC GAA CCG ATA TGT CAT AC - #T GTA AAA AAG GAT GAA 672Leu Asn Glu Lys His Glu Pro Ile Cys His Th - #r Val Lys Lys Asp Glu# 220- AAT GTG TAT GAA CTT TTA CTA GGT TTG CAT GG - #A AAT ATA ACT GAT GAT 720Asn Val Tyr Glu Leu Leu Leu Gly Leu His Gl - #y Asn Ile Thr Asp Asp225 2 - #30 2 - #35 2 -#40- ATT TTT CTC GAT GAG GAT TCT GAA TTG CTT AA - #A AGA GTA AAT ATA CCT 768Ile Phe Leu Asp Glu Asp Ser Glu Leu Leu Ly - #s Arg Val Asn Ile Pro# 255- ACA ACG ACA AAT AAT TAT ATA TTT AAG CCT TA - #C CTA GAC CAA CGT AAT 816Thr Thr Thr Asn Asn Tyr Ile Phe Lys Pro Ty - #r Leu Asp Gln Arg Asn# 270- AGA AAA TTT TTA ATT ATT GTA ATT TCG ATT TC - #G ATA ATT TTA CTT ATT 864Arg Lys Phe Leu Ile Ile Val Ile Ser Ile Se - #r Ile Ile Leu Leu Ile# 285- CTT TTG GTA TTA ATT GGA TCA ATT ATT AAC AA - #T ATT ATT CGT AGA CAC 912Leu Leu Val Leu Ile Gly Ser Ile Ile Asn As - #n Ile Ile Arg Arg His# 300- TTT TCT TCT TCT AGG CGT ATT TAT CGT CCT AA - #A GGT AAC TCG GAA TCT 960Phe Ser Ser Ser Arg Arg Ile Tyr Arg Pro Ly - #s Gly Asn Ser Glu Ser305 3 - #10 3 - #15 3 -#20- GAA AAT ATA GAA CTG ACA TGT GGG GAA AAC TC - #A GTA AAC AAA AAT AAT1008Glu Asn Ile Glu Leu Thr Cys Gly Glu Asn Se - #r Val Asn Lys Asn Asn# 335- CCA TTA CCA AAA AAA CCT AAC CGC CAA AAA AG - #A TCT TCA ACT ATT CAA1056Pro Leu Pro Lys Lys Pro Asn Arg Gln Lys Ar - #g Ser Ser Thr Ile Gln# 350# 1095G ACA TCT CTT GAA ACT ATT AAG GAA GA - #A GTA TAAArg Glu Thr Ser Leu Glu Thr Ile Lys Glu Gl - #u Val# 360- (2) INFORMATION FOR SEQ ID NO:56:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 364 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:- Met Tyr Leu Gln Leu Leu Phe Thr Cys Lys Ar - #g Val Glu Thr Arg Leu# 15- Leu Ile Thr Met Phe Leu Pro Ile Leu Phe Le - #u Phe Leu Tyr Gly Val# 30- Asn Gly Phe Val Tyr Lys Gly Thr Tyr Ile Se - #r Met Phe Leu Asn Thr# 45- Ser Ser Gly Phe Ser Ile Phe Pro Asp Asp Ly - #s Phe Ile Val Ser Gly# 60- Arg Leu Leu Phe Leu Asp Asp Gln His Leu Se - #r Val Asn Asn Tyr Ser# 80- Gly Thr Ile Glu Phe Ile His Phe Asn Asn Se - #r Cys Tyr Thr Val Tyr# 95- Gln Thr Ile Glu Tyr Phe Ser Cys Pro Arg Il - #e Phe Asn Asn Ala Phe# 110- Arg Ser Cys Leu Lys Lys Val Ser Lys His Hi - #s Glu Ser Gln Leu Arg# 125- Ile Asn Ser Ser Ile Glu Asn Gly Val Leu Le - #u Glu Ile Thr Asn Pro# 140- Lys Pro Asn Asp Ser Gly Val Tyr Phe Ile Ar - #g Val Gln Leu Glu Asn145 1 - #50 1 - #55 1 -#60- Asn Lys Thr Asp Val Phe Gly Ile Pro Ala Ph - #e Ile Tyr Ser Phe Asn# 175- Met Ser Asn Glu Val Asn Lys Ser Asn Phe As - #p Asp Val Thr Thr Ser# 190- Leu Tyr Thr Ser Ser His Pro Ser Ser Gln Th - #r Ile Thr Pro Ile Tyr# 205- Leu Asn Glu Lys His Glu Pro Ile Cys His Th - #r Val Lys Lys Asp Glu# 220- Asn Val Tyr Glu Leu Leu Leu Gly Leu His Gl - #y Asn Ile Thr Asp Asp225 2 - #30 2 - #35 2 -#40- Ile Phe Leu Asp Glu Asp Ser Glu Leu Leu Ly - #s Arg Val Asn Ile Pro# 255- Thr Thr Thr Asn Asn Tyr Ile Phe Lys Pro Ty - #r Leu Asp Gln Arg Asn# 270- Arg Lys Phe Leu Ile Ile Val Ile Ser Ile Se - #r Ile Ile Leu Leu Ile# 285- Leu Leu Val Leu Ile Gly Ser Ile Ile Asn As - #n Ile Ile Arg Arg His# 300- Phe Ser Ser Ser Arg Arg Ile Tyr Arg Pro Ly - #s Gly Asn Ser Glu Ser305 3 - #10 3 - #15 3 -#20- Glu Asn Ile Glu Leu Thr Cys Gly Glu Asn Se - #r Val Asn Lys Asn Asn# 335- Pro Leu Pro Lys Lys Pro Asn Arg Gln Lys Ar - #g Ser Ser Thr Ile Gln# 350- Arg Glu Thr Ser Leu Glu Thr Ile Lys Glu Gl - #u Val# 360- (2) INFORMATION FOR SEQ ID NO:57:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1569 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1566- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:- ATG TTT CGT TTA TTT TTT TTA ATC GCG TCT AC - #A TTA TGT TCG GTA AGA 48Met Phe Arg Leu Phe Phe Leu Ile Ala Ser Th - #r Leu Cys Ser Val Arg# 15- TTT GGT TTT TCA ACA ATT CGT AAT GTT ATT GT - #T TCT GAA AAA TCT GGA 96Phe Gly Phe Ser Thr Ile Arg Asn Val Ile Va - #l Ser Glu Lys Ser Gly# 30- TTT GTA ATT GAT GGT TAT AGT ACT AAC CCA CC - #A TTT AAT GAG ACT AAA 144Phe Val Ile Asp Gly Tyr Ser Thr Asn Pro Pr - #o Phe Asn Glu Thr Lys# 45- AAA TTT ACT AGA GGA TGG GTA TTT TTA CAA AC - #C CCC CCT TCT TAT TGT 192Lys Phe Thr Arg Gly Trp Val Phe Leu Gln Th - #r Pro Pro Ser Tyr Cys# 60- AAA GAT GGG ATA TCA ATA TCT AAT ATA TGC AT - #T GAA CGT AAT ATT TGT 240Lys Asp Gly Ile Ser Ile Ser Asn Ile Cys Il - #e Glu Arg Asn Ile Cys# 80- GAA GAA GAT ATT TTT TTG AAT AAA CGA TGT AC - #A ATT AAA ACT ATT AAT 288Glu Glu Asp Ile Phe Leu Asn Lys Arg Cys Th - #r Ile Lys Thr Ile Asn# 95- TAT CCC TTA GCT GTA GCA GAT TTT GAG ATT AG - #T AAT AAT ACT ATT AAA 336Tyr Pro Leu Ala Val Ala Asp Phe Glu Ile Se - #r Asn Asn Thr Ile Lys# 110- AAA ATA AAT GAT GTT TAT TTT GTT AAT GAT AG - #T GTT TTT CCA ATA ATA 384Lys Ile Asn Asp Val Tyr Phe Val Asn Asp Se - #r Val Phe Pro Ile Ile# 125- ACT ACA AAT AAA AGT GGT ATC CAT ATC ACA AA - #T GTG ACT ATA AAT AAT 432Thr Thr Asn Lys Ser Gly Ile His Ile Thr As - #n Val Thr Ile Asn Asn# 140- TCT GGA ATT TAT ACA TTG TAT GAA AAT AAT GA - #T AAG TGG AGT CAT CAA 480Ser Gly Ile Tyr Thr Leu Tyr Glu Asn Asn As - #p Lys Trp Ser His Gln145 1 - #50 1 - #55 1 -#60- TCA AAA ATC TTG GTA ACT ATA AAG AAA AAA GA - #A ACA GTA ATT ACT AAA 528Ser Lys Ile Leu Val Thr Ile Lys Lys Lys Gl - #u Thr Val Ile Thr Lys# 175- CCT AAA GTA TAT ATA AAA AAA CAT GGT GGA TT - #T TTT CAT GTA AAA AAT 576Pro Lys Val Tyr Ile Lys Lys His Gly Gly Ph - #e Phe His Val Lys Asn# 190- TAT CAC TCT CAT GTA TTT GTA CCA AAT GAT TC - #A TTT AAA ATT GAA CTT 624Tyr His Ser His Val Phe Val Pro Asn Asp Se - #r Phe Lys Ile Glu Leu# 205- AAT CTT GAA TCG GAA ATT TAT GAT TCT GAA TT - #T TCA GCA AGT ATT GAT 672Asn Leu Glu Ser Glu Ile Tyr Asp Ser Glu Ph - #e Ser Ala Ser Ile Asp# 220- TGG TAT TAT ATG AAA ACT AGC TCG GAA TGT TC - #A GTG TTT CAT ATA TAT 720Trp Tyr Tyr Met Lys Thr Ser Ser Glu Cys Se - #r Val Phe His Ile Tyr225 2 - #30 2 - #35 2 -#40- GAA ACT TGT ATA TTT CAC CCT CAT GCA AAC TC - #T TGT TTG AAT CCA ATA 768Glu Thr Cys Ile Phe His Pro His Ala Asn Se - #r Cys Leu Asn Pro Ile# 255- AAC CCA TTG TGT AGT TTT ACT TCC CCT TTG AG - #G GCA ACA TCA CTA ATT 816Asn Pro Leu Cys Ser Phe Thr Ser Pro Leu Ar - #g Ala Thr Ser Leu Ile# 270- AAT AGA TTT TAT TTT AGA TGT AAA CCT GAA GG - #T AAA AAC TGG ACA ACT 864Asn Arg Phe Tyr Phe Arg Cys Lys Pro Glu Gl - #y Lys Asn Trp Thr Thr# 285- GAT TGT ATA AAC ACC TTT TCT ATT AAT GCA GA - #T AAA CAT ATT AAA CAG 912Asp Cys Ile Asn Thr Phe Ser Ile Asn Ala As - #p Lys His Ile Lys Gln# 300- CAT TCA AAT AAT GTA GAT TTG ATT TTT TTA AA - #T ACT CCA ACT AAT GCA 960His Ser Asn Asn Val Asp Leu Ile Phe Leu As - #n Thr Pro Thr Asn Ala305 3 - #10 3 - #15 3 -#20- TCT GGT TTG TAT GTT TTT ATT CTT AAG TAT AA - #T GGT CAT CCA GAG GCT1008Ser Gly Leu Tyr Val Phe Ile Leu Lys Tyr As - #n Gly His Pro Glu Ala# 335- TGG ACA TAT ACT TTG GTT TCA ACG GTT AAA AA - #T TTT ATG AAT GTA ATT1056Trp Thr Tyr Thr Leu Val Ser Thr Val Lys As - #n Phe Met Asn Val Ile# 350- AAG GAT ATG ACA CGC CCC CTT TTG TCA AAT AA - #T AAA ATG AAA AAA CCT1104Lys Asp Met Thr Arg Pro Leu Leu Ser Asn As - #n Lys Met Lys Lys Pro# 365- GAG CAT TCT ACT CAA CCA CCA ACC ATA ACC AA - #C ATA ACA CCT GGC TTT1152Glu His Ser Thr Gln Pro Pro Thr Ile Thr As - #n Ile Thr Pro Gly Phe# 380- AAA TCT AAA AAT TGG GTA GAT AAA TAT ATA AT - #T TCA GTA GCG GTG GTT1200Lys Ser Lys Asn Trp Val Asp Lys Tyr Ile Il - #e Ser Val Ala Val Val385 3 - #90 3 - #95 4 -#00- TCT TGT ATT ACT ATT GTT ATA TTG ATT GTG GT - #A ATA ACC TTT TGT GTT1248Ser Cys Ile Thr Ile Val Ile Leu Ile Val Va - #l Ile Thr Phe Cys Val# 415- CAT CAA TGT ATC GGT TTA AAT CGT AAA CCA TA - #T GAA ATT ATA AAC CCA1296His Gln Cys Ile Gly Leu Asn Arg Lys Pro Ty - #r Glu Ile Ile Asn Pro# 430- TTT AAT ACA GCT TAT AAA AGT ATA CCT ACA AA - #T GAA AAA AAT ATT CTT1344Phe Asn Thr Ala Tyr Lys Ser Ile Pro Thr As - #n Glu Lys Asn Ile Leu# 445- CAT TTT GCT GAA GTA ACA GAA TCT GAT TAT TC - #C TCC GAC GAA TCC TTC1392His Phe Ala Glu Val Thr Glu Ser Asp Tyr Se - #r Ser Asp Glu Ser Phe# 460- GAC AGT GAC TCA GAA GAG CTA AAT CAA CGA GG - #T GAA ACA ATA CAA CAA1440Asp Ser Asp Ser Glu Glu Leu Asn Gln Arg Gl - #y Glu Thr Ile Gln Gln465 4 - #70 4 - #75 4 -#80- GGG AAA AAG GAA CAA TCT GGA TAT ACT ATT TG - #G TTT AAT GAA GAT TTA1488Gly Lys Lys Glu Gln Ser Gly Tyr Thr Ile Tr - #p Phe Asn Glu Asp Leu# 495- GAA GAA TCC GTC TCC AAA AAA CTT AAC CAA CC - #A AAC TAT TCA AAA ATA1536Glu Glu Ser Val Ser Lys Lys Leu Asn Gln Pr - #o Asn Tyr Ser Lys Ile# 510# 1569C TTA AAA TCA ATC CAG AAT GAA TA - #AIle Asn Ser Leu Lys Ser Ile Gln Asn Glu# 520- (2) INFORMATION FOR SEQ ID NO:58:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 522 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:- Met Phe Arg Leu Phe Phe Leu Ile Ala Ser Th - #r Leu Cys Ser Val Arg# 15- Phe Gly Phe Ser Thr Ile Arg Asn Val Ile Va - #l Ser Glu Lys Ser Gly# 30- Phe Val Ile Asp Gly Tyr Ser Thr Asn Pro Pr - #o Phe Asn Glu Thr Lys# 45- Lys Phe Thr Arg Gly Trp Val Phe Leu Gln Th - #r Pro Pro Ser Tyr Cys# 60- Lys Asp Gly Ile Ser Ile Ser Asn Ile Cys Il - #e Glu Arg Asn Ile Cys# 80- Glu Glu Asp Ile Phe Leu Asn Lys Arg Cys Th - #r Ile Lys Thr Ile Asn# 95- Tyr Pro Leu Ala Val Ala Asp Phe Glu Ile Se - #r Asn Asn Thr Ile Lys# 110- Lys Ile Asn Asp Val Tyr Phe Val Asn Asp Se - #r Val Phe Pro Ile Ile# 125- Thr Thr Asn Lys Ser Gly Ile His Ile Thr As - #n Val Thr Ile Asn Asn# 140- Ser Gly Ile Tyr Thr Leu Tyr Glu Asn Asn As - #p Lys Trp Ser His Gln145 1 - #50 1 - #55 1 -#60- Ser Lys Ile Leu Val Thr Ile Lys Lys Lys Gl - #u Thr Val Ile Thr Lys# 175- Pro Lys Val Tyr Ile Lys Lys His Gly Gly Ph - #e Phe His Val Lys Asn# 190- Tyr His Ser His Val Phe Val Pro Asn Asp Se - #r Phe Lys Ile Glu Leu# 205- Asn Leu Glu Ser Glu Ile Tyr Asp Ser Glu Ph - #e Ser Ala Ser Ile Asp# 220- Trp Tyr Tyr Met Lys Thr Ser Ser Glu Cys Se - #r Val Phe His Ile Tyr225 2 - #30 2 - #35 2 -#40- Glu Thr Cys Ile Phe His Pro His Ala Asn Se - #r Cys Leu Asn Pro Ile# 255- Asn Pro Leu Cys Ser Phe Thr Ser Pro Leu Ar - #g Ala Thr Ser Leu Ile# 270- Asn Arg Phe Tyr Phe Arg Cys Lys Pro Glu Gl - #y Lys Asn Trp Thr Thr# 285- Asp Cys Ile Asn Thr Phe Ser Ile Asn Ala As - #p Lys His Ile Lys Gln# 300- His Ser Asn Asn Val Asp Leu Ile Phe Leu As - #n Thr Pro Thr Asn Ala305 3 - #10 3 - #15 3 -#20- Ser Gly Leu Tyr Val Phe Ile Leu Lys Tyr As - #n Gly His Pro Glu Ala# 335- Trp Thr Tyr Thr Leu Val Ser Thr Val Lys As - #n Phe Met Asn Val Ile# 350- Lys Asp Met Thr Arg Pro Leu Leu Ser Asn As - #n Lys Met Lys Lys Pro# 365- Glu His Ser Thr Gln Pro Pro Thr Ile Thr As - #n Ile Thr Pro Gly Phe# 380- Lys Ser Lys Asn Trp Val Asp Lys Tyr Ile Il - #e Ser Val Ala Val Val385 3 - #90 3 - #95 4 -#00- Ser Cys Ile Thr Ile Val Ile Leu Ile Val Va - #l Ile Thr Phe Cys Val# 415- His Gln Cys Ile Gly Leu Asn Arg Lys Pro Ty - #r Glu Ile Ile Asn Pro# 430- Phe Asn Thr Ala Tyr Lys Ser Ile Pro Thr As - #n Glu Lys Asn Ile Leu# 445- His Phe Ala Glu Val Thr Glu Ser Asp Tyr Se - #r Ser Asp Glu Ser Phe# 460- Asp Ser Asp Ser Glu Glu Leu Asn Gln Arg Gl - #y Glu Thr Ile Gln Gln465 4 - #70 4 - #75 4 -#80- Gly Lys Lys Glu Gln Ser Gly Tyr Thr Ile Tr - #p Phe Asn Glu Asp Leu# 495- Glu Glu Ser Val Ser Lys Lys Leu Asn Gln Pr - #o Asn Tyr Ser Lys Ile# 510- Ile Asn Ser Leu Lys Ser Ile Gln Asn Glu# 520- (2) INFORMATION FOR SEQ ID NO:59:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 237 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..234- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:- ATG AAT AAA TCT AAA CTC TCA TTT AAA GAA AA - #A AAC GCT ATA TAT GAA 48Met Asn Lys Ser Lys Leu Ser Phe Lys Glu Ly - #s Asn Ala Ile Tyr Glu# 15- TTT AAA AAT ATT TTA TCA AAC ACT TCA TTG TC - #A ACT TTT CCT GTA TTA 96Phe Lys Asn Ile Leu Ser Asn Thr Ser Leu Se - #r Thr Phe Pro Val Leu# 30- TCG TTT AAT GAG GAG CCA AAA TCC AGA TTT TT - #T AAA ATG TTT AAA AAT 144Ser Phe Asn Glu Glu Pro Lys Ser Arg Phe Ph - #e Lys Met Phe Lys Asn# 45- ATT TTA CTG GAA AAA ATA AAA AAA ACT TCA AT - #G GAT TAT TTA ATT TAT 192Ile Leu Leu Glu Lys Ile Lys Lys Thr Ser Me - #t Asp Tyr Leu Ile Tyr# 60- TGT ACT CTA AAA ATC TCA CTT TCA TTT ATA CT - #T TAT AAT AAA# 234Cys Thr Leu Lys Ile Ser Leu Ser Phe Ile Le - #u Tyr Asn Lys# 75# 237- (2) INFORMATION FOR SEQ ID NO:60:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 78 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:- Met Asn Lys Ser Lys Leu Ser Phe Lys Glu Ly - #s Asn Ala Ile Tyr Glu# 15- Phe Lys Asn Ile Leu Ser Asn Thr Ser Leu Se - #r Thr Phe Pro Val Leu# 30- Ser Phe Asn Glu Glu Pro Lys Ser Arg Phe Ph - #e Lys Met Phe Lys Asn# 45- Ile Leu Leu Glu Lys Ile Lys Lys Thr Ser Me - #t Asp Tyr Leu Ile Tyr# 60- Cys Thr Leu Lys Ile Ser Leu Ser Phe Ile Le - #u Tyr Asn Lys# 75- (2) INFORMATION FOR SEQ ID NO:61:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 360 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..357- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:- ATG GCT TTA CCA GAT AAC GTT TTT AGT ATT AT - #T AAT GAA AAT TAT ATC 48Met Ala Leu Pro Asp Asn Val Phe Ser Ile Il - #e Asn Glu Asn Tyr Ile# 15- GAT GGA ATT TTA ACT ATG AAA ATG GGT GAA GA - #A ATA GAA AGC TCA TCA 96Asp Gly Ile Leu Thr Met Lys Met Gly Glu Gl - #u Ile Glu Ser Ser Ser# 30- CCA TTA AAT GAA ACA AAT GTT AAT ATA GAT CA - #A CAT ACA ATA GAT ATT 144Pro Leu Asn Glu Thr Asn Val Asn Ile Asp Gl - #n His Thr Ile Asp Ile# 45- TTT GAT TAC GAT TCA GAT AAT GGA TGT TAT TA - #T AGT GAA AGA GAT AAT 192Phe Asp Tyr Asp Ser Asp Asn Gly Cys Tyr Ty - #r Ser Glu Arg Asp Asn# 60- GAA ACC GCA ACT CTT TTT TTA AAA CGT GTT GG - #T TAT AGA GAA ACC TCA 240Glu Thr Ala Thr Leu Phe Leu Lys Arg Val Gl - #y Tyr Arg Glu Thr Ser# 80- AAA AAG CGT AAA CGG ATT TGT GGA TTT ATT GT - #T TTA GCA ATT TTT ATG 288Lys Lys Arg Lys Arg Ile Cys Gly Phe Ile Va - #l Leu Ala Ile Phe Met# 95- GTT ATT ATA TTA TGT TTT TTA TCA ATA ATT TT - #G GGA GTT TTT ATA GCG 336Val Ile Ile Leu Cys Phe Leu Ser Ile Ile Le - #u Gly Val Phe Ile Ala# 110# 360AA GGC CTA TAGPro His Ile Tyr Lys Gly Leu 115- (2) INFORMATION FOR SEQ ID NO:62:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 119 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:- Met Ala Leu Pro Asp Asn Val Phe Ser Ile Il - #e Asn Glu Asn Tyr Ile# 15- Asp Gly Ile Leu Thr Met Lys Met Gly Glu Gl - #u Ile Glu Ser Ser Ser# 30- Pro Leu Asn Glu Thr Asn Val Asn Ile Asp Gl - #n His Thr Ile Asp Ile# 45- Phe Asp Tyr Asp Ser Asp Asn Gly Cys Tyr Ty - #r Ser Glu Arg Asp Asn# 60- Glu Thr Ala Thr Leu Phe Leu Lys Arg Val Gl - #y Tyr Arg Glu Thr Ser# 80- Lys Lys Arg Lys Arg Ile Cys Gly Phe Ile Va - #l Leu Ala Ile Phe Met# 95- Val Ile Ile Leu Cys Phe Leu Ser Ile Ile Le - #u Gly Val Phe Ile Ala# 110- Pro His Ile Tyr Lys Gly Leu 115- (2) INFORMATION FOR SEQ ID NO:63:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2044 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:- AAATTTACTA GAACAGAACC TGGATCTGGT GTTATTTTTT CCAGTAAGCC TA - #TATCCCTT 60- CAGTAATACC CCAAAAACAC CAAAATTTCC ATGGTATGGA GCCACTCATT TG - #TATAACAA 120- AAATGTTTTT TGTGAAGCTG TACGTCGATG TGCTTCTAAA CATGCTATAG AA - #GCCGCATC 180- ATCTATTTGG GATTTAAATC CACCACAGTC AAATGAAGAA TTGGAAAAGT TT - #CTAACTAA 240- AGCGGTTATT CGCATAACCA TATCTGAGGG ACTAGGTATT TTAAAAACTG CA - #AATACCCC 300- ATTTAGCTGT GGTCAAAAAA CTGCTGATGA TGTTAAATTT AAGTCTCACT CC - #TCACGTAG 360- GAGTAAGAGT CAGTCAAGAA GTAGACACAG TCGGGGTGAT TTCGACGACA GT - #AGTGATTA 420- AAGTTTGTTA CACCCACTAA TTTAAATAAA TAAAAAATTT ATATTTAAAG CT - #ATTTGTCT 480- GTCTTTTTTT GTTATATATA TTCTTGCTTA GTGAGAGTAT AAACTATTTT GT - #TTTTAAAA 540- ATGGAATTTA ACATAGAAGA CTTTGATGAA TCGTTGCTAG GGGCTGTTGG AT - #ACTCTAAT 600- AATTTTAAAG GTAAGCAAAG CCTTCCGATT AAGGCTTCTA GTCCATCATC GT - #TAATTAAA 660- AATCTTTTAG ATGAATTAAA TTTTCCGGAA GGTCCTAGTT TATTATCTTC TA - #TGGAAAAA 720- TGGAATGAGG ATTTATTTTC CTGCATCCCA AGATTTTTGG AAATCTACAT TG - #AAAATTCT 780- ATTTTATCAA CATCTGTCGA TGAGGTTATT AAAAATTTGG ATAATTCTTT AA - #ATTATGAT 840- GATGTAATCG ATTTTCAGGT CCATGGACCT GAAACATTTC CAAAAACCCC AT - #TATTGGAA 900- GAGGAATTGG AAAATTATGT AACATCTGTT CAAAAGTATT TTTTATCTGA AC - #TTAAAGCT 960- AGAGAAGTTA CATATTCATT TCTACTCACT AAATATTGTA AAGCGCTTTT GT - #TATATCTT1020- CGCTATAATA CAAAATCATC GATTAAGGGT AATAAGGACA TAAATGCATT TC - #ACCAAAAA1080- TTTAAACAAA ATGTGCGGGA ACGTTATTAT AGAGAGGTTG CAAATATAGC AC - #GATTGTTA1140- TATTTACATC TGTATTTATC AGTAACTAGG GAAGTGTCTT GGAAACTACA TG - #CCGATCAA1200- GTATTACTCC AAAGTGTTTT TGTTTCATTG TCTTATTCTT GGAGCCACCG AC - #GACAGTTT1260- GAGTGTATAT TTCATCCAAT TTTATTTAAT CATGGTATTG TGAATTTGGA AA - #ATAACCCT1320- TTGACATTTA AGGAACTACA AAAAATAAAT TATAGACGTC ATATTCTTGG TT - #TACCATTG1380- ATTAGAGCTG GATTGGTAGA AGAAGATAAT CAACCTTTAA TGATACCTCC AG - #AGTTTTCC1440- AGTAAACTAC CTCGAACAAT AGGATTTTTA ACTCAACAAA TTAGAGCCAA AA - #TGGAAGCT1500- TATTCAGACA ACCATCCTGT AACACCAAAA TTTCCTCGTA TTGAACATTC AT - #ATGCTAAA1560- CCTATAGATC CTATTAACTA TGGAACTACA ATAGAAGCTA TGATGGACCC AC - #CATCACCA1620- AGCGCTATTT TACCAGGAGA TCCAAATCCT GAAATTAATG TTAAGGTTAA AA - #GCACTGTT1680- TCATCCTTTC AAATTCCACC TAATATTACC TTGGAAGAAC TGGAGTCAGG TG - #AATATAAT1740- TTATTTACAG ATGGTGTTAC CTACAATGAT ATACCTGAAA ATGAGTTAAA TA - #AAATGTTT1800- CAATTATAAT TTTTTTTTAA TTTTTTCCAT TTAAAACGTT AGTATATAAT AT - #GAGGTTAT1860- ATTAATCAAT AACACCAATA TATTGGGGAA TTGCCACTAA GATACACGTG AG - #TGGTACTT1920- TTGTAGTTAG TGGGTATAAA TAAGGTGGGG TAAGGTGGGG TTCAAATCAT TT - #TTTATTAC1980- TCAGTGTTTG CTTAAGAAAT TATATATTTA ATATATTTAC TATGGAAAGA GA - #CCATGGTT2040# 2044- (2) INFORMATION FOR SEQ ID NO:64:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2044 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:- GCAAAACCAT GGTCTCTTTC CATAGTAAAT ATATTAAATA TATAATTTCT TA - #AGCAAACA 60- CTGAGTAATA AAAAATGATT TGAACCCCAC CTTACCCCAC CTTATTTATA CC - #CACTAACT 120- ACAAAAGTAC CACTCACGTG TATCTTAGTG GCAATTCCCC AATATATTGG TG - #TTATTGAT 180- TAATATAACC TCATATTATA TACTAACGTT TTAAATGGAA AAAATTAAAA AA - #AAATTATA 240- ATTGAAACAT TTTATTTAAC TCATTTTCAG GTATATCATT GTAGGTAACA CC - #ATCTGTAA 300- ATAAATTATA TTCACCTGAC TCCAGTTCTT CCAAGGTAAT ATTAGGTGGA AT - #TTGAAAGG 360- ATGAAACAGT GCTTTTAACC TTAACATTAA TTTCAGGATT TGGATCTCCT GG - #TAAAATAG 420- CGCTTGGTGA TGGTGGGTCC ATCATAGCTT CTATTGTAGT TCCATAGTTA AT - #AGGATCTA 480- TAGGTTTAGC ATATGAATGT TCAATACGAG GAAATTTTGG TGTTACAGGA TG - #GTTGTCTG 540- AATAAGCTTC CATTTTGGCT CTAATTTGTT GAGTTAAAAA TCCTATTGTT CG - #AGGTAGTT 600- TACTGGAAAA CTCTGGAGGT ATCATTAAAG GTTGATTATC TTCTTCTACC AA - #TCCAGCTC 660- TAATCAATGG TAAACCAAGA ATATGACGTC TATAATTTAT TTTTTGTAGT TC - #CTTAAATG 720- TCAAAGGGTT ATTTTCCAAA TTCACAATAC CATGATTAAA TAAAATTGGA TG - #AAATATAC 780- ACTCAAACTG TCGTCGGTGG CTCCAAGAAT AAGACAATGA AACAAAAACA CT - #TTGGAGTA 840- ATACTTGATC GGCATGTAGT TTCCAAGACA CTTCCCTAGT TACTGATAAA TA - #CAGATGTA 900- AATATAACAA TCGTGCTATA TTTGCAACCT CTCTATAATA ACGTTCCCGC AC - #ATTTTGTT 960- TAAATTTTTG GTGAAATGCA TTTATGTCCT TATTACCCTT AATCGATGAT TT - #TGTATTAT1020- AGCGAAGATA TAACAAAAGC GCTTTACAAT ATTTAGTGAG TAGAAATGAA TA - #TGTAACTT1080- CTCTAGCTTT AAGTTCAGAT AAAAAATACT TTTGAACAGA TGTTACATAA TT - #TTCCAATT1140- CCTCTTCCAA TAATGGGGTT TTTGGAAATG TTTCAGGTCC ATGGACCTGA AA - #ATCGATTA1200- CATCATCATA ATTTAAAGAA TTATCCAAAT TTTTAATAAC CTCATCGACA GA - #TGTTGATA1260- AAATAGAATT TTCAATGTAG ATTTCCAAAA ATCTTGGGAT GCAGGAAAAT AA - #ATCCTCAT1320- TCCATTTTTC CATAGAAGAT AATAAACTAG GACCTTCCGG AAAATTTAAT TC - #ATCTAAAA1380- GATTTTTAAT TAACGATGAT GGACTAGAAG CCTTAATCGG AAGGCTTTGC TT - #ACCTTTAA1440- AATTATTAGA GTATCCAACA GCCCCTAGCA ACGATTCATC AAAGTCTTCT AT - #GTTAAATT1500- CCATTTTTAA AAACAAAATA GTTTATACTC TCACTAAGCA AGAATATATA TA - #ACAAAAAA1560- AGACAGACAA ATAGCTTTAA ATATAAATTT TTTATTTATT TAAATTAGTG GG - #TGTAACAA1620- ACTTTAATCA CTACTGTCGT CGAAATCACC CCGACTGTGT CTACTTCTTG AC - #TGACTCTT1680- ACTCCTACGT GAGGAGTGAG ACTTAAATTT AACATCATCA GCAGTTTTTT GA - #CCACAGCT1740- AAATGGGGTA TTTGCAGTTT TTAAAATACC TAGTCCCTCA GATATGGTTA TG - #CGAATAAC1800- CGCTTTAGTT AGAAACTTTT CCAATTCTTC ATTTGACTGT GGTGGATTTA AA - #TCCCAAAT1860- AGATGATGCG GCTTCTATAG CATGTTTAGA AGCACATCGA CGTACAGCTT CA - #CAAAAAAC1920- ATTTTTGTTA TACAAATGAG TGGCTCCATA CCATGGAAAT TTTGGTGTTT TT - #GGGGTATT1980- ACTGAAGGGA TATAGGCTTA CTGGAAAAAA TAACACCAGA TCCAGGTTCT GT - #TCTAGTAA2040# 2044- (2) INFORMATION FOR SEQ ID NO:65:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 420 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..417- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:- AAT TTA CTA GAA CAG AAC CTG GAT CTG GTG TT - #A TTT TTT CCA GTA AGC 48Asn Leu Leu Glu Gln Asn Leu Asp Leu Val Le - #u Phe Phe Pro Val Ser# 15- CTA TAT CCC TTC AGT AAT ACC CCA AAA ACA CC - #A AAA TTT CCA TGG TAT 96Leu Tyr Pro Phe Ser Asn Thr Pro Lys Thr Pr - #o Lys Phe Pro Trp Tyr# 30- GGA GCC ACT CAT TTG TAT AAC AAA AAT GTT TT - #T TGT GAA GCT GTA CGT 144Gly Ala Thr His Leu Tyr Asn Lys Asn Val Ph - #e Cys Glu Ala Val Arg# 45- CGA TGT GCT TCT AAA CAT GCT ATA GAA GCC GC - #A TCA TCT ATT TGG GAT 192Arg Cys Ala Ser Lys His Ala Ile Glu Ala Al - #a Ser Ser Ile Trp Asp# 60- TTA AAT CCA CCA CAG TCA AAT GAA GAA TTG GA - #A AAG TTT CTA ACT AAA 240Leu Asn Pro Pro Gln Ser Asn Glu Glu Leu Gl - #u Lys Phe Leu Thr Lys# 80- GCG GTT ATT CGC ATA ACC ATA TCT GAG GGA CT - #A GGT ATT TTA AAA ACT 288Ala Val Ile Arg Ile Thr Ile Ser Glu Gly Le - #u Gly Ile Leu Lys Thr# 95- GCA AAT ACC CCA TTT AGC TGT GGT CAA AAA AC - #T GCT GAT GAT GTT AAA 336Ala Asn Thr Pro Phe Ser Cys Gly Gln Lys Th - #r Ala Asp Asp Val Lys# 110- TTT AAG TCT CAC TCC TCA CGT AGG AGT AAG AG - #T CAG TCA AGA AGT AGA 384Phe Lys Ser His Ser Ser Arg Arg Ser Lys Se - #r Gln Ser Arg Ser Arg# 125# 420CGG GGT GAT TTC GAC GAC AGT AGT GA - #T TAAHis Ser Arg Gly Asp Phe Asp Asp Ser Ser As - #p# 135- (2) INFORMATION FOR SEQ ID NO:66:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 139 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:- Asn Leu Leu Glu Gln Asn Leu Asp Leu Val Le - #u Phe Phe Pro Val Ser# 15- Leu Tyr Pro Phe Ser Asn Thr Pro Lys Thr Pr - #o Lys Phe Pro Trp Tyr# 30- Gly Ala Thr His Leu Tyr Asn Lys Asn Val Ph - #e Cys Glu Ala Val Arg# 45- Arg Cys Ala Ser Lys His Ala Ile Glu Ala Al - #a Ser Ser Ile Trp Asp# 60- Leu Asn Pro Pro Gln Ser Asn Glu Glu Leu Gl - #u Lys Phe Leu Thr Lys# 80- Ala Val Ile Arg Ile Thr Ile Ser Glu Gly Le - #u Gly Ile Leu Lys Thr# 95- Ala Asn Thr Pro Phe Ser Cys Gly Gln Lys Th - #r Ala Asp Asp Val Lys# 110- Phe Lys Ser His Ser Ser Arg Arg Ser Lys Se - #r Gln Ser Arg Ser Arg# 125- His Ser Arg Gly Asp Phe Asp Asp Ser Ser As - #p# 135- (2) INFORMATION FOR SEQ ID NO:67:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1269 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1266- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:- ATG GAA TTT AAC ATA GAA GAC TTT GAT GAA TC - #G TTG CTA GGG GCT GTT 48Met Glu Phe Asn Ile Glu Asp Phe Asp Glu Se - #r Leu Leu Gly Ala Val# 15- GGA TAC TCT AAT AAT TTT AAA GGT AAG CAA AG - #C CTT CCG ATT AAG GCT 96Gly Tyr Ser Asn Asn Phe Lys Gly Lys Gln Se - #r Leu Pro Ile Lys Ala# 30- TCT AGT CCA TCA TCG TTA ATT AAA AAT CTT TT - #A GAT GAA TTA AAT TTT 144Ser Ser Pro Ser Ser Leu Ile Lys Asn Leu Le - #u Asp Glu Leu Asn Phe# 45- CCG GAA GGT CCT AGT TTA TTA TCT TCT ATG GA - #A AAA TGG AAT GAG GAT 192Pro Glu Gly Pro Ser Leu Leu Ser Ser Met Gl - #u Lys Trp Asn Glu Asp# 60- TTA TTT TCC TGC ATC CCA AGA TTT TTG GAA AT - #C TAC ATT GAA AAT TCT 240Leu Phe Ser Cys Ile Pro Arg Phe Leu Glu Il - #e Tyr Ile Glu Asn Ser# 80- ATT TTA TCA ACA TCT GTC GAT GAG GTT ATT AA - #A AAT TTG GAT AAT TCT 288Ile Leu Ser Thr Ser Val Asp Glu Val Ile Ly - #s Asn Leu Asp Asn Ser# 95- TTA AAT TAT GAT GAT GTA ATC GAT TTT CAG GT - #C CAT GGA CCT GAA ACA 336Leu Asn Tyr Asp Asp Val Ile Asp Phe Gln Va - #l His Gly Pro Glu Thr# 110- TTT CCA AAA ACC CCA TTA TTG GAA GAG GAA TT - #G GAA AAT TAT GTA ACA 384Phe Pro Lys Thr Pro Leu Leu Glu Glu Glu Le - #u Glu Asn Tyr Val Thr# 125- TCT GTT CAA AAG TAT TTT TTA TCT GAA CTT AA - #A GCT AGA GAA GTT ACA 432Ser Val Gln Lys Tyr Phe Leu Ser Glu Leu Ly - #s Ala Arg Glu Val Thr# 140- TAT TCA TTT CTA CTC ACT AAA TAT TGT AAA GC - #G CTT TTG TTA TAT CTT 480Tyr Ser Phe Leu Leu Thr Lys Tyr Cys Lys Al - #a Leu Leu Leu Tyr Leu145 1 - #50 1 - #55 1 -#60- CGC TAT AAT ACA AAA TCA TCG ATT AAG GGT AA - #T AAG GAC ATA AAT GCA 528Arg Tyr Asn Thr Lys Ser Ser Ile Lys Gly As - #n Lys Asp Ile Asn Ala# 175- TTT CAC CAA AAA TTT AAA CAA AAT GTG CGG GA - #A CGT TAT TAT AGA GAG 576Phe His Gln Lys Phe Lys Gln Asn Val Arg Gl - #u Arg Tyr Tyr Arg Glu# 190- GTT GCA AAT ATA GCA CGA TTG TTA TAT TTA CA - #T CTG TAT TTA TCA GTA 624Val Ala Asn Ile Ala Arg Leu Leu Tyr Leu Hi - #s Leu Tyr Leu Ser Val# 205- ACT AGG GAA GTG TCT TGG AAA CTA CAT GCC GA - #T CAA GTA TTA CTC CAA 672Thr Arg Glu Val Ser Trp Lys Leu His Ala As - #p Gln Val Leu Leu Gln# 220- AGT GTT TTT GTT TCA TTG TCT TAT TCT TGG AG - #C CAC CGA CGA CAG TTT 720Ser Val Phe Val Ser Leu Ser Tyr Ser Trp Se - #r His Arg Arg Gln Phe225 2 - #30 2 - #35 2 -#40- GAG TGT ATA TTT CAT CCA ATT TTA TTT AAT CA - #T GGT ATT GTG AAT TTG 768Glu Cys Ile Phe His Pro Ile Leu Phe Asn Hi - #s Gly Ile Val Asn Leu# 255- GAA AAT AAC CCT TTG ACA TTT AAG GAA CTA CA - #A AAA ATA AAT TAT AGA 816Glu Asn Asn Pro Leu Thr Phe Lys Glu Leu Gl - #n Lys Ile Asn Tyr Arg# 270- CGT CAT ATT CTT GGT TTA CCA TTG ATT AGA GC - #T GGA TTG GTA GAA GAA 864Arg His Ile Leu Gly Leu Pro Leu Ile Arg Al - #a Gly Leu Val Glu Glu# 285- GAT AAT CAA CCT TTA ATG ATA CCT CCA GAG TT - #T TCC AGT AAA CTA CCT 912Asp Asn Gln Pro Leu Met Ile Pro Pro Glu Ph - #e Ser Ser Lys Leu Pro# 300- CGA ACA ATA GGA TTT TTA ACT CAA CAA ATT AG - #A GCC AAA ATG GAA GCT 960Arg Thr Ile Gly Phe Leu Thr Gln Gln Ile Ar - #g Ala Lys Met Glu Ala305 3 - #10 3 - #15 3 -#20- TAT TCA GAC AAC CAT CCT GTA ACA CCA AAA TT - #T CCT CGT ATT GAA CAT1008Tyr Ser Asp Asn His Pro Val Thr Pro Lys Ph - #e Pro Arg Ile Glu His# 335- TCA TAT GCT AAA CCT ATA GAT CCT ATT AAC TA - #T GGA ACT ACA ATA GAA1056Ser Tyr Ala Lys Pro Ile Asp Pro Ile Asn Ty - #r Gly Thr Thr Ile Glu# 350- GCT ATG ATG GAC CCA CCA TCA CCA AGC GCT AT - #T TTA CCA GGA GAT CCA1104Ala Met Met Asp Pro Pro Ser Pro Ser Ala Il - #e Leu Pro Gly Asp Pro# 365- AAT CCT GAA ATT AAT GTT AAG GTT AAA AGC AC - #T GTT TCA TCC TTT CAA1152Asn Pro Glu Ile Asn Val Lys Val Lys Ser Th - #r Val Ser Ser Phe Gln# 380- ATT CCA CCT AAT ATT ACC TTG GAA GAA CTG GA - #G TCA GGT GAA TAT AAT1200Ile Pro Pro Asn Ile Thr Leu Glu Glu Leu Gl - #u Ser Gly Glu Tyr Asn385 3 - #90 3 - #95 4 -#00- TTA TTT ACA GAT GGT GTT ACC TAC AAT GAT AT - #A CCT GAA AAT GAG TTA1248Leu Phe Thr Asp Gly Val Thr Tyr Asn Asp Il - #e Pro Glu Asn Glu Leu# 415# 1269 TTA TAAAsn Lys Met Phe Gln Leu 420- (2) INFORMATION FOR SEQ ID NO:68:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 422 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:- Met Glu Phe Asn Ile Glu Asp Phe Asp Glu Se - #r Leu Leu Gly Ala Val# 15- Gly Tyr Ser Asn Asn Phe Lys Gly Lys Gln Se - #r Leu Pro Ile Lys Ala# 30- Ser Ser Pro Ser Ser Leu Ile Lys Asn Leu Le - #u Asp Glu Leu Asn Phe# 45- Pro Glu Gly Pro Ser Leu Leu Ser Ser Met Gl - #u Lys Trp Asn Glu Asp# 60- Leu Phe Ser Cys Ile Pro Arg Phe Leu Glu Il - #e Tyr Ile Glu Asn Ser# 80- Ile Leu Ser Thr Ser Val Asp Glu Val Ile Ly - #s Asn Leu Asp Asn Ser# 95- Leu Asn Tyr Asp Asp Val Ile Asp Phe Gln Va - #l His Gly Pro Glu Thr# 110- Phe Pro Lys Thr Pro Leu Leu Glu Glu Glu Le - #u Glu Asn Tyr Val Thr# 125- Ser Val Gln Lys Tyr Phe Leu Ser Glu Leu Ly - #s Ala Arg Glu Val Thr# 140- Tyr Ser Phe Leu Leu Thr Lys Tyr Cys Lys Al - #a Leu Leu Leu Tyr Leu145 1 - #50 1 - #55 1 -#60- Arg Tyr Asn Thr Lys Ser Ser Ile Lys Gly As - #n Lys Asp Ile Asn Ala# 175- Phe His Gln Lys Phe Lys Gln Asn Val Arg Gl - #u Arg Tyr Tyr Arg Glu# 190- Val Ala Asn Ile Ala Arg Leu Leu Tyr Leu Hi - #s Leu Tyr Leu Ser Val# 205- Thr Arg Glu Val Ser Trp Lys Leu His Ala As - #p Gln Val Leu Leu Gln# 220- Ser Val Phe Val Ser Leu Ser Tyr Ser Trp Se - #r His Arg Arg Gln Phe225 2 - #30 2 - #35 2 -#40- Glu Cys Ile Phe His Pro Ile Leu Phe Asn Hi - #s Gly Ile Val Asn Leu# 255- Glu Asn Asn Pro Leu Thr Phe Lys Glu Leu Gl - #n Lys Ile Asn Tyr Arg# 270- Arg His Ile Leu Gly Leu Pro Leu Ile Arg Al - #a Gly Leu Val Glu Glu# 285- Asp Asn Gln Pro Leu Met Ile Pro Pro Glu Ph - #e Ser Ser Lys Leu Pro# 300- Arg Thr Ile Gly Phe Leu Thr Gln Gln Ile Ar - #g Ala Lys Met Glu Ala305 3 - #10 3 - #15 3 -#20- Tyr Ser Asp Asn His Pro Val Thr Pro Lys Ph - #e Pro Arg Ile Glu His# 335- Ser Tyr Ala Lys Pro Ile Asp Pro Ile Asn Ty - #r Gly Thr Thr Ile Glu# 350- Ala Met Met Asp Pro Pro Ser Pro Ser Ala Il - #e Leu Pro Gly Asp Pro# 365- Asn Pro Glu Ile Asn Val Lys Val Lys Ser Th - #r Val Ser Ser Phe Gln# 380- Ile Pro Pro Asn Ile Thr Leu Glu Glu Leu Gl - #u Ser Gly Glu Tyr Asn385 3 - #90 3 - #95 4 -#00- Leu Phe Thr Asp Gly Val Thr Tyr Asn Asp Il - #e Pro Glu Asn Glu Leu# 415- Asn Lys Met Phe Gln Leu 420- (2) INFORMATION FOR SEQ ID NO:69:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 626 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:- AAGCTTATTG TCCGTGCTTT GCTGATGGTT TCTGGAACTG TCTCCCCTAT TT - #TAAGATAC 60- AATATAGAAG GAGTAAAATG TAAACTAAGT TCATGGAACC TTACAACCGC TG - #CCTTTTCT 120- ACCCCATCTA CTGTTAATGA AAAAATTAAT GATGTGGTTG AAACAACTTC AA - #ACCCTTTG 180- AGTAAACTAA AAAAGAATTG TAATAGAGAA AAGGAACTTT CAAAATCAAA AA - #GTATAGTT 240- TCAGGAGGTG TTAGTGTTCA TGGATTAGAA CAAAGCTGTA GCTCTCATAC CT - #CCAATTTT 300- CAGAAATGCC CAGATAAAAC CAAGTCATCA AATAAAAATG ATGCAAACAA AC - #GTGAGTCA 360- AGGGGAAAAA GAAAGTCTGA ACCAATAGTA AATAGTTTTG GAGTCGCAAA AG - #TTTCATCC 420- AACCCACCGC CATCAAAAAA GAGAGCATCA TCACAATCTA CCGGACCACT TG - #GACCAATG 480- CCAGAAGAAG GACCGACCCC CAAGGGTGGT TTTAGAAGAA TACCTTCTGG GG - #ATTGTCAT 540- ACCCCAGTTC CAAGGGACAT TGTAAAATCT ATCTACTGTT CACCAGAGAC TG - #TGAAAGAA 600# 626 TGTT TCCTGA- (2) INFORMATION FOR SEQ ID NO:70:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 626 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:- TCAGGAAACA ATGGATGATC TGTTAATTCT TTCACAGTCT CTGGTGAACA GT - #AGATAGAT 60- TTTACAATGT CCCTTGGAAC TGGGGTATGA CAATCCCCAG AAGGTATTCT TC - #TAAAACCA 120- CCCTTGGGGG TCGGTCCTTC TTCTGGCATT GGTCCAAGTG GTCCGGTAGA TT - #GTGATGAT 180- GCTCTCTTTT TTGATGGCGG TGGGTTGGAT GAAACTTTTG CGACTCCAAA AC - #TATTTACT 240- ATTGGTTCAG ACTTTCTTTT TCCCCTTGAC TCACGTTTGT TTGCATCATT TT - #TATTTGAT 300- GACTTGGTTT TATCTGGGCA TTTCTGAAAA TTGGAGGTAT GAGAGCTACA GC - #TTTGTTCT 360- AATCCATGAA CACTAACACC TCCTGAAACT ATACTTTTTG ATTTTGAAAG TT - #CCTTTTCT 420- CTATTACAAT TCTTTTTTAG TTTACTCAAA GGGTTTGAAG TTGTTTCAAC CA - #CATCATTA 480- ATTTTTTCAT TAACAGTAGA TGGGGTAGAA AAGGCAGCGG TTGTAAGGTT CC - #ATGAACTT 540- AGTTTACATT TTACTCCTTC TATATTGTAT CTTAAAATAG GGGAGACAGT TC - #CAGAAACC 600# 626 CAAT AAGCTT- (2) INFORMATION FOR SEQ ID NO:71:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 624 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..624- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:- AAG CTT ATT GTC CGT GCT TTG CTG ATG GTT TC - #T GGA ACT GTC TCC CCT 48Lys Leu Ile Val Arg Ala Leu Leu Met Val Se - #r Gly Thr Val Ser Pro# 15- ATT TTA AGA TAC AAT ATA GAA GGA GTA AAA TG - #T AAA CTA AGT TCA TGG 96Ile Leu Arg Tyr Asn Ile Glu Gly Val Lys Cy - #s Lys Leu Ser Ser Trp# 30- AAC CTT ACA ACC GCT GCC TTT TCT ACC CCA TC - #T ACT GTT AAT GAA AAA 144Asn Leu Thr Thr Ala Ala Phe Ser Thr Pro Se - #r Thr Val Asn Glu Lys# 45- ATT AAT GAT GTG GTT GAA ACA ACT TCA AAC CC - #T TTG AGT AAA CTA AAA 192Ile Asn Asp Val Val Glu Thr Thr Ser Asn Pr - #o Leu Ser Lys Leu Lys# 60- AAG AAT TGT AAT AGA GAA AAG GAA CTT TCA AA - #A TCA AAA AGT ATA GTT 240Lys Asn Cys Asn Arg Glu Lys Glu Leu Ser Ly - #s Ser Lys Ser Ile Val# 80- TCA GGA GGT GTT AGT GTT CAT GGA TTA GAA CA - #A AGC TGT AGC TCT CAT 288Ser Gly Gly Val Ser Val His Gly Leu Glu Gl - #n Ser Cys Ser Ser His# 95- ACC TCC AAT TTT CAG AAA TGC CCA GAT AAA AC - #C AAG TCA TCA AAT AAA 336Thr Ser Asn Phe Gln Lys Cys Pro Asp Lys Th - #r Lys Ser Ser Asn Lys# 110- AAT GAT GCA AAC AAA CGT GAG TCA AGG GGA AA - #A AGA AAG TCT GAA CCA 384Asn Asp Ala Asn Lys Arg Glu Ser Arg Gly Ly - #s Arg Lys Ser Glu Pro# 125- ATA GTA AAT AGT TTT GGA GTC GCA AAA GTT TC - #A TCC AAC CCA CCG CCA 432Ile Val Asn Ser Phe Gly Val Ala Lys Val Se - #r Ser Asn Pro Pro Pro# 140- TCA AAA AAG AGA GCA TCA TCA CAA TCT ACC GG - #A CCA CTT GGA CCA ATG 480Ser Lys Lys Arg Ala Ser Ser Gln Ser Thr Gl - #y Pro Leu Gly Pro Met145 1 - #50 1 - #55 1 -#60- CCA GAA GAA GGA CCG ACC CCC AAG GGT GGT TT - #T AGA AGA ATA CCT TCT 528Pro Glu Glu Gly Pro Thr Pro Lys Gly Gly Ph - #e Arg Arg Ile Pro Ser# 175- GGG GAT TGT CAT ACC CCA GTT CCA AGG GAC AT - #T GTA AAA TCT ATC TAC 576Gly Asp Cys His Thr Pro Val Pro Arg Asp Il - #e Val Lys Ser Ile Tyr# 190- TGT TCA CCA GAG ACT GTG AAA GAA TTA ACA GA - #T CAT CCA TTG TTT CCT 624Cys Ser Pro Glu Thr Val Lys Glu Leu Thr As - #p His Pro Leu Phe Pro# 205- (2) INFORMATION FOR SEQ ID NO:72:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 208 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:- Lys Leu Ile Val Arg Ala Leu Leu Met Val Se - #r Gly Thr Val Ser Pro# 15- Ile Leu Arg Tyr Asn Ile Glu Gly Val Lys Cy - #s Lys Leu Ser Ser Trp# 30- Asn Leu Thr Thr Ala Ala Phe Ser Thr Pro Se - #r Thr Val Asn Glu Lys# 45- Ile Asn Asp Val Val Glu Thr Thr Ser Asn Pr - #o Leu Ser Lys Leu Lys# 60- Lys Asn Cys Asn Arg Glu Lys Glu Leu Ser Ly - #s Ser Lys Ser Ile Val# 80- Ser Gly Gly Val Ser Val His Gly Leu Glu Gl - #n Ser Cys Ser Ser His# 95- Thr Ser Asn Phe Gln Lys Cys Pro Asp Lys Th - #r Lys Ser Ser Asn Lys# 110- Asn Asp Ala Asn Lys Arg Glu Ser Arg Gly Ly - #s Arg Lys Ser Glu Pro# 125- Ile Val Asn Ser Phe Gly Val Ala Lys Val Se - #r Ser Asn Pro Pro Pro# 140- Ser Lys Lys Arg Ala Ser Ser Gln Ser Thr Gl - #y Pro Leu Gly Pro Met145 1 - #50 1 - #55 1 -#60- Pro Glu Glu Gly Pro Thr Pro Lys Gly Gly Ph - #e Arg Arg Ile Pro Ser# 175- Gly Asp Cys His Thr Pro Val Pro Arg Asp Il - #e Val Lys Ser Ile Tyr# 190- Cys Ser Pro Glu Thr Val Lys Glu Leu Thr As - #p His Pro Leu Phe Pro# 205- (2) INFORMATION FOR SEQ ID NO:73:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 655 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:- AAGCTTGACT TGTTGATTAA AGTTAAAGAA TTGTTTAACA AATTAACATT CT - #TAGGTCTT 60- CCTCTAGGTC GTTTAATAAC AGGCTCATTT TTGTTGTCTG TAGAGTCATA CC - #TGTTTTCG 120- AGTTTGTGTT TAGAAGTCAT CATAAACAAG AAGTAGTTTC AGTCAAACCG GT - #TTTTTGAG 180- ATATACAACC AAGTGGTGGT GGAGGTAATA TAGGAGCTTC TGGTGAAAGC TG - #TGATGGAT 240- AAAATAATCT GTCTATTATA TCAAAAAATT TGGTTTTTAA ACCTTTGGGT GT - #ATTTATTT 300- TCATAATATC ATCAGCCAAT CCCCGGAGAG CTATAAATGG ATTAACCCAA AA - #TACATCAT 360- TCGTTGATTT GAACCATAAA ATGATTTCTA TTGGGTTACA ATCCGTTCTT AT - #TATAATTC 420- CAGAAAGGTT TTTTATATCT TTATTTATTT TTTTATATAT ATTTTTTTCT AT - #TTGATGAT 480- TACGGCATGG TCCTTGAAGT AGTATATTAA TGTTGTTATA TTGATTTTTA CT - #CGACGGAA 540- GCATGGTTAA AATATCTTTT ATATACGAAG AAACAATTAG AATTATTAAT GA - #ATTTATTA 600- AACCCCATCT TCTAAAATTG TGGAGAATAT GAAAAATATT CCGTTTTATA TA - #CAA 655- (2) INFORMATION FOR SEQ ID NO:74:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 655 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:- TTGTATATAA AACGGAATAT TTTTCATATT CTCCACAATT TTAGAAGATG GG - #GTTTAATA 60- AATTCATTAA TAATTCTAAT TGTTTCTTCG TATATAAAAG ATATTTTAAC CA - #TGCTTCCG 120- TCGAGTAAAA ATCAATATAA CAACATTAAT ATACTACTTC AAGGACCATG CC - #GTAATCAT 180- CAAATAGAAA AAAATATATA TAAAAAAATA AATAAAGATA TAAAAAACCT TT - #CTGGAATT 240- ATAATAAGAA CGGATTGTAA CCCAATAGAA ATCATTTTAT GGTTCAAATC AA - #CGAATGAT 300- GTATTTTGGG TTAATCCATT TATAGCTCTC CGGGGATTGG CTGATGATAT TA - #TGAAAATA 360- AATACACCCA AAGGTTTAAA AACCAAATTT TTTGATATAA TAGACAGATT AT - #TTTATCCA 420- TCACAGCTTT CACCAGAAGC TCCTATATTA CCTCCACCAC CACTTGGTTG TA - #TATCTCAA 480- AAAACCGGTT TGACTGAAAC TACTTCTTGT TTATGATGAC TTCTAAACAC AA - #ACTCGAAA 540- ACAGGTATGA CTCTACAGAC AACAAAAATG AGCCTGTTAT TAAACGACCT AG - #AGGAAGAC 600- CTAAGAATGT TAATTTGTTA AACAATTCTT TAACTTTAAT CAACAAGTCA AG - #CTT 655- (2) INFORMATION FOR SEQ ID NO:75:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 516 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..513- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:- TTG TAT ATA AAA CGG AAT ATT TTT CAT ATT CT - #C CAC AAT TTT AGA AGA 48Leu Tyr Ile Lys Arg Asn Ile Phe His Ile Le - #u His Asn Phe Arg Arg# 15- TGG GGT TTA ATA AAT TCA TTA ATA ATT CTA AT - #T GTT TCT TCG TAT ATA 96Trp Gly Leu Ile Asn Ser Leu Ile Ile Leu Il - #e Val Ser Ser Tyr Ile# 30- AAA GAT ATT TTA ACC ATG CTT CCG TCG AGT AA - #A AAT CAA TAT AAC AAC 144Lys Asp Ile Leu Thr Met Leu Pro Ser Ser Ly - #s Asn Gln Tyr Asn Asn# 45- ATT AAT ATA CTA CTT CAA GGA CCA TGC CGT AA - #T CAT CAA ATA GAA AAA 192Ile Asn Ile Leu Leu Gln Gly Pro Cys Arg As - #n His Gln Ile Glu Lys# 60- AAT ATA TAT AAA AAA ATA AAT AAA GAT ATA AA - #A AAC CTT TCT GGA ATT 240Asn Ile Tyr Lys Lys Ile Asn Lys Asp Ile Ly - #s Asn Leu Ser Gly Ile# 80- ATA ATA AGA ACG GAT TGT AAC CCA ATA GAA AT - #C ATT TTA TGG TTC AAA 288Ile Ile Arg Thr Asp Cys Asn Pro Ile Glu Il - #e Ile Leu Trp Phe Lys# 95- TCA ACG AAT GAT GTA TTT TGG GTT AAT CCA TT - #T ATA GCT CTC CGG GGA 336Ser Thr Asn Asp Val Phe Trp Val Asn Pro Ph - #e Ile Ala Leu Arg Gly# 110- TTG GCT GAT GAT ATT ATG AAA ATA AAT ACA CC - #C AAA GGT TTA AAA ACC 384Leu Ala Asp Asp Ile Met Lys Ile Asn Thr Pr - #o Lys Gly Leu Lys Thr# 125- AAA TTT TTT GAT ATA ATA GAC AGA TTA TTT TA - #T CCA TCA CAG CTT TCA 432Lys Phe Phe Asp Ile Ile Asp Arg Leu Phe Ty - #r Pro Ser Gln Leu Ser# 140- CCA GAA GCT CCT ATA TTA CCT CCA CCA CCA CT - #T GGT TGT ATA TCT CAA 480Pro Glu Ala Pro Ile Leu Pro Pro Pro Pro Le - #u Gly Cys Ile Ser Gln145 1 - #50 1 - #55 1 -#60# 516GGT TTG ACT GAA ACT ACT TCT TGT TT - #A TGALys Thr Gly Leu Thr Glu Thr Thr Ser Cys Le - #u# 170- (2) INFORMATION FOR SEQ ID NO:76:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 171 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:- Leu Tyr Ile Lys Arg Asn Ile Phe His Ile Le - #u His Asn Phe Arg Arg# 15- Trp Gly Leu Ile Asn Ser Leu Ile Ile Leu Il - #e Val Ser Ser Tyr Ile# 30- Lys Asp Ile Leu Thr Met Leu Pro Ser Ser Ly - #s Asn Gln Tyr Asn Asn# 45- Ile Asn Ile Leu Leu Gln Gly Pro Cys Arg As - #n His Gln Ile Glu Lys# 60- Asn Ile Tyr Lys Lys Ile Asn Lys Asp Ile Ly - #s Asn Leu Ser Gly Ile# 80- Ile Ile Arg Thr Asp Cys Asn Pro Ile Glu Il - #e Ile Leu Trp Phe Lys# 95- Ser Thr Asn Asp Val Phe Trp Val Asn Pro Ph - #e Ile Ala Leu Arg Gly# 110- Leu Ala Asp Asp Ile Met Lys Ile Asn Thr Pr - #o Lys Gly Leu Lys Thr# 125- Lys Phe Phe Asp Ile Ile Asp Arg Leu Phe Ty - #r Pro Ser Gln Leu Ser# 140- Pro Glu Ala Pro Ile Leu Pro Pro Pro Pro Le - #u Gly Cys Ile Ser Gln145 1 - #50 1 - #55 1 -#60- Lys Thr Gly Leu Thr Glu Thr Thr Ser Cys Le - #u# 170- (2) INFORMATION FOR SEQ ID NO:77:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1823 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:- GCTTTGGACG AGATTTAGGC TGGGAAATTG TTAGTTGAGC ATATTGATTT TC - #GCATAGTT 60- CATAAATATG GTCTTCGTCA TCATCATCAC AAACTTGATC ATACACATTT TT - #ATACTCAA 120- AAGTTGGAAT AGTTCGTTCG TAAATAGGAT TTTCCCTTTC AATTCGTTGA GA - #TGACTTTC 180- TTCTTACACC GTTTTGTCTC TTAATAGTAG CATATATCGG TTCATCTTCA TA - #TGATGAAA 240- TACGACGGCT GGCCATAATT CTATAAATAA GAGAAGGTTA AAAATAAGTT GC - #TTAACTGG 300- TTTAGGCAAC TAATAAAATA TCTCTAAAAC ATACCCCCTT TTATATAAAT CT - #GTGGATTA 360- GTTTCGGATT TCGAAACCCA CCTTCTTATT AGTGTTGCAT CTGACGAAGT TC - #CCGACTAA 420- CCATTCTCAA ACAGGTTCTA TAAGAATAAC AAAATATCGC AACCCCTACT GT - #TACCAGGG 480- ATATATAAAA CAAAATAGCG GAAGTTGAAG GCGTATTAAT ATTGATACCC CT - #AGCTGAAC 540- AACTAGAGCT CCAAAACTGT CTCCTAGCTT CAGCTCTAGA ATAATCTAAA CG - #ATCATCGT 600- CGAAGGCATA AACTGAAAAA ATAATGGATA GTAAAAATAC TATCTCCATT GC - #TTTGATTG 660- AAAAACAAAA ACCTTTTAAT TGGACTATCA ACAAAATAAA TGAAAGCCTT CT - #GATGACCA 720- ACAACGAAGA AATAAACTTG ACTGAAAATT TTAAAAATAC GGGCACCTTT TA - #TAGCAAGA 780- TAATTGACCT TGAAATCCGA ACTGCTACAT CTAGTCAATA TGCAGTCTTT GT - #TACACAAA 840- TGTGTTCTGA TGACGAAAAT ATGAATAATA CAAATATTTT TGTTATTAAT GG - #TGTTATTG 900- ATTCTGGATA TAGAGGAATA GTTAAAGCGT TAGTTTATTA CCATCCAACT GT - #AGAAAAAT 960- TAAATCCATA CGATCTTAAA ATTAAACTTC CACTAATAGA ACTTAGTAAA GA - #TTTAATAC1020- CACTATCACC TAGTTTACAT AGTTATAGTG AATTATATAA TTTTTTTAAT GT - #CTTTAATA1080- AAAAACGTGA TGAAGATGCT GGTTATGATA TACCATCTCC AAATTTAGTT CA - #AATAAAAC1140- CGGGATATAG TTACCTTTTT TGTCTTCCTA TTTTTCAATT AGAAATGAAA AA - #CCCACCAA1200- TCGCTTGTAT TTTTGGTAGA TCATCCTTAA ATTCAAGCGG AATAATTGTT CT - #TCCAACTA1260- TATGGAAACC AAAAACAATT TGTCAATTTT TTATTAAAAA TATATCCTCT AA - #AACTGTAA1320- CTATAGAAAA AGGTCAGAGA ATAGCTCAGT TAGTTCTTTT AAAAAACAAT CA - #ACCACTAT1380- GGTTACAACC ACAAATTAAT TGTCATTCTT TATTTCCAAA GTCAAACTAT TT - #AAGCTTAT1440- CAAATCGAGA ATGTGATATG TGGAAGTTTA CAGAAGATCT GAATTTTGAA GC - #ACCGAAAA1500- GTTTACGAGG AATAAATGGA TTTGGATCCA CGGGATTGTA AAATTCGTTA AT - #AAAGTTAT1560- ATTTAAAGTG CCAAACTTTC ACGTGTCATT TTTTTGGGAC CGTTTCTTTT TT - #GTTTAGTC1620- GATAAAATAT TTTCAGTTTC CATAGAACTT ATTAGAGGTT CTGTATCTAG TA - #TATCTGTA1680- GAATTATTTT CATCATATTT AACGGTTTGA AGAGATAAGG GTTTTGTTGT AT - #TAGAATCT1740- ATACCAAGGG TTTTTTCTAA AACCGCTACA TCTGCCATAA CAATATTATT TT - #CTGAAGTC1800# 1823CACC ACC- (2) INFORMATION FOR SEQ ID NO:78:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1823 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:- GGTGGTGCCC AAGCCATAAA AATGACTTCA GAAAATAATA TTGTTATGGC AG - #ATGTAGCG 60- GTTTTAGAAA AAACCCTTGG TATAGATTCT AATACAACAA AACCCTTATC TC - #TTCAAACC 120- GTTAAATATG ATGAAAATAA TTCTACAGAT ATACTAGATA CAGAACCTCT AA - #TAAGTTCT 180- ATGGAAACTG AAAATATTTT ATCGACTAAA CAAAAAAGAA ACGGTCCCAA AA - #AAATGACA 240- CGTGAAAGTT TGGCACTTTA AATATAACTT TATTAACGAA TTTTACAATC CC - #GTGGATCC 300- AAATCCATTT ATTCCTCGTA AACTTTTCGG TGCTTCAAAA TTCAGATCTT CT - #GTAAACTT 360- CCACATATCA CATTCTCGAT TTGATAAGCT TAAATAGTTT GACTTTGGAA AT - #AAAGAATG 420- ACAATTAATT TGTGGTTGTA ACCATAGTGG TTGATTGTTT TTTAAAAGAA CT - #AACTGAGC 480- TATTCTCTGA CCTTTTTCTA TAGTTACAGT TTTAGAGGAT ATATTTTTAA TA - #AAAAATTG 540- ACAAATTGTT TTTGGTTTCC ATATAGTTGG AAGAACAATT ATTCCGCTTG AA - #TTTAAGGA 600- TGATCTACCA AAAATACAAG CGATTGGTGG GTTTTTCATT TCTAATTGAA AA - #ATAGGAAG 660- ACAAAAAAGG TAACTATATC CCGGTTTTAT TTGAACTAAA TTTGGAGATG GT - #ATATCATA 720- ACCAGCATCT TCATCACGTT TTTTATTAAA GACATTAAAA AAATTATATA AT - #TCACTATA 780- ACTATGTAAA CTAGGTGATA GTGGTATTAA ATCTTTACTA AGTTCTATTA GT - #GGAAGTTT 840- AATTTTAAGA TCGTATGGAT TTAATTTTTC TACAGTTGGA TGGTAATAAA CT - #AACGCTTT 900- AACTATTCCT CTATATCCAG AATCAATAAC ACCATTAATA ACAAAAATAT TT - #GTATTATT 960- CATATTTTCG TCATCAGAAC ACATTTGTGT AACAAAGACT GCATATTGAC TA - #GATGTAGC1020- AGTTCGGATT TCAAGGTCAA TTATCTTGCT ATAAAAGGTG CCCGTATTTT TA - #AAATTTTC1080- AGTCAAGTTT ATTTCTTCGT TGTTGGTCAT CAGAAGGCTT TCATTTATTT TG - #TTGATAGT1140- CCAATTAAAA GGTTTTTGTT TTTCAATCAA AGCAATGGAG ATAGTATTTT TA - #CTATCCAT1200- TATTTTTTCA GTTTATGCCT TCGACGATGA TCGTTTAGAT TATTCTAGAG CT - #GAAGCTAG1260- GAGACAGTTT TGGAGCTCTA GTTGTTCAGC TAGGGGTATC AATATTAATA CG - #CCTTCAAC1320- TTCCGCTATT TTGTTTTATA TATCCCTGGT AACAGTAGGG GTTGCGATAT TT - #TGTTATTC1380- TTATAGAACC TGTTTGAGAA TGGTTAGTCG GGAACTTCGT CAGATGCAAC AC - #TAATAAGA1440- AGGTGGGTTT CGAAATCCGA AACTAATCCA CAGATTTATA TAAAAGGGGG TA - #TGTTTTAG1500- AGATATTTTA TTAGTTGCCT AAACCAGTTA AGCAACTTAT TTTTAACCTT CT - #CTTATTTA1560- TAGAATTATG GCCAGCCGTC GTATTTCATC ATATGAAGAT GAACCGATAT AT - #GCTACTAT1620- TAAGAGACAA AACGGTGTAA GAAGAAAGTC ATCTCAACGA ATTGAAAGGG AA - #AATCCTAT1680- TTACGAACGA ACTATTCCAA CTTTTGAGTA TAAAAATGTG TATGATCAAG TT - #TGTGATGA1740- TGATGACGAA GACCATATTT ATGAACTATG CGAAAATCAA TATGCTCAAC TA - #ACAATTTC1800# 1823CCAA AGC- (2) INFORMATION FOR SEQ ID NO:79:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..915- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:- ATG GAT AGT AAA AAT ACT ATC TCC ATT GCT TT - #G ATT GAA AAA CAA AAA 48Met Asp Ser Lys Asn Thr Ile Ser Ile Ala Le - #u Ile Glu Lys Gln Lys# 15- CCT TTT AAT TGG ACT ATC AAC AAA ATA AAT GA - #A AGC CTT CTG ATG ACC 96Pro Phe Asn Trp Thr Ile Asn Lys Ile Asn Gl - #u Ser Leu Leu Met Thr# 30- AAC AAC GAA GAA ATA AAC TTG ACT GAA AAT TT - #T AAA AAT ACG GGC ACC 144Asn Asn Glu Glu Ile Asn Leu Thr Glu Asn Ph - #e Lys Asn Thr Gly Thr# 45- TTT TAT AGC AAG ATA ATT GAC CTT GAA ATC CG - #A ACT GCT ACA TCT AGT 192Phe Tyr Ser Lys Ile Ile Asp Leu Glu Ile Ar - #g Thr Ala Thr Ser Ser# 60- CAA TAT GCA GTC TTT GTT ACA CAA ATG TGT TC - #T GAT GAC GAA AAT ATG 240Gln Tyr Ala Val Phe Val Thr Gln Met Cys Se - #r Asp Asp Glu Asn Met# 80- AAT AAT ACA AAT ATT TTT GTT ATT AAT GGT GT - #T ATT GAT TCT GGA TAT 288Asn Asn Thr Asn Ile Phe Val Ile Asn Gly Va - #l Ile Asp Ser Gly Tyr# 95- AGA GGA ATA GTT AAA GCG TTA GTT TAT TAC CA - #T CCA ACT GTA GAA AAA 336Arg Gly Ile Val Lys Ala Leu Val Tyr Tyr Hi - #s Pro Thr Val Glu Lys# 110- TTA AAT CCA TAC GAT CTT AAA ATT AAA CTT CC - #A CTA ATA GAA CTT AGT 384Leu Asn Pro Tyr Asp Leu Lys Ile Lys Leu Pr - #o Leu Ile Glu Leu Ser# 125- AAA GAT TTA ATA CCA CTA TCA CCT AGT TTA CA - #T AGT TAT AGT GAA TTA 432Lys Asp Leu Ile Pro Leu Ser Pro Ser Leu Hi - #s Ser Tyr Ser Glu Leu# 140- TAT AAT TTT TTT AAT GTC TTT AAT AAA AAA CG - #T GAT GAA GAT GCT GGT 480Tyr Asn Phe Phe Asn Val Phe Asn Lys Lys Ar - #g Asp Glu Asp Ala Gly145 1 - #50 1 - #55 1 -#60- TAT GAT ATA CCA TCT CCA AAT TTA GTT CAA AT - #A AAA CCG GGA TAT AGT 528Tyr Asp Ile Pro Ser Pro Asn Leu Val Gln Il - #e Lys Pro Gly Tyr Ser# 175- TAC CTT TTT TGT CTT CCT ATT TTT CAA TTA GA - #A ATG AAA AAC CCA CCA 576Tyr Leu Phe Cys Leu Pro Ile Phe Gln Leu Gl - #u Met Lys Asn Pro Pro# 190- ATC GCT TGT ATT TTT GGT AGA TCA TCC TTA AA - #T TCA AGC GGA ATA ATT 624Ile Ala Cys Ile Phe Gly Arg Ser Ser Leu As - #n Ser Ser Gly Ile Ile# 205- GTT CTT CCA ACT ATA TGG AAA CCA AAA ACA AT - #T TGT CAA TTT TTT ATT 672Val Leu Pro Thr Ile Trp Lys Pro Lys Thr Il - #e Cys Gln Phe Phe Ile# 220- AAA AAT ATA TCC TCT AAA ACT GTA ACT ATA GA - #A AAA GGT CAG AGA ATA 720Lys Asn Ile Ser Ser Lys Thr Val Thr Ile Gl - #u Lys Gly Gln Arg Ile225 2 - #30 2 - #35 2 -#40- GCT CAG TTA GTT CTT TTA AAA AAC AAT CAA CC - #A CTA TGG TTA CAA CCA 768Ala Gln Leu Val Leu Leu Lys Asn Asn Gln Pr - #o Leu Trp Leu Gln Pro# 255- CAA ATT AAT TGT CAT TCT TTA TTT CCA AAG TC - #A AAC TAT TTA AGC TTA 816Gln Ile Asn Cys His Ser Leu Phe Pro Lys Se - #r Asn Tyr Leu Ser Leu# 270- TCA AAT CGA GAA TGT GAT ATG TGG AAG TTT AC - #A GAA GAT CTG AAT TTT 864Ser Asn Arg Glu Cys Asp Met Trp Lys Phe Th - #r Glu Asp Leu Asn Phe# 285- GAA GCA CCG AAA AGT TTA CGA GGA ATA AAT GG - #A TTT GGA TCC ACG GGA 912Glu Ala Pro Lys Ser Leu Arg Gly Ile Asn Gl - #y Phe Gly Ser Thr Gly# 300# 918Leu305- (2) INFORMATION FOR SEQ ID NO:80:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:- Met Asp Ser Lys Asn Thr Ile Ser Ile Ala Le - #u Ile Glu Lys Gln Lys# 15- Pro Phe Asn Trp Thr Ile Asn Lys Ile Asn Gl - #u Ser Leu Leu Met Thr# 30- Asn Asn Glu Glu Ile Asn Leu Thr Glu Asn Ph - #e Lys Asn Thr Gly Thr# 45- Phe Tyr Ser Lys Ile Ile Asp Leu Glu Ile Ar - #g Thr Ala Thr Ser Ser# 60- Gln Tyr Ala Val Phe Val Thr Gln Met Cys Se - #r Asp Asp Glu Asn Met# 80- Asn Asn Thr Asn Ile Phe Val Ile Asn Gly Va - #l Ile Asp Ser Gly Tyr# 95- Arg Gly Ile Val Lys Ala Leu Val Tyr Tyr Hi - #s Pro Thr Val Glu Lys# 110- Leu Asn Pro Tyr Asp Leu Lys Ile Lys Leu Pr - #o Leu Ile Glu Leu Ser# 125- Lys Asp Leu Ile Pro Leu Ser Pro Ser Leu Hi - #s Ser Tyr Ser Glu Leu# 140- Tyr Asn Phe Phe Asn Val Phe Asn Lys Lys Ar - #g Asp Glu Asp Ala Gly145 1 - #50 1 - #55 1 -#60- Tyr Asp Ile Pro Ser Pro Asn Leu Val Gln Il - #e Lys Pro Gly Tyr Ser# 175- Tyr Leu Phe Cys Leu Pro Ile Phe Gln Leu Gl - #u Met Lys Asn Pro Pro# 190- Ile Ala Cys Ile Phe Gly Arg Ser Ser Leu As - #n Ser Ser Gly Ile Ile# 205- Val Leu Pro Thr Ile Trp Lys Pro Lys Thr Il - #e Cys Gln Phe Phe Ile# 220- Lys Asn Ile Ser Ser Lys Thr Val Thr Ile Gl - #u Lys Gly Gln Arg Ile225 2 - #30 2 - #35 2 -#40- Ala Gln Leu Val Leu Leu Lys Asn Asn Gln Pr - #o Leu Trp Leu Gln Pro# 255- Gln Ile Asn Cys His Ser Leu Phe Pro Lys Se - #r Asn Tyr Leu Ser Leu# 270- Ser Asn Arg Glu Cys Asp Met Trp Lys Phe Th - #r Glu Asp Leu Asn Phe# 285- Glu Ala Pro Lys Ser Leu Arg Gly Ile Asn Gl - #y Phe Gly Ser Thr Gly# 300- Leu305- (2) INFORMATION FOR SEQ ID NO:81:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 261 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..258- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:- ATG GAG ATA GTA TTT TTA CTA TCC ATT ATT TT - #T TCA GTT TAT GCC TTC 48Met Glu Ile Val Phe Leu Leu Ser Ile Ile Ph - #e Ser Val Tyr Ala Phe# 15- GAC GAT GAT CGT TTA GAT TAT TCT AGA GCT GA - #A GCT AGG AGA CAG TTT 96Asp Asp Asp Arg Leu Asp Tyr Ser Arg Ala Gl - #u Ala Arg Arg Gln Phe# 30- TGG AGC TCT AGT TGT TCA GCT AGG GGT ATC AA - #T ATT AAT ACG CCT TCA 144Trp Ser Ser Ser Cys Ser Ala Arg Gly Ile As - #n Ile Asn Thr Pro Ser# 45- ACT TCC GCT ATT TTG TTT TAT ATA TCC CTG GT - #A ACA GTA GGG GTT GCG 192Thr Ser Ala Ile Leu Phe Tyr Ile Ser Leu Va - #l Thr Val Gly Val Ala# 60- ATA TTT TGT TAT TCT TAT AGA ACC TGT TTG AG - #A ATG GTT AGT CGG GAA 240Ile Phe Cys Tyr Ser Tyr Arg Thr Cys Leu Ar - #g Met Val Ser Arg Glu# 80# 261 CAC TAALeu Arg Gln Met Gln His 85- (2) INFORMATION FOR SEQ ID NO:82:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 86 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:- Met Glu Ile Val Phe Leu Leu Ser Ile Ile Ph - #e Ser Val Tyr Ala Phe# 15- Asp Asp Asp Arg Leu Asp Tyr Ser Arg Ala Gl - #u Ala Arg Arg Gln Phe# 30- Trp Ser Ser Ser Cys Ser Ala Arg Gly Ile As - #n Ile Asn Thr Pro Ser# 45- Thr Ser Ala Ile Leu Phe Tyr Ile Ser Leu Va - #l Thr Val Gly Val Ala# 60- Ile Phe Cys Tyr Ser Tyr Arg Thr Cys Leu Ar - #g Met Val Ser Arg Glu# 80- Leu Arg Gln Met Gln His 85- (2) INFORMATION FOR SEQ ID NO:83:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 255 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..255- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:- ATG GCC AGC CGT CGT ATT TCA TCA TAT GAA GA - #T GAA CCG ATA TAT GCT 48Met Ala Ser Arg Arg Ile Ser Ser Tyr Glu As - #p Glu Pro Ile Tyr Ala# 15- ACT ATT AAG AGA CAA AAC GGT GTA AGA AGA AA - #G TCA TCT CAA CGA ATT 96Thr Ile Lys Arg Gln Asn Gly Val Arg Arg Ly - #s Ser Ser Gln Arg Ile# 30- GAA AGG GAA AAT CCT ATT TAC GAA CGA ACT AT - #T CCA ACT TTT GAG TAT 144Glu Arg Glu Asn Pro Ile Tyr Glu Arg Thr Il - #e Pro Thr Phe Glu Tyr# 45- AAA AAT GTG TAT GAT CAA GTT TGT GAT GAT GA - #T GAC GAA GAC CAT ATT 192Lys Asn Val Tyr Asp Gln Val Cys Asp Asp As - #p Asp Glu Asp His Ile# 60- TAT GAA CTA TGC GAA AAT CAA TAT GCT CAA CT - #A ACA ATT TCC CAG CCT 240Tyr Glu Leu Cys Glu Asn Gln Tyr Ala Gln Le - #u Thr Ile Ser Gln Pro# 80# 255 AGLys Ser Arg Pro Lys 85- (2) INFORMATION FOR SEQ ID NO:84:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 85 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:- Met Ala Ser Arg Arg Ile Ser Ser Tyr Glu As - #p Glu Pro Ile Tyr Ala# 15- Thr Ile Lys Arg Gln Asn Gly Val Arg Arg Ly - #s Ser Ser Gln Arg Ile# 30- Glu Arg Glu Asn Pro Ile Tyr Glu Arg Thr Il - #e Pro Thr Phe Glu Tyr# 45- Lys Asn Val Tyr Asp Gln Val Cys Asp Asp As - #p Asp Glu Asp His Ile# 60- Tyr Glu Leu Cys Glu Asn Gln Tyr Ala Gln Le - #u Thr Ile Ser Gln Pro# 80- Lys Ser Arg Pro Lys 85- (2) INFORMATION FOR SEQ ID NO:85:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 749 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:- AAGCTTTCAA AATGTGCCAA GTAAATATAA TTAATAAACT CTCTATCAGA AA - #CTTTTAAA 60- CTCTGTCTAT CAGCAGAAAT ATAATTTCTC AATACACCAA CCTCTGAAAT AT - #CGGCATTA 120- ATTCGATGTG TTATATAATC TTCTAGTTTA ACAGCAATCT TTCCTGTAGC AT - #ACCCACTT 180- TGACAACAAA ATTTTGATAA CAAAGAAAAT GATATTAAAT CTATACATTT AA - #GATTAGTT 240- TTGTTTTGTT GTACAGGTAT TTTATATGTT TCGATAAAAT CTTTTATAGC TT - #GTAGGTCA 300- TAGGTATGAA AAGGCTTTAA ACTGTTTGTA GCTTGAAATA GATAAAATCT TG - #TTGCTAAA 360- ACTAAAGTTT TTTCTTCAGG ACCAAATTTT GAAGTAAACC AAAACGGTGT AG - #GATTTGTT 420- CCATATATTC GTCTAAAGGC TGCAAGTATT TGTTGTTCGT GATGAATATA TA - #ATAATGTT 480- AACCCATGGC GTCCTTTATT ACATTTCGAT AAGCATGTTT TTATAGATAA TG - #TAGGGTCA 540- TATTTAGCAG ATTCTAAAGT TCTTCCAGAT TTAGGAGTTA GACGCTCTGT CG - #TTATAGAT 600- AATATAGTTA TTAAATCATC ATGAATATTA AACGTATGCT GATCATCAAT AC - #AAGAAAGT 660- ATTAATTTTG TAGAGATTGG GTTTCCATAT AATAAAGATT TAGCTATAAC AG - #ACGCTTCA 720# 749 AACA TATAAACAT- (2) INFORMATION FOR SEQ ID NO:86:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 749 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:- ATGTTTATAT GTTCAATTAA AAATAATTAT GAAGCGTCTG TTATAGCTAA AT - #CTTTATTA 60- TATGGAAACC CAATCTCTAC AAAATTAATA CTTTCTTGTA TTGATGATCA GC - #ATACGTTT 120- AATATTCATG ATGATTTAAT AACTATATTA TCTATAACGA CAGAGCGTCT AA - #CTCCTAAA 180- TCTGGAAGAA CTTTAGAATC TGCTAAATAT GACCCTACAT TATCTATAAA AA - #CATGCTTA 240- TCGAAATGTA ATAAAGGACG CCATGGGTTA ACATTATTAT ATATTCATCA CG - #AACAACAA 300- ATACTTGCAG CCTTTAGACG AATATATGGA ACAAATCCTA CACCGTTTTG GT - #TTACTTCA 360- AAATTTGGTC CTGAAGAAAA AACTTTAGTT TTAGCAACAA GATTTTATCT AT - #TTCAAGCT 420- ACAAACAGTT TAAAGCCTTT TCATACCTAT GACCTACAAG CTATAAAAGA TT - #TTATCGAA 480- ACATATAAAA TACCTGTACA ACAAAACAAA ACTAATCTTA AATGTATAGA TT - #TAATATCA 540- TTTTCTTTGT TATCAAAATT TTGTTGTCAA AGTGGGTATG CTACAGGAAA GA - #TTGCTGTT 600- AAACTAGAAG ATTATATAAC ACATCGAATT AATGCCGATA TTTCAGAGGT TG - #GTGTATTG 660- AGAAATTATA TTTCTGCTGA TAGACAGAGT TTAAAAGTTT CTGATAGAGA GT - #TTATTAAT 720# 749 ATTT TGAAAGCTT- (2) INFORMATION FOR SEQ ID NO:87:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 747 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..747- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:- ATG TTT ATA TGT TCA ATT AAA AAT AAT TAT GA - #A GCG TCT GTT ATA GCT 48Met Phe Ile Cys Ser Ile Lys Asn Asn Tyr Gl - #u Ala Ser Val Ile Ala# 15- AAA TCT TTA TTA TAT GGA AAC CCA ATC TCT AC - #A AAA TTA ATA CTT TCT 96Lys Ser Leu Leu Tyr Gly Asn Pro Ile Ser Th - #r Lys Leu Ile Leu Ser# 30- TGT ATT GAT GAT CAG CAT ACG TTT AAT ATT CA - #T GAT GAT TTA ATA ACT 144Cys Ile Asp Asp Gln His Thr Phe Asn Ile Hi - #s Asp Asp Leu Ile Thr# 45- ATA TTA TCT ATA ACG ACA GAG CGT CTA ACT CC - #T AAA TCT GGA AGA ACT 192Ile Leu Ser Ile Thr Thr Glu Arg Leu Thr Pr - #o Lys Ser Gly Arg Thr# 60- TTA GAA TCT GCT AAA TAT GAC CCT ACA TTA TC - #T ATA AAA ACA TGC TTA 240Leu Glu Ser Ala Lys Tyr Asp Pro Thr Leu Se - #r Ile Lys Thr Cys Leu# 80- TCG AAA TGT AAT AAA GGA CGC CAT GGG TTA AC - #A TTA TTA TAT ATT CAT 288Ser Lys Cys Asn Lys Gly Arg His Gly Leu Th - #r Leu Leu Tyr Ile His# 95- CAC GAA CAA CAA ATA CTT GCA GCC TTT AGA CG - #A ATA TAT GGA ACA AAT 336His Glu Gln Gln Ile Leu Ala Ala Phe Arg Ar - #g Ile Tyr Gly Thr Asn# 110- CCT ACA CCG TTT TGG TTT ACT TCA AAA TTT GG - #T CCT GAA GAA AAA ACT 384Pro Thr Pro Phe Trp Phe Thr Ser Lys Phe Gl - #y Pro Glu Glu Lys Thr# 125- TTA GTT TTA GCA ACA AGA TTT TAT CTA TTT CA - #A GCT ACA AAC AGT TTA 432Leu Val Leu Ala Thr Arg Phe Tyr Leu Phe Gl - #n Ala Thr Asn Ser Leu# 140- AAG CCT TTT CAT ACC TAT GAC CTA CAA GCT AT - #A AAA GAT TTT ATC GAA 480Lys Pro Phe His Thr Tyr Asp Leu Gln Ala Il - #e Lys Asp Phe Ile Glu145 1 - #50 1 - #55 1 -#60- ACA TAT AAA ATA CCT GTA CAA CAA AAC AAA AC - #T AAT CTT AAA TGT ATA 528Thr Tyr Lys Ile Pro Val Gln Gln Asn Lys Th - #r Asn Leu Lys Cys Ile# 175- GAT TTA ATA TCA TTT TCT TTG TTA TCA AAA TT - #T TGT TGT CAA AGT GGG 576Asp Leu Ile Ser Phe Ser Leu Leu Ser Lys Ph - #e Cys Cys Gln Ser Gly# 190- TAT GCT ACA GGA AAG ATT GCT GTT AAA CTA GA - #A GAT TAT ATA ACA CAT 624Tyr Ala Thr Gly Lys Ile Ala Val Lys Leu Gl - #u Asp Tyr Ile Thr His# 205- CGA ATT AAT GCC GAT ATT TCA GAG GTT GGT GT - #A TTG AGA AAT TAT ATT 672Arg Ile Asn Ala Asp Ile Ser Glu Val Gly Va - #l Leu Arg Asn Tyr Ile# 220- TCT GCT GAT AGA CAG AGT TTA AAA GTT TCT GA - #T AGA GAG TTT ATT AAT 720Ser Ala Asp Arg Gln Ser Leu Lys Val Ser As - #p Arg Glu Phe Ile Asn225 2 - #30 2 - #35 2 -#40# 747 CA CAT TTT GAA AGCTyr Ile Tyr Leu Ala His Phe Glu Ser 245- (2) INFORMATION FOR SEQ ID NO:88:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 249 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:- Met Phe Ile Cys Ser Ile Lys Asn Asn Tyr Gl - #u Ala Ser Val Ile Ala# 15- Lys Ser Leu Leu Tyr Gly Asn Pro Ile Ser Th - #r Lys Leu Ile Leu Ser# 30- Cys Ile Asp Asp Gln His Thr Phe Asn Ile Hi - #s Asp Asp Leu Ile Thr# 45- Ile Leu Ser Ile Thr Thr Glu Arg Leu Thr Pr - #o Lys Ser Gly Arg Thr# 60- Leu Glu Ser Ala Lys Tyr Asp Pro Thr Leu Se - #r Ile Lys Thr Cys Leu# 80- Ser Lys Cys Asn Lys Gly Arg His Gly Leu Th - #r Leu Leu Tyr Ile His# 95- His Glu Gln Gln Ile Leu Ala Ala Phe Arg Ar - #g Ile Tyr Gly Thr Asn# 110- Pro Thr Pro Phe Trp Phe Thr Ser Lys Phe Gl - #y Pro Glu Glu Lys Thr# 125- Leu Val Leu Ala Thr Arg Phe Tyr Leu Phe Gl - #n Ala Thr Asn Ser Leu# 140- Lys Pro Phe His Thr Tyr Asp Leu Gln Ala Il - #e Lys Asp Phe Ile Glu145 1 - #50 1 - #55 1 -#60- Thr Tyr Lys Ile Pro Val Gln Gln Asn Lys Th - #r Asn Leu Lys Cys Ile# 175- Asp Leu Ile Ser Phe Ser Leu Leu Ser Lys Ph - #e Cys Cys Gln Ser Gly# 190- Tyr Ala Thr Gly Lys Ile Ala Val Lys Leu Gl - #u Asp Tyr Ile Thr His# 205- Arg Ile Asn Ala Asp Ile Ser Glu Val Gly Va - #l Leu Arg Asn Tyr Ile# 220- Ser Ala Asp Arg Gln Ser Leu Lys Val Ser As - #p Arg Glu Phe Ile Asn225 2 - #30 2 - #35 2 -#40- Tyr Ile Tyr Leu Ala His Phe Glu Ser 245- (2) INFORMATION FOR SEQ ID NO:89:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..30#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:# 30 GGAC GAGATTTAGG- (2) INFORMATION FOR SEQ ID NO:90:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..29#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:# 29 TTAA TAAACTCTC- (2) INFORMATION FOR SEQ ID NO:91:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..28#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:# 28 GAGA GTATAAAC- (2) INFORMATION FOR SEQ ID NO:92:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..28#/label= primerTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:# 28 TTAT ATACTAAC__________________________________________________________________________
While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

Number	Name	Date
5223424	Cochran et al.	Jun 1993
5266489	Rey-Senelonge et al.	Nov 1993
5310668	Ellis et al.	May 1994
5324664	Nunberg et al.	Jun 1994

Recombinant canine herpesviruses

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

US Referenced Citations (4)

Foreign Referenced Citations (1)

Non-Patent Literature Citations (40)

Divisions (1)

Continuation in Parts (1)

Entry
Limcumpao et al., J Vet Med Sci, 53(3), 1991, p. 423-432.
Xuan et al., Arch Virol, 122(3-4), 1992, p. 359-365.
Limbach et al., J Gen Virol, 75(8), 1994, p. 2029-2039.
Xuan et al., Japan J Vet Sci, 52(50, 1990, p. 899-905.
Binn, et al., "Viruses Recovered from Laboratory Dogs with Respiratory Disease," pp. 140-145, P.S.E.B.M., (rec'd May 17, 1967) v. 126.
Breeden, et al., "Identification and Transcriptional Mapping of Genes Encoded at the IR/Us Junction of Equine Herpesvirus Type 1," pp. 649-660, Virology, 191 (1992).
Carmichael, "Herpesvirus canis: Aspects of Pathogenesis and Immune Response," pp. 1714-1721, J.A.V.M.A., vol. 156 (Jun. 15, 1970).
de Wind, et al., "Ribonucleotide reductase-deficient mutants of pseudorabies virus are avirulent for pigs and induce partial protective immunity," pp. 351-359, Journal of General Virology, 74 (1993).
Elton, et al., "Sequence analysis of the 4.7-kb BamHI-EcoRI fragment of the equine herpesvirus type-1 short unique region," pp. 203-208, Elsevier Science Publishers B.V. 0378-1119/91 (1991).
Graham, et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," pp. 456-467, Virology, 52 (1973).
Holliday, et al., "Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine," pp. 197-203, Antiviral Research, 16 (1991).
Kit, et al., "Nucleotide Sequence Changes in Thymidine Kinase Gene of Herpes Simplex Virus Type 2 Clones from an Isolate of a Patient Treated with Acyclovir," pp. 1483-1490, Antimicrobial Agents and Chemotherapy, vol. 31, No. 10 (Oct. 1987).
Kit, et al., "Thymidine Kinase (TK) Induction after Infection of TK-Deficient Rabbit Cell Mutants with Bovine Herpesvirus Type 1 (BHV-1): Isolation of TK .sup.- BHV-1 Mutants" pp. 381-389, Virology, 130 (1983).
Lees, et al., "The Epstein-Barr Virus Candidate Vaccine Antigen gp340/220 is Highly Conserved between Virus Types A and B," pp. 578-586, Virology, 195 (1993).
Liang, et al., "Identification and Deletion Mutagenesis of the Bovine Herpesvirus 1 dUTPase Gene and a Gene Homologous to Herpes Simplex Virus UL49.5," pp. 42-50, Virology, 195 (1993).
Limbach, et al., "Nucleotide sequence of the genes encoding the canine herpesvirus gB, gC and gC homologues," pp. 2029-2039, Journal of General Virology, 75 (1994).
McGeoch, et al., The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1, pp. 1531-1574, Journal of General Virology, 69 (1988).
McGeoch, et al., "Sequence Determination and Genetic Content of the Short Unique Region in the Genome of Herpes Simplex Virus Type 1," pp. 1-13, 1985 Academic Press Inc. (London) Ltd. (received Jul. 30, 1984).
Meignier, et al., "Virulence of and Establishment of Latency by Genetically Engineered Deletion Mutants of Herpes Simplex Virus 1," pp. 251-254, Virology, 162 (1988).
Meinkoth, et al., "Hybridization of Nucleic Acids Immobilized on Solid Supports," pp. 267-284, Analytical Biochemistry, 138 (1984).
Nunberg, et al., "Identification of the Thymidine Kinase Gene of Feline Herpesvirus: Use of Degenerate Oligonucleotides in the Polymerase Chain Reaction to Isolate Herpesvirus Gene Homologs," pp. 3240-3249, Journal of Virology, vol. 63, No. 8 (Aug. 1989).
Peterson, et al., "Propagation and Quantitation of Animal Herpesviruses in Eight Cell Culture Systems," pp. 93-98, Comp. Immun. Microbiol. Infect. Dis., vol. 11, No. 2 (1988).
Remond, et al., "Gene organization in the U.sub.L region and inverted repeats of the canine herpesvirus genome," pp. 37-48, Journal of General Virology, 77 (1996).
Remond, et al., "Sequence of the canine herpesvirus thymidine kinase gene: taxon-preferred amino acid residues in the alphaherpesviral thymidine kinases," pp. 341-354, Virus Research, 39 (1995).
Riggio, et al., "DNA sequence of a gene cluster in the equine herpesvirus-4 genome which contains a newly identified herpesvirus gene encoding a membrane protein," pp. 171-178, Archives of Virology, 133 (1993).
Robertson, et al., Evolution of the herpes thymidine kinase: identification and comparison of the equine herpesvirus 1 thymidine kinase gene reveals similarity to a cell-encoded thymidylate kinase, pp. 11303-11317, Nucleic Acids Research, vol. 16, No. 23 (1988).
Simard, et al., "Sequencing and 5'- and 3'-end Transcript Mapping of the Gene Encoding the Small Subunit of Ribonucleotide Reductase from Bovine Herpesvirus Type-1," pp. 689-701, Virology, 190 (1992).
Spatz, et al., "Identification of the feline herpesvirus type 1 (FHV-1) genes encoding glycoproteins G, D, I and E: expression of FHV-1 glycoprotein D in vaccinia and raccoon poxviruses," pp. 1235-1244, Journal of General Virology, 75 (1994).
Tack, et al., The Complete DNA Sequence and the Genetic Organization of the Short Unique Region (U.sub.s) of the Bovine Herpesvirus Type 1 (ST Strain), pp. 409-421, Virology, 199 (1994).
Telford, et al., "The DNA Sequence of Equine Herpesvirus-1," pp. 304, 316, Virology, 18 (1992).
van Zijl, et al., "Regeneration of Herpesviruses from Molecularly Cloned Subgenomic Fragments," pp. 2191-2195, Journal of Virology, vol. 61, No. 6 (Jun. 1988).
Walboomers, et al., "A New Method for the Isolation of Herpes Simplex Virus Type 2 DNA," pp. 256-258, Virology, 74 (1976).
Wolff, et al., "Detect Gene Transfer into Mouse Muscle in Vivo," pp. 1465-1468, Science, vol. 247 (Mar. 23, 1990).
Pyles, et al., 1994, J. Virol., vol. 68(7), pp. 4514-4524.
Feng, et al., 1985, J. Mol. Evol. 21, pp. 112-125.
Haanes, et al., Virus Research, vol. 53, pp. 151-162, 1998.
Johnson, et al., 1993, J. Mol. Biol. 233, pp. 716-738.
Shulze, et al., Vet Pathol, vol. 35, pp. 209-217, 1998.
Smith, K.C., The Veterinary Journal, vol. 153, pp. 253-268, 1997.
Tyack, et al., 1997, DNA Sequence--The Journal of Sequencing and Mapping, vol. 7(6), pp. 365-368.